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 The phosphatidylinositol 4,5-bisphosphate 3’-OH kinase (PI3K) is a 
lipid kinase that regulates cell survival, proliferation and metabolism in 
response to external growth factors. PI3K signaling regulates a diverse set of 
effectors via the phosphoinositide dependent kinase 1 (PDK1), AKT/PKB, 
and the mechanistic target of rapamycin complexes 1 and 2 (mTORC2). The 
components of this pathway are frequently mutated in human cancers, which 
give rise to oncogenic signals that drive tumorigenesis. As such, the proteins 
involved in PI3K/AKT signaling are attractive targets for targeted therapies.  
 It is thought that most tumors upregulate PI3K/AKT signaling in some 
way. However, a large portion of tumors do not have any identifiable genetic 
lesions in the genes that code for proteins that regulate this pathway. Thus, 
we reasoned that there are likely to be many proteins that regulate PI3K/AKT 
signaling that are currently unappreciated. To identify novel regulators of the 
PI3K axis, we undertook an arrayed loss-of-function RNAi screen using a 
library of shRNA reagents that targeted all known human kinases and 
GTPases to identify proteins whose depletion altered AKT phosphorylation. 
Further, we triaged genes from this screen using oncogenomic databases to 
identify screen hit genes that were mutated in human tumor samples or cell 
lines. We reasoned that this approach could identify novel components of 
PI3K/AKT signaling that also play a role in tumorigenesis.  
 This screen identified the small GTPase RAB35 as a novel positive 
regulator of PI3K/AKT signaling. Depletion of RAB35 in a variety of human 
and murine cell lines suppressed phosphorylation of PI3K-dependent 
proteins like AKT, FOXO1/3A and NDRG1. Moreover, stable expression of a 
GTPase-deficient, constitutively active allele of RAB35—but not wildtype 
RAB35—potently activated AKT signaling in the absence of growth factors. 
Further, we identified two RAB35 mutations in human tumor genome 
sequence databases that activated PI3K signaling and transformed NIH-3T3 
cells in vitro in a PI3K-dependent manner. Finally, we find that RAB35 is 
likely regulating PI3K signaling by trafficking the platelet derived growth 
factor receptor (PDGFR) to a RAB7-positive compartment in the cell where 
the receptor actively signals PI3K. Thus, RAB35 is a novel oncogenic 
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INTRODUCTION: PI3K/AKT SIGNALING IN HUMAN CANCERS AND 
RNAi SCREENS TO IDENTIFY NOVEL REGULATORS OF THE PI3K/AKT 
AXIS 
1.1 EXTRACELLULAR SIGNALS REGULATE INTRACELLULAR 
SIGNALING 
1.1.1 Growth factor receptor tyrosine kinases initiate phosphoinositide-
dependent signaling 
Growth factors and other extracellular factors regulate intracellular 
signal transduction networks by transmitting their signals through the cell 
membrane via transmembrane receptors. While many mechanisms for 
transducing extracellular signals to the inside of cells exist, most growth 
factors (e.g. insulin and similar signaling molecules) bind to transmembrane 
growth factor receptor tyrosine kinases (RTKs). The family of 
transmembrane RTKs is diverse, but most RTKs share a common 
mechanism: once bound by their cognate growth factors, RTKs form 
homodimers, and their tyrosine kinase activity is upregulated. RTKs then 
auto-phosphorylate themselves in trans, which forms phosphotyrosine sites 
that can serve as docking sites to recruit a diverse array of proteins that 
transduce signals in response to growth factor stimulation.  
Activated RTKs can initiate signaling through a number of different 
transduction pathways, and one of the most well studied of these is the 
phosphatidylinositol 3-OH kinase (PI3K)/AKT pathway, which is responsible 
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for a large portion of the cellular processes that lie downstream of RTK 
activation (Figure 1.1). Because signaling through RTKs typically suppresses 
apoptosis and activates cell growth, it is not surprising that RTKs and the 
signaling machinery they regulate are often altered in human tumors. 
 
 
Figure 1.1: The PI3K/AKT/mTOR Pathway. Growth factor signaling is 
initiated at the cell membrane when growth factor ligands bind to their 
receptor tyrosine kinases (RTKs). RTKs then dimerize, phosphorylate 
one another in trans, and can recruit effectors to the cell membrane. One 
effector—phosphatidylinositol 3’-OH kinase (PI3K)—is recruited either 
directly or by adaptor proteins like the insulin receptor substrate 1 (IRS-1, 
not shown). PI3K is then proximal to phosphatidylinositol bisphosphate 
(PIP2), a lipid membrane that PI3K phosphorylates to convert to 
phosphatidylinositol trisphosphate (PIP3). PIP3 can then recruit effectors 
such as phosphatidylinositol-dependent kinase 1 (PDK1) or mammalian 
target of rapamycin complex 2 (mTORC2), which phosphorylate the 
kinase AKT on distinct sites. Once activated by these phosphorylations, 
AKT regulates a number of physiological processes such as cell survival, 




1.1.2 Phosphatidylinositol 3’-OH kinases phosphorylate membrane lipids to 
transduce growth factor signals 
The Class I PI3 kinases are medium-sized lipid kinases that were 
initially identified to have in vitro lipid kinase activity that was activated in 
response to growth factors like insulin and the platelet derived growth factor 
(PDGF) [5-11]. Once activated, PI3Ks phosphorylate the 3’ hydroxyl (3’-OH) 
group of the inositol ring on phosphatidylinositol 4, 5-bisphosphate (PIP2) to 
form phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) [10]. PIP3 is a potent 
second messenger that can then activate an array of signaling molecules. 
Thus, growth factor stimulation of RTKs activates PI3K signaling to 
accumulate PIP3, which in turn activates pro-growth signaling (Figure 1.1). 
Several isoforms—α, β, δ and γ—of Class I PI3Ks exist. Further, other 
PI3Ks—such as Class II and Class III PI3Ks—are also present in cells, but 
their lipid substrates and products do not play as central a role in growth 
factor signal transduction [12-14]. 
PI3Kα is thought to be the PI3K that is primarily responsible for 
transducing signals from activated RTKs [15]. PI3Kα exists as an obligate 
heterodimer of two proteins: the p110α catalytic subunit, and a regulatory 
subunit such as p85α, p55α or p50α (three different products of the PIK3R1 
gene) [16]. In resting cells, p110α-p85α heterodimers exist as a tightly 
bound complex within the cytosol that are recruited to the cell membrane 
upon the activation of growth factor RTKs. PI3Kα then interacts with RTKs 
via SRC homology 2 (SH2) domains on p85 [17-18], which bind 
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phosphotyrosine motifs (pYXXM) on either the RTK itself or on adapter 
molecules like the insulin receptor substrates IRS1 and IRS2 [19].  Once 
recruited to RTKs, PI3Kα is in close proximity to its substrate PIP2 and is 
able to generate PIP3. Interestingly, while the p85/p55 adapter subunits are 
necessary to link PI3Kα to RTKs, it is clear that p85 actually negatively 
regulates the lipid kinase activity of p110α [20-23]. Thus, although the 
p85/p55 adapter subunits are necessary to link p110α to RTKs,  
The PI3Kβ isoform is distinct in that it can transduce signals 
downstream of either RTKs or G-protein coupled receptors (GPCRS) [24-
26]. Interestingly, some data suggest that PI3Kβ is the PI3K isoform that is 
primarily responsible for oncogenic signaling in the context of PTEN 
inactivation [27-28], which may suggest a complex spatial and temporal 
regulation of phosphoinositide pools by the PI3Ks and PTEN. However, this 
concept remains controversial, as several groups have published data which 
suggests that the loss of PTEN can utilize either PI3Kα or PI3Kβ to drive 
transformation [29-30]. The development of isoform specific inhibitors of the 
different PI3Ks should help to clarify which genetic contexts (PTEN loss, 
etc.) are dependent on which PI3Ks. 
While PI3Kα and PI3Kβ are the most well studied class I PI3Ks, 
signaling by PI3Kγ and PI3Kδ occurs under various contexts. Dysregulation 
of PI3Kγ and PI3Kδ is not a common event in tumors, but overexpression of 
these kinases can indeed drive transformation in vitro [31]. PI3Kδ—encoded 
by the gene PIK3CD—is primarily expressed in immune cells [32]. Like the 
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other Class IA PI3Ks, PI3Kδ is associated with p85α, p55α, p50α or p85β 
regulatory subunits. Although the function of PI3Kδ is not completely 
understood, it appears that in leukocytes PI3Kδ is involved in B and T cell 
development and antigen receptor signaling [33-36]. The first PI3Kδ isoform-
specific inhibitors were recently approved for chronic lymphocytic leukemia 
and may have an additional role in autoimmune and inflammatory disorders 
[37-42].  
PI3Kγ is the sole member of the Class IB group of PI3Ks [13]. Rather 
than being regulated by RTKs, PI3Kγ is activated mostly by G-protein 
coupled receptors (GPCRs) [43-44]. Further, PI3Kγ does not interact with the 
p85α, p55α, p50α or p85β regulatory subunits, but is instead tightly 
associated with either p101 or p87PIKAP [45-46]. Similar to PI3Kβ, PI3Kγ 
kinase signaling is activated by the Gβ and Gγ subunits of heterotrimeric 
GTPases [47-48]. PI3Kγ is thought to function primarily in cardiac muscle 
and immune cells, but these functions are poorly defined.  
 
1.1.3 PTEN and lipid phosphatases negatively regulate PI3K signaling 
Signaling events downstream of RTKs and PI3Ks are exquisitely 
regulated under normal physiological conditions. Because prolonged growth 
factor signaling would result in aberrant growth, there exist a multitude of 
negative regulatory mechanisms that are set in motion after signal cascades 
are initiated. One mechanism of negative regulation of PI3K/AKT signaling is 
the breakdown of PIP3 by lipid phosphatases like PTEN and SHIP2. 
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The phosphatase and tensin homologue (PTEN) protein is coded for 
by the gene PTEN, and was originally identified as a tumor suppressor that 
is frequently altered in human cancers [49-53]. PTEN was originally thought 
to be a protein tyrosine phosphatase [53], but it is now understood that it is a 
lipid phosphatase that dephosphorylates PIP3 at the 3’ hydroxyl group of the 
inositol ring to form phosphatidylinositol 4,5-bisphosphate (PIP2) [54]. 
Genetic studies have verified that PTEN is a tumor suppressor, while clinical 
studies have implicated PTEN deletion or mutation in tumorigenesis [55-59]. 
The PTEN protein is localized to the inner leaf of the cell membrane by virtue 
of its C2 domain, which allows the phosphatase to reside in proximity to its 
substrate PIP3 [60]. 
Another less commonly mutated lipid phosphatase and tumor 
suppressor is the SH2-domain containing phosphatidylinositol-3, 4, 5-
trisphosphate 5’-phosphatase 2 (SHIP2) protein, which is coded for by the 
gene INPPL1 [61-62]. Unlike PTEN, SHIP2 dephosphorylates PIP3 at the 5’-
OH group of the inositol ring [61, 63]. Further, rather than being targeted to 
membrane lipids, SHIP2 is localized to the cell membrane by recruitment to 
growth factor receptors via its phospho-tyrosine binding SH2 domains, 
where it is phosphorylated at tyrosine residues by the RTK [64-68]. Its 
phosphatase activity is activated by these phosphorylation events, thus 
allowing SHIP2 to locally dephosphorylate PIP3 to form phosphatidylinositol 
3, 4-bisphosphate. The closely related phosphatase phosphatidylinositol- 3, 
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4, 5-trisphosphate 5’-phosphatase 1 (SHIP1) functions similarly to SHIP2, 
but is less well characterized.  
In addition to PTEN and the SHIP phosphatases, there exist a 
number of other lipid phosphatases: 1.) the Lowe oculocerebrorenal 
syndrome protein (OCRL), an inositol polyphosphate 5-phosphatase [69-70], 
2.) the phosphatidylinositol 3-phosphate and phosphatidylinositol 3, 5-
bisphosphate 3’-OH phosphatase myotubularin (MTM) [71], and several 
others. These proteins are less well characterized within the context of 
PI3K/AKT signaling, although it is clear that they may play a role in spatial 
and temporally specific regulation of signal transduction. Because their roles 
as tumor suppressors are less prominent, they will not be further discussed 
here.  
 
1.1.4 The Ras/Raf/MAPK/ERK signaling axis 
Although numerous signaling pathways intersect with the PI3K/AKT 
axis, one other well-studied signal transduction axis is the Ras/Raf/mitogen 
activated protein kinase (MAPK)/extracellular regulated kinase (ERK) 
pathway [72]. Although the Ras/Raf/MAPK/ERK signaling axis is a distinct 
pathway from the PI3K/AKT axis, because of the interrelationship between 
the two, Ras/Raf/MAPK/ERK signaling will be very briefly reviewed here.  
Like PI3K/AKT signaling, Ras/Raf/MAPK/ERK signaling is initiated at 
the cell membrane when growth factors activate RTKs. Unlike PI3K/AKT 
signaling, however, the RAS cascade does not rely upon the generation of 
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the lipid second messenger PIP3. Instead, tyrosine phosphorylation of 
growth factor receptors promotes the recruitment of the adapter protein 
growth factor receptor 2 (GRB2) [73], which interacts with the guanine 
nucleotide exchange factor (GEF) son of sevenless (SOS) [74]. SOS then 
facilitates the exchange of guanine diphosphate (GDP) for guanine 
triphosphate (GTP) on the RAS GTPases (HRas, KRAS and NRas). Thus, 
growth factor receptor activation leads to activated, GTP-bound RAS 
GTPases. 
Once loaded with GTP, the RAS proteins regulate a number of 
signaling molecules. Key among these is the serine/threonine protein 
kinases a-Raf, b-Raf and c-Raf [75-76]. When bound to RAS proteins that 
are loaded with GTP, the Raf kinases are activated and phosphorylate the 
MAPK or ERK kinases 1 and 2 (MEK1/2) [77]. MEKs are dual-specificity 
protein kinases that—when activated by Raf—phosphorylate the 
extracellular regulated kinases (ERK1/2) on tyrosine residues [78-80]. 
ERK—also known as MAPK—then regulates a set of effectors to encourage 
cell division and survival. The best characterized of these are ETS family 
transcription factors like Elk-1 [81-82], the p90 ribosomal S6 kinase (RSK) 
[83-84], and mitogen-and stress-activated protein kinase 1(MSK1) [85].  
While they are two distinct signaling cascades, the PI3K and MAPK 
pathways are by no means unconnected. Indeed, they intersect at many 
points. In some instances, they serve to downregulate the activity of one 
another. For example, Raf is phosphorylated at several sites by AKT, which 
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inhibits Raf activity [86], while activated BRAFV600E can inhibit AKT signaling 
by inhibiting mTORC2 activity [87]. Moreover, treatment with specific small 
molecule inhibitors of MEK1 can induce AKT phosphorylation, while 
inhibition of PI3K, mTORC1, mTORC1/2 or AKT can upregulate ERK 
phosphorylation in many contexts [88]. 
However, there exist a number of cooperative circuits between MAPK 
and PI3K pathway. Phosphorylation of the TSC1/2 complex by ERK and 
RSK at multiple sites can activate mTORC1 [89-93]. A particularly interesting 
example of cooperation between PI3K and MAPK lies upstream, where 
KRAS can interact with and activate PI3K isoforms [94-100]. Although this 
finding was initially controversial, genetic evidence suggests that this 
interaction is indeed meaningful in tumors as well as some regular 
physiological contexts [101]. Thus, the interaction between the PI3K/AKT 
and Ras/MAPK pathways are numerous and complex.  
 
1.2 SIGNALING DOWNSTREAM OF PIP3 
1.2.1 PDK1 activates AKT in a phosphoinositide dependent manner 
The generation of PIP3 initiates a cascade of signaling events that 
positively regulates cell growth, metabolism and survival. One direct effector 
of PIP3 is the phosphoinositide-dependent kinase 1 (PDK1) [102-104], which 
was originally identified from tissue extracts as a kinase that could 
phosphorylate AKT at threonine 308 (T308). This threonine resides in the 
catalytic domain of AKT, and its phosphorylation is necessary for AKT kinase 
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activity [105-106]. Interestingly, the inherent kinase activity of PDK1 is very 
high regardless of growth factor stimulation or PIP3 levels in the cell [102]. 
Rather than being catalytically activated by growth factors, the key 
determinant in PDK1 signaling to downstream effectors is its localization to 
the cell membrane, which is accomplished via PDK1’s C-terminal pleckstrin 
homology (PH) domain [107], which binds to PIP3 and the PIP2 
phosphatidylinositol 3, 4-bisphosphate with high affinity. At the membrane, 
the constitutively active PDK1 can phosphorylate its substrates. The most 
well studied PDK1 substrates are the AGC family member kinases AKT/PKB 
and PKC. 
Unequivocal genetic evidence for PDK1’s role in activating AKT 
arrived when murine embryonic stem (ES) cells null for the PDK1 gene were 
generated [108]. In PDK1-/- ES cells the phosphorylation of AKT’s kinase 
domain residue at T308 was completely absent after growth factor 
stimulation. Further, the homologous residue in the catalytic domain of other 
AGC kinases (SGK1 and PKC isoforms) was not phosphorylated in these 
cells. Lastly, PDK1 is also necessary for activation of a Ras/Raf/MEK/ERK 
regulated kinase, the 90 kDa ribosomal S6 kinase (p90 RSK) [109-111]. 
Unlike S6K1/2, RSK phosphorylates the ribosomal S6 protein in a 
rapamycin-independent manner and largely takes its cues through the ERK 
signaling cascade. Therefore, although PDK1 is important in PI3K 
dependent signaling, it is also able to signal to other effectors outside of the 




1.2.2 AKT/PKB is a major effector of PI3K signaling 
As mentioned above, one of the most well characterized effectors of 
PI3K signaling is AKT (also known as protein kinase B (PKB)). AKT was 
originally discovered as a viral oncogene that was found to be transforming 
in a mouse thymoma model [112-114]. Higher eukaryotes have at least one 
conserved homologue of the viral AKT gene. Indeed, mice and humans have 
three distinct versions of AKT, coded for by the genes AKT1, AKT2, and 
AKT3 [115]. These isoforms are similar in their structure, but the functional 
outputs of the signaling by each kinase are unique as well as overlapping. 
Nevertheless, the signaling events downstream of AKT—i.e. anti-apoptotic, 
pro-metabolic, pro-growth, and pro-cell division—are generally shared by the 
AKT isoforms.  
The three AKT isoforms are similar in their structure in that they 
contain an N-terminal PH domain, a kinase domain similar to other AGC 
kinase family members in the middle, and an inhibitory C-terminal domain 
that contains a hydrophobic motif (Figure 1.2) [116]. Similar to PDK1, the PH 
domain on AKT serves to localize the kinase to the cell membrane when 
PIP3 is generated [117]. At the membrane, the kinase activity of AKT is 
upregulated by phosphorylation of its catalytic domain at residue T308 by 
PDK1, a step which is required for AKT to exhibit enzymatic activity [118]. 
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However, maximal kinase activity of AKT towards its substrates is only 
achieved after phosphorylation at serine 473 (S473) by the mammalian 
target of rapamycin complex 2 (mTORC2) [119]. These two phosphorylation 
events occur concomitantly and are PIP3-dependent, and the 
phosphorylation of some AKT substrates depend on S473 phosphorylation 
more than others [120-121]. Once activated, AKT signals to a variety of 
effectors to encourage cell growth and survival. 
 
 
Figure 1.2: Structure of the AKT1, AKT2 and AKT3 isoforms. The 
AKT1, AKT2 and AKT3 isoforms are structurally similar in that they 
consist of an N-terminal pleckstrin homology (PH) domain (green), an 
AGC-kinase like kinase domain (red), and a C-terminal hydrophobic motif 
(blue). The catalytic domain threonine (T308, T309 and T305 in AKTs1, 2 
and 3, respectively) is phosphorylated by PDK1, while the hydrophobic 
motif serine (S473, S474 and S472) is phosphorylated by mTORC2. 




1.2.3 AKT/PKB positively regulates cell metabolism, growth and survival 
Activated AKT transmits a pro-metabolic signal by regulating several 
steps in glucose metabolism. Importantly, AKT plays a critical step in the 
insulin-dependent internalization of glucose by the glucose transporter 
GLUT4 [122]. Once insulin has activated PI3K, AKT phosphorylates the AKT 
Substrate of 160 kDa (AS160), which is a RAB GTPase-activating protein 
(RabGAP) [123] that is required for the translocation of GLUT4 to the cell 
membrane, where it facilitates glucose uptake into the cell [124]. AKT also 
regulates glycogen metabolism by phosphorylating and inhibiting the 
glycogen synthase kinase 3 (GSK3) [125-126]. By inhibiting GSK3—which 
itself inhibits glycogen synthase—AKT upregulates the incorporation of 
glucose into glycogen. 
AKT also negatively regulates apoptosis to encourage cell survival. 
This is thought to primarily occur through the Forkhead family of transcription 
factors, particularly FOXO1 and FOXO3a (referred to here collectively as 
FOXO) [127]. FOXO is a transcription factor that activates the expression of 
apoptotic proteins like BIM-1, bNIP3, Bcl-6, FasL, and TRAIL [128-129]. AKT 
directly phosphorylates FOXO at threonine 24 (T24), serine 256 (S256) and 
serine 319 (S319) which prevents FOXO from entering the nucleus and 
regulating gene expression. Thus, the phosphorylation of FOXO by AKT 
sequesters FOXO in the cytosol, which inhibits the expression of members 
of the apoptotic machinery. Further, AKT can regulate the apoptotic 
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machinery more directly by phosphorylating targets like Bad, which  AKT 
phosphorylates to inhibit the apoptotic functions of Bad [130-131]. 
The discovery and elucidation of the mechanistic target of rapamycin 
(mTOR) signal transduction network has revealed several mechanisms 
through which AKT regulates cell growth and protein synthesis. Briefly, AKT 
negatively regulates two inhibitors of mTOR signaling, which upregulate 
ribosome biogenesis, protein synthesis, and the accumulation of cell mass. 
These mechanisms will be reviewed in the section below that discusses 
mTORC1 signaling.  
In addition to AKT, other members of the AGC kinase family regulate 
survival signaling in a PI3K-dependent manner. This is not surprising 
considering that AGC kinases share a remarkable amount of overlapping 
characteristics in terms of protein structure [132-133]. One prominent 
example of a kinase with a similar signaling role to AKT is the serum and 
glucocorticoid-induced kinase 1 (SGK1) [134]. Interestingly, SGK1 can 
phosphorylate AKT substrates like FOXO1/3A [135]. Further, recent 
evidence suggests that SGK1 might take over the PI3K-dependent survival 
that is usually regulated by AKT in certain tumors and cell lines [136]. The 
reason for this shift in signaling is unclear, but it highlights the fact that 
tumors with activated PI3K may not all respond equally to small molecules 




1.2.4 The mechanistic target of rapamycin (mTOR) is a master regulator of 
cell growth that is downstream of PI3K/AKT 
One of the more recently well studied members of PI3K/AKT signaling 
is the mechanistic target of rapamycin (mTOR).  Rapamycin is a small 
molecule (~900 Da) product of Streptomyces hygroscopicus that was 
discovered from soil samples collected on Rapa Nui (Easter Island) [137-
140]. The molecular mechanism of rapamycin was initially unclear, but early 
studies demonstrated that rapamycin blocks the activation of T and B cells 
by interleukin-2 (IL-2) [140-141]. Thus, even before the target of rapamycin 
was known, it was appreciated that rapamycin could function as a potent 
immunosuppressant. 
The precise molecular target was elusive until genetic experiments in 
yeast and affinity purification approaches in mammalian cells identified the 
kinase mTOR (TOR in yeast) as the binding partner of rapamycin when 
rapamycin is bound to the prolyl-isomerase FK506 binding protein, 12 kDa 
(FKBP12) [142-146]. mTOR is a large (~289 kDa) protein kinase that is very 
similar to the yeast proteins TOR1 (42% homology) and TOR2 (39% 
homology), which were identified as the yeast targets of rapamycin prior to 
the identification of mammalian mTOR [147]. The mTOR protein shares a 
large degree of homology to PI3K family members, and is the founding 
member of the phosphatidylinositol kinase-like kinase (PIKK) family [148]. 
Indeed, it was originally thought to phosphorylate phospholipids at the 4’-OH 
group of the inositol ring [149-150]. Despite its amino acid sequence 
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similarity to PI-kinases, mTOR is indeed a serine/threonine kinase [151]. The 
most well characterized effectors of mTOR are the protein kinase ribosomal 
S6 kinase1/2 (S6K1 and S6K2), and the translation initiation inhibitor 4E-
BP1.  
 
1.2.5 mTOR Complex 1 (mTORC1) is a nutrient and growth factor sensitive 
protein kinase that regulates cell size and cell growth through S6K1 
and 4EBP1 
For some time after the discovery of mTOR, it was apparent that 
mTOR phosphorylation of S6K1/2 is regulated by growth factors, amino 
acids, and glucose. However, interacting proteins remained elusive until 
gentler purification conditions and chemical crosslinking approaches were 
used to identify the regulatory associated protein of mTOR (Raptor) [152-
153]. Together with mTOR, Raptor can be considered the founding member 
of a protein complex that is now referred to as the mammalian target of 
rapamycin complex 1 (mTORC1). mTORC1 is comprised of mTOR, Raptor, 
the G-beta like protein GβL, the proline-rich AKT substrate of 40 kDa 
(PRAS40), and the mTOR kinase inhibitor protein DEP-domain containing 
protein DEPTOR. mTORC1 is a rapamycin-sensitive complex that positively 
controls protein translation, cell size, and cell growth. mTORC1 is itself 
regulated by several inputs, such as growth factors, redox conditions within 
the cell, and glucose and amino acid availability.  
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By far, the most well understood mTORC1 substrates are the AGC 
family kinase ribosomal S6 kinase 1/2 (S6K1/2) and eIF4e-binding protein 1 
(4EBP1) [151, 154-157]. Both of these proteins are positive regulators of cell 
growth, primarily through their regulation of mRNA translation [158]. S6K1 
and S6K2 phosphorylate the ribosomal S6 protein to positively regulate 
mRNA translation [159-161]. One important consequence of activated 
S6K1/2 regulation of S6 is an increase in protein synthesis. Further, S6K-S6 
positively regulates both cellular and organismal size [158, 162-164]. In 
addition to regulating signaling to the ribosome machinery, S6K1 can 
negatively control growth factor RTK signaling in a negative feedback circuit 
that will be described below.  
mTORC1 is activated by growth factor signaling via AKT through at 
least two different mechanisms. The first of these to be described is a circuit 
where AKT signals through a GTPase activating protein (GAP) complex 
comprised of Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) [165-
166]. Phosphorylation of TSC2 by AKT destabilizes the interaction of the two 
subunits and compromises the GAP activity of TSC1/2 towards the small 
RAS-like GTPase RHEB (Ras homolog enhanced in brain) [167-172]. When 
bound to GTP and in its active state, RHEB catalytically activates the kinase 
activity of mTORC1 towards its substrates S6K1 and 4E-BP1 [173-176]. 
Thus, activated AKT phosphorylates TSC2, which inhibits the GAP activity of 
the TSC complex, which allows GTP-bound RHEB to catalytically activate 
mTORC1 signaling.  
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A second route through which AKT regulates mTORC1 is the 
mTORC1 inhibitor Proline Rich AKT Substrate, 40 kDa (PRAS40). PRAS40 
was initially identified as a component of mTORC1 that eluded detection 
because the PRAS40-mTORC1 interaction is disrupted by lysis buffers that 
contain NaCl [177-178]. Once identified, it was demonstrated that PRAS40 
binds mTORC1 via Raptor to suppress mTORC1 kinase activity both in vivo 
and in vitro. Phosphorylation of PRAS40 by AKT at threonine 246 (T246) 
destabilizes the mTORC1-PRAS40 interaction to allow for mTORC1 
activation. PRAS40 has also been described as an mTORC1 substrate [179-
180]. Activated mTORC1 phosphorylates PRAS40 at serine 183 (S183), 
which further destabilizes the ability of PRAS40 to interact with Raptor. Thus, 
mTORC1 is able to activate itself in response to growth factors via a 
mTORC1-PRAS40 feed-forward circuit.  
One of the major signaling inputs that regulate mTORC1 signaling is 
intracellular amino acids [181]. mTORC1 activity towards S6K1 and 4E-BP1 
is tightly regulated by the availability of amino acids. The past several years 
have seen a flurry of studies that describe an elegant mechanism for amino 
acid sensing by mTORC1 [182]. First, the Rag GTPases were found to be 
necessary for amino acid induced activation of mTORC1 [183]. The Rags 
exist as heterodimers (RAGA/RAGC and RAGB/RAGD) anchored on the 
surface of the lysosome by the Ragulator complex, the whole of which 
serves to localize mTORC1 to the lysosome by interacting with Raptor [184]. 
Once there, mTORC1 is in proximity to the aforementioned GTPase RHEB, 
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which then catalytically activates mTORC1. In a step that is only partially 
understood, this sensing of amino acids by the machinery upstream of 
mTORC1 relies upon a vacuolar (H+)-ATPase on the lysosome surface 
[185]. These data suggest that amino acid sensing by mTORC1 might 
actually be initiated within the lumen of the lysosome. Finally, the recently 
described GATOR complexes act as Rag GAPs to downregulate mTORC1 
signaling at the lysosome [186]. 
 
1.2.6 mTOR Complex 2 (mTORC2) is a PI3K-dependent kinase that 
regulates AKT/PKB and other AGC kinases 
One of the long-missing pieces of phosphoinositide-dependent 
signaling was the kinase that phosphorylates AKT at the hydrophobic motif—
PDK2 [132, 187-191]. Whereas PDK1 had been well documented as an 
AKT-phosphorylating, phosphoinositide-dependent kinase, PDK2 remained 
elusive for several years. In fact, it had been speculated at several points 
that PDK2 was one of any number of kinases: PDK1 [187], DNA-dependent 
protein kinase (DNA-PK) [192], integrin-linked kinase (ILK) [193-194], or 
even AKT itself [118]. 
The identity of PDK2 was clarified when it was found that mTOR—in a 
second, rapamycin-insensitive kinase complex—is the hydrophobic motif 
kinase that phosphorylates AKT at S473 [119, 195]. Examination of 
immunopurified mTOR complexes revealed the existence of a second 
mTORC (mTORC2) that is defined by the presence of the rapamycin-
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insensitive companion of mTOR, or RICTOR [196]. mTORC2 was initially 
described as the hydrophobic-motif kinase for several Protein Kinase C 
(PKC) isoforms, but was subsequently found to phosphorylate other AGC 
kinases such as AKT and serum and glucocorticoid-induced kinase 1 
(SGK1) [197]. 
Like mTORC1, mTORC2 is a protein complex of several subunits. It 
shares with mTORC1 the mTOR kinase itself and GβL (also known as 
mLST8) [198], but is distinct from mTORC1 in that it contains RICTOR 
instead of Raptor. Further, mTORC2 contains MAP kinase-associated 
protein 1 (MAPKAP1)/mammalian stress-activated protein kinase (SAPK)-
interacting protein (mSIN1), a protein that is necessary for mTORC2 stability 
and activity towards its substrates [199-201]. It has been recently 
appreciated that mSIN1 likely functions to provide substrate specificity for 
mTORC2, as it is apparently necessary for mTORC2 to interact with 
substrates like AKT and SGK1 [202-204]. mTORC2 also contains one of two 
proline-rich proteins—PRR5 and PRR5L—which are also known as Protor-1 
and Protor-2 [177, 205-206]. The physiological role of these proteins was 
initially unclear, as they are not required for mTORC2 complex stability or 
activity towards AKT [206]. Studies of Protor-1 and the similar Protor-2 have 
revealed that they can suppress apoptosis through PDGFRβ-dependent 
signaling [177, 205], and that Protor-1 is important in regulating SGK1 
function and sodium channel activation in the kidney [207].  
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Recently, mTORC2 has been found to share another component with 
mTORC1—the previously mentioned DEPTOR, which is a negative regulator 
of mTORC1 and mTORC2 kinase activity [208]. Although DEPTOR 
intrinsically inhibits mTORC2 activation, increased expression of DEPTOR in 
a cell can lead to a somewhat paradoxical increase in mTORC2 signaling, as 
the inhibition of mTORC1 triggers activation of PI3K-dependent signaling, 
which then activates mTORC2. Thus, DEPTOR could potentially be a 
context-dependent tumor suppressor or oncogene. Indeed, elevated 
expression of DEPTOR in certain forms of multiple myeloma appears to be 
required for elevated PI3K/AKT signaling and survival of these cells [208]. 
Under normal physiological conditions, DEPTOR appears to positively 
regulate adipogenesis [209].  
Although many proteins have been described as parts of both the 
mTORC1 and mTORC2 complexes, it is likely that even more binding 
partners, adapter proteins, and regulators will be described for both of these 
large signaling complexes. Interestingly, because of a complex web of 
feedback circuits within and around the PI3K/AKT/mTOR axis, the mTOR 
kinase can be considered to be both upstream and downstream of itself. 
 
1.2.7 Feedback signaling within the PI3K/AKT/mTOR pathway 
As with many biological signaling networks, there exist within the 
PI3K/AKT/mTOR axis several mechanisms for downregulation of signaling 
once it has been initiated. One of the first circuits to be appreciated was an 
22 
 
inhibitory circuit where activation of insulin signaling leads to the degradation 
of the IRS1/2 adapter subunits [210-211]. It is now understood that both 
S6K1 and mTORC1 phosphorylate IRS1/2 at several residues [212-215], 
and that—unlike tyrosine phosphorylation of IRS1/2—these phosphorylation 
events serve to destabilize the protein and facilitate its degradation by the 
 
 
Figure 1.3: mTORC1 or mTORC1/2 inhibition activate PI3K/AKT 
signaling by relieving negative feedback circuits to upstream RTK 
signaling machinery. (A) Under normal signaling conditions, RTK 
activation is inhibited by a negative regulatory circuit where S6K1 inhibits 
IRS1 stability. (B) mTORC1 inhibition prevents S6K1 phosphorylation of 
IRS1, which activates mTORC2, PI3K, and AKT. (C) ATP-competitive 
inhibitors of mTOR potently relieve the aforementioned negative 
regulatory circuits, which upregulates IRS1/RTK signaling to PI3K, and 
hyperphosphorylates AKT at T308 despite an ablation in S473 




proteasome. Thus, mTORC1 inhibition with rapamycin leads to accumulation 
of IRS1/2, activates PI3K, and leads to an increase in membrane PIP3 and 
phosphorylation of AKT at T308 and S473 (Figure 1.3). Similarly, the 
development of ATP-competitive mTOR kinase inhibitors has demonstrated 
that dual mTORC1/2 inhibition also potently de-engages the negative 
regulatory circuits between downstream and upstream signaling, despite the 
inactivation of mTORC2 by these inhibitors [208]. Thus, simultaneous 
inhibition of mTORC1/2 can potently hyperactivate PI3K activity and AKT 
T308 phosphorylation, thus upregulating AKT.  
Phosphoproteomic approaches have recently uncovered yet another 
feedback inhibitory mechanism between mTORC1 and the upstream growth 
factor machinery. The recently described mTORC1 substrate GRB10 serves 
to inhibit insulin and IGF-I signaling under normal conditions, but this effect is 
blunted when mTORC1 is inhibited with rapamycin or ATP-competitive 
inhibitors like Torin1 [216-218]. Further, GRB10 is downregulated in some 
tumors [218], which suggests that these patients may respond better to 
therapies that utilize PI3K inhibitors, rather than ones that rely on mTOR 
inhibitors. 
These feedback circuits are likely to have consequences for the 
efficacy of small molecule inhibitors in the clinic. Indeed, 
immunohistochemistry from tumors of rapamycin treated patients has 
demonstrated that rapamycin can potently upregulate AKT phosphorylation 
in vivo [219-220]. Thus, while certain tumors—for examples, cancers with 
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activating mTOR mutations or inactivating TSC1/2 mutations—may respond 
ideally to mTOR inhibitors, great caution should be exercised in determining 
which patients would respond best to these therapies [221-222]. 
 
1.3 THE PI3K/AKT SIGNALING AXIS IS FREQUENTLY ALTERED IN 
HUMAN CANCERS 
A number of dysregulations in regular cellular physiology are 
necessary in the course of tumorigenesis [223]. For example, cells typically 
respond to a number of cues that encourage regular apoptosis, restrict 
inappropriate growth, maintain genomic integrity, and keep interactions with 
surrounding cells physiologically regular. However, in deregulating one or 
several of these characteristics—typically by genetic or epigenetic 
mechanisms—cancer cells can escape the normal life and fate of regular 
cells and become “masters of their own destinies” [223]. Given the central 
role of PI3K/AKT signaling in regular cellular and organismal physiology, it is 
unsurprising that a variety of mutations within this pathway are found in 
human tumors.  
It is now appreciated that direct gain-of-function mutations in 
PIK3CA—such as mutations that code for amino acid changes E545K and 
H1047R in the p110α protein, among others—are found relatively frequently 
in certain tumor types [31, 224]. Indeed, mutations such as these activate 
the inherent kinase activity of p110α, which activates downstream kinases 
like AKT and mTOR. Further, mutations in the regulatory p85 subunit of PI3K 
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can serve to activate the pathway in tumors [225-227]. The oncogenicitiy of 
certain hotspot mutations make possible the specific targeting of mutant 
PI3K proteins with small molecule inhibitors [228]. This work is in relatively 
early stages, but could be a promising way to target PI3K/AKT signaling in 
patients.  
The most commonly mutated and well understood tumor suppressor 
within the PI3K pathway is the lipid phosphatase PTEN. As described above, 
PTEN is a lipid phosphatase that plays a critical role in downregulating 
PI3K/AKT signaling by dephosphorylating the 3’-OH of PIP3. Loss of PTEN 
function can occur in tumors a number of ways—methylation of the PTEN 
promoter can silence PTEN mRNA expression [229], missense or nonsense 
mutations can lead to loss-of-function mutant proteins [230-231], and 
heterozygous or homozygous deletions of PTEN can give cells a selective 
growth advantage [52, 232]. Strikingly, depending on the cancer type, loss of 
PTEN function can be found in up to 40-80% of tumors. Further, conditional 
knockout studies in the mouse have confirmed that PTEN loss is sufficient to 
drive tumorigenesis in the prostate and other tissues [233]. Interestingly, 
even haploinsufficiency of PTEN in some systems is sufficient to dysregulate 
PI3K/AKT signaling and drive tumor growth [234]. PTEN loss poses a 
significant challenge in the clinic because reconstituting the lost function of a 
tumor suppressor within diseased cells is far less straightforward than 
drugging an oncoprotein that is a kinase or transcription factor. However, the 
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recent description of a soluble PTEN protein that is excreted by cells may 
suggest interesting therapeutic approaches available in the future [235]. 
In addition to mutations in PIK3CA and PTEN, mutations in the 
receptor tyrosine kinases upstream of PIP3 generation are able to potently 
activate PI3K signaling and drive tumorigenesis. The most commonly 
deranged RTK is EGFR, which is found amplified or mutated in a variety of 
tumors, most typically in various subtypes of lung and brain tumors [225]. 
Copy number amplification of the EGFR gene is sufficient to drive oncogenic 
signaling [236], and oncogenic mutations in the EGFR gene can arise in the 
kinase domain itself, the extracellular domain of the receptor [237], or by 
heterozygous deletion of an autoinhibitory domain of the kinase (the so-
called EGFRviii variant) [238-239]. Indeed, these alterations—copy number 
gain, activating point mutations, and deletion of inhibitory domains—are 
themes that are repeated with other receptor tyrosine kinases in various 
tumors (c-Kit, c-Met, PDGFR, etc.). 
Finally, several kinases downstream of PIP3 generation can activate 
tumorigenic signaling as well. Mutations in AKT1 have recently been 
described, where an E17K mutation in the PH domain results in an 
increased affinity for the phospholipid membrane, thus localizing AKT to the 
membrane even in the absence of accumulated PIP3 [240-243]. Although 
once thought rare, the E17K AKT1 mutation is now found relatively regularly 
in multiple tumor types. Downstream of AKT, mutations in MTOR have 
recently been identified in tumor samples that confer increased kinase 
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activity to mTORC1 and in some cases mTORC2 [244][245]. Interestingly, 
many of these MTOR mutants render mTORC1 signaling exquisitely 
sensitive to rapamycin, which suggests that tumors harboring these 
mutations may be ideal candidates for mTOR inhibitor-based therapies.  
 
1.4  TARGETING THE PI3K/AKT PATHWAY IN HUMAN CANCERS 
1.4.1 From chemotherapy to targeted therapy 
The elucidation of the various genetic derangements within growth 
regulating pathways that can drive tumorigenesis has led to the development 
of therapies that can specifically target the causative lesion in a tumor [246]. 
The prospect of identifying the genetic lesions of an individual’s tumor and 
then drugging those lesions has offered a welcome alternative to traditional 
radiation- and chemotherapy-based treatments for cancer. Rather than 
targeting all growing cells, targeted inhibition of the oncoprotein(s) that drive 
the growth of a tumor could ostensibly provide greatly diminished toxicity and 
better clinical responses. Indeed, some of the first targeted therapies—
Gleevec® (imatinib) for chronic myelogenous leukemia (CML) and 
Herceptin® (trastuzumab) for ERBB2-driven breast cancers—have proved 
themselves to be superior to the previous therapies for those tumors. 
However, the hope of targeted therapies has been tempered by the 
emergence of many mechanisms of resistance. A more complete 
understanding of the complex balance of survival signal transduction within 
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the cell (and the mutations that alter these pathways) would greatly improve 
the design and deployment of targeted therapies for cancer. 
 
1.4.2 Strategies for targeting tyrosine kinases 
As mentioned above, the development of kinase inhibitors like 
Imatinib demonstrated the possibility that small molecules targeting specific 
signaling proteins could be effectively deployed in the clinic. In the clinic, the 
most successful type of small molecule kinase inhibitor for cancer therapy 
have been tyrosine kinase inhibitors. Although it was originally developed to 
target the BCR-ABL fusion protein, imatinib is also useful for targeting 
tumors with other activated tyrosine kinases such as PDGFR. Further, 
several imatinib derivatives—like dasatinib, nilotinib and bosutinib—have 
been developed to counter the different imatinib-resistant mutations that 
arise in BCR-ABL [247-249]. 
Beyond BCR-ABL, several tyrosine kinase inhibitors have also found 
some success in the clinic. The first of these was monoclonal antibody—
trastuzumab—that targets the human epidermal growth factor receptor 2 
(HER-2) [250-251]. Trastuzumab was approved by the FDA for use against 
breast cancer in 1998, and has also found use as a treatment for some types 
of gastric tumors [252-253]. Other antibodies that target HER-2 or EGFR, 
like pertuzumab [254], cetuximab [255], and panitumumab [256] are also 
FDA approved, mostly for use in different types of HER-2 or EGFR-positive 
breast cancers. EGFR and HER-2 are also targeted by a number of small 
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molecule inhibitors such as lapatinib [257], erlotinib [258] and gefitinib [259]. 
These molecules are typically deployed against various breast tumors, non-
small cell lung cancers, or pancreatic tumors.  
 
1.4.3 PI3K inhibitors 
Considering the central role that PI3Ks play in survival signaling, it is 
unsurprising that many inhibitors targeting PI3K isoforms are in either 
preclinical or clinical development [260]. Many groups and private 
companies have developed isoform-specific inhibitors for p110α [261], 
p110β [262]. Further, a potentially attractive method for specifically targeting 
the aberrant PI3K signaling within tumors that harbor activating PIK3CA 
mutations is the use of mutant-specific small molecule inhibitors [228]. These 
inhibitors are, however, in their early stages of development and it remains 
unclear how clinically useful they will prove.   
PI3K inhibitors have great potential as anti-tumor tools in the clinic 
[263]. However, that they have yet to gain FDA approval suggests that more 
effort must be put into properly identifying which patients are most likely to 
respond favorably to treatment with PI3K inhibitors.  For example, while 
patients with activating EGFR or PIK3CA mutations may both have 
hyperactive PI3K/AKT signaling, PI3K blockade would likely be most 
advantageous to the patient with the PIK3CA mutant tumor. Since not all 
clinical trials evaluating PI3K inhibitors have triaged patients based on the 
mutational status of the genes in the PI3K/AKT pathway, it is quite possible 
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that the antitumor benefits of several of these molecules has been masked 
by tumors predestined by their genotypes to be refractory to PI3K inhibition.  
 
1.4.4 Serine/threonine kinase inhibitors: targeting AKT and mTOR 
Because the genetic lesions that drive tumors can occur at multiple 
points within a given pathway, it may not always be advantageous or even 
useful to target upstream regulators like RTKs and PI3Ks. For example, 
some tumors are likely driven by mutations in AKT or MTOR, and thus 
inhibiting PI3K signaling would pose little to no benefit. Indeed, several 
groups have described both ATP-competitive and allosteric inhibitors of 
AKT1-3 [264-267]. These inhibitors have either shown little advantage over 
current therapies in the clinic—like perifosine [268]—or are in very early 
stages of clinical evaluation [269]. However, AKT inhibitors could be very 
advantageous for patients with tumors driven by oncogenic AKT mutations.  
As mentioned above, the mTOR inhibitor rapamycin has been 
deployed in the clinic as an immunosuppressant, an anti-restenotic agent, 
and most recently as an anti-tumor agent. Although rapamycin and its 
“rapalogue” derivatives have been clinically evaluated for activity against a 
variety of tumors, mTORC1 inhibitors like CCI-779 (temsirolimus) were first 
FDA approved for the treatment of renal cell carcinoma [270-271]. 
Subsequent studies have led to approval in breast cancer in combination 
with hormone therapy [272-275]. As is the case for the other small molecule 
inhibitors discussed above, it is likely that clinical trials that specifically target 
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patients based on which genetic lesions are present in their tumors (e.g. 
activating MTOR mutations or inactivating TSC1/TSC2 mutations) will be 
useful in identifying which patient populations would benefit most from 
molecules that inhibit mTOR. 
 
1.4.5 The promises and risks of targeted therapies 
The successes of targeted therapies like Gleevec® and Herceptin has 
often been heralded as a harbinger of a new era of “personalized medicine” 
driven by targeted therapies [276-277]. It should be kept in mind that despite 
the early successes of drugs like BCR-ABL inhibitors (Gleevec, etc.) in 
treating CML, most cancers are dauntingly complex in the number of genetic 
lesions that may drive a tumor. Much of the success of BCR-ABL inhibitors is 
likely due to the fact that oncogenesis in CML is driven primarily by the BCR-
ABL fusion protein. In contrast, tumorigenesis in solid tumors and non-CML 
liquid tumors is typically driven by a number of genetic lesions [223]. 
The development of resistance to targeted therapies by tumors is a 
complex challenge. For example, CML often develops resistance to BCR-
ABL inhibitors through mutations within or near the ATP-binding pocket of 
the kinase domain [276, 278-280]. Similarly, EGFR and ERBB2-driven 
tumors can easily develop resistant kinase mutations in response to 
treatment with inhibitors like erlotinib or lapatinib [278].  Beyond mutations in 
the targeted signaling molecule, resistance to EGFR inhibitors can arise from 
compensatory upregulation of ERK/MAPK signaling [281] or downregulation 
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of NF-ΚB signaling [282]. Finally, as mentioned above, mTORC1 inhibition in 
the clinic should be pursued with caution, as it is likely that the anti-growth 
properties of rapamycin are blunted by the fact that mTORC1 inhibitors 
activate PI3K/AKT [219-220].  
It is tempting to wish that the success of drugs like Gleevec® could be 
generalizable to other tumor types. Unfortunately, the signal transduction 
pathways that regulate tumorigenesis are complex, as is the scope of the 
genomic alterations that activate these pathways. Thus, the emphasis of the 
cancer research community should be focused on the discovery of as many 
regulatory steps, circuits and nodes as possible. This would allow for the 
design of multitudes of specific inhibitors that could be used to tailor targeted 
therapies to each individual tumor with an eye towards circumventing 
resistance to targeted therapies.  
 
1.5  RNAi SCREENS TO IDENTIFY NOVEL COMPONENTS OF 
ONCOGENIC SIGNALING 
1.5.1 RNA interference (RNAi) as a loss-of-function tool to study gene 
function 
RNA interference (RNAi) is a relatively new technology in the toolkit of 
the modern molecular biologist that takes advantage of an evolutionary 
conserved mechanism of the regulation of mRNA through the micro RNA 
(miRNA) pathway [283-286]. miRNAs are small (22 nt), non-coding RNAs 
that are endogenous to the cell that serve to regulate the abundance and 
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translation of mRNA transcripts that code for genes [286-288]. When bound 
to their target mRNAs, miRNAs down-regulates translation of the mRNA by 
one of two mechanisms: 1.) blocking the ribosome from translating the 
mRNA, or 2.) facilitating degradation of the mRNA by the RNA-induced 
silencing complex (RISC). 
The mechanism for RNAi-mediated gene silencing is similar to the 
miRNA pathway with the exception that RNAi is not an endogenous process. 
Rather, it simply takes advantage of the miRNA machinery that exists within 
the cell. Indeed, RNAi has been tremendously advantageous to investigators 
of biology because it provides a relatively easy—albeit imperfect—method of 
silencing the mRNA transcript of a gene of interest, thus allowing for loss-of-
function studies of proteins. Further, in contrast to miRNAs, RNAi reagents 
are most always perfectly complementary to their target transcripts, which 
facilitate destruction of targeted mRNA. 
There are many methods of delivering RNAi reagents to mammalian 
cells. For example, small interfering RNAs (siRNAs) can be readily 
transfected into some cell types. However, this method can induce unwanted 
toxicity to the transfected cells [3]. To remedy the issues of transient 
transfection and transfection toxicity associated with siRNA delivery, several 
groups designed retroviral or lentiviral approaches to facilitate RNAi studies 
[289-294]. Although these methods differ in some regards, they are similar in 
that 1.) they rely upon viral delivery of DNA that stably integrates into the 
host cell’s genome, 2.) stable expression of miRNA-like RNAs or short 
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hairpin RNAs (shRNAs) is achieved from the integrated DNA, and 3.) 
suppression of the targeted mRNA transcript can be achieved for longer 
periods than with siRNA-based approaches.  
Not long after the initial characterization of mammalian and 
Drosophila RNAi, several groups undertook efforts to generate large scale 
RNAi libraries to facilitate loss-of-function genetic screens [289, 295-308]. 
The most prevalent deployment of these RNAi libraries has been in pooled 
screens, where each shRNA reagent is administered to a population of cells 
at a multiplicity of infection (MOI) of <1 [282, 305]. Although well suited for 
high-throughput RNAi, pooled screens are limited by the fact that their 
readouts rely on the measurement of shRNA or shRNA barcode abundance 
within the pool. Hairpin abundance is itself an ersatz readout of the viability 
of a cell population that has been transduced with an individual shRNA 
reagent. Thus, this approach has been useful in identifying genes that confer 
drug resistance [282, 305] or in performing in vivo loss-of-function screens 
[306, 309-312].  
Although non-pooled, arrayed shRNA screens were described before 
pooled approaches were refined, the number of arrayed screens that have 
successfully identified novel biology is relatively limited. Arrayed screens are 
less technically straightforward than pooled RNAi screens in that they 
require resources like plate handling robots and high throughput, often high-
content microscopy. However, arrayed screens do not require the 
deconvolution that is inherent to pooled screening. Further, arrayed formats 
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allow for more biologically interesting assays than pooled screens. For 
instance, an arrayed RNAi screen can be used to assay the activity of 
signaling pathways. Indeed, several groups have used this approach to 
successfully identify novel components of Ras/ERK signaling in Drosophila 
[298, 313-314] and new regulators of cell division and histone 
phosphorylation [302-303]. Thus, arrayed screens are useful tools for 
probing signal transduction in ways that pooled approaches are not. 
 
1.5.2 RNAi screens to identify novel oncogenic regulators of PI3K/AKT 
signaling 
Although discovery of new components of signal transduction 
pathways can be achieved a number of ways—through proteomics, small 
molecule inhibitor screens, cDNA microarray studies—we reasoned that a 
loss-of-function RNAi screen could be a potent tool if combined with a robust 
signaling assay. We were fortunate that the Broad Institute RNAi Consortium 
(TRC) platform has undertaken a long-term effort to design, synthesize, and 
make available lentivirus-delivered shRNAs targeting every known human 
and mouse gene [302-303, 315]. This collection provides an impressive 
amount of coverage in that a minimum of 5 shRNAs are provided for gene, 
and many genes are targeted by 10-20 different, non-overlapping shRNA 
reagents. In addition to a library of shRNA reagents, the TRC has performed 
extensive validation with quantitative reverse-transcription PCR (qRT-PCR) 
to validate which hairpins succeed in depleting their target mRNAs. 
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While the biochemistry and genetics of PI3K/AKT signaling are both 
very well studied, we theorized that there are likely a number of 
unappreciated proteins that regulate this pathway. Our rationale was that 
while most tumors likely upregulate PI3K/AKT in some way, not all tumors in 
queried oncogenomic databases display obvious lesions in the genes within 
this signaling axis. Although the assumption of PI3K upregulation in all 
tumors is not a certain one, we reasoned that tumors with no obvious 
RTK/PI3K/PTEN/AKT/MTOR pathway lesions must be activating PI3K/AKT 
signaling via genes that regulate—but are currently not understood to be 
involved in—this pathway.   
This thesis details a set of RNAi screens that we performed at the 
Broad Institute to identify novel regulators of PI3K/AKT signaling. Our goal 
was to identify novel proteins that regulate the PI3K/AKT pathway, then to 
interrogate the mutational status of these genes in oncogenomic databases. 
We suggest that this approach—targeted loss-of-function screening whose 
results are prioritized by utilizing oncogenomic data—is a useful tactic to 





CHAPTER TWO:  
AN RNAi SCREEN IDENTIFIES THE SMALL GTPASE RAB35 AS A 
NOVEL ONCOGENIC REGULATOR OF PI3K/AKT SIGNALING 
 
2.1  ABSTRACT 
In an RNAi screen for genes that affect AKT phosphorylation, we 
identified the RAB35 small GTPase—a protein previously implicated in 
endomembrane trafficking—as a new regulator of the PI3K pathway. Depletion 
of RAB35 in human and mouse cells suppresses AKT phosphorylation in 
response to growth factors, whereas expression of a GTPase-deficient mutant 
of RAB35 constitutively activates the PI3K/AKT pathway. RAB35 functions 
downstream of growth factor receptors and upstream of PDK1 and mTORC2, 
two established regulators of AKT, and interacts with PI3K. We identified two 
RAB35 mutations in human tumors that activate PI3K/AKT signaling, suppress 
apoptosis, and transform cells in a PI3K-dependent manner. Thus, we identify 
RAB35 as a proto-oncogene that is both necessary and sufficient for activating 
PI3K/AKT signaling. That a RAB GTPase can activate PI3K/AKT signaling and 
transform cells suggests that there may be latent oncogenic potential in 







2.2 INTRODUCTION  
The phosphatidylinositol 3’-OH kinase alpha (PI3Kα) is a lipid kinase 
and a key regulator of cell survival, proliferation and growth that is commonly 
activated in human cancers [316-317]. PI3Kα is comprised of a 110 kDa 
catalytic subunit (p110α) and an 85 kDa adapter subunit (p85) that links 
PI3Kα to activated growth factor receptor tyrosine kinases (RTKs) [318]. At 
the cell membrane, PI3Kα phosphorylates the membrane lipid 
phosphatidylinositol (4, 5)-bisphosphate (PIP2) to form the second 
messenger phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3), which then 
recruits a number of effectors to the lipid membrane. Key among these is the 
serine/threonine kinase AKT, which regulates an array of cellular processes 
such as glucose transport, the cell cycle, and anti-apoptotic signaling [133]. 
Activating mutations in oncogenes (PIK3CA, EGFR, AKT1) or loss-of-
function alterations in tumor suppressors (PTEN) have been well 
characterized for their ability to drive tumorigenesis in a PI3K-dependent 
fashion [225]. Thus, the components of this pathway are attractive targets for 
cancer therapy, and many small molecules that target components of the 
PI3K/AKT pathway are either currently deployed in the clinic or in clinical 
trials [263, 319].  
To identify new regulators of the PI3K/AKT pathway, we performed a 
loss-of-function RNA interference (RNAi) screen using lentiviruses that 
express short hairpin RNAs (shRNAs) [303]. We reasoned that the proteins 
most likely to be regulators of PI3K/AKT signaling would be GTPases and 
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kinases, so we limited the screen to shRNAs targeting genes coding for all 
known G-proteins and lipid/protein kinases. Because AKT phosphorylation is 
a faithful indicator of PI3K activity, we used an immunofluourescent 
approach to quantitatively measure phosphorylation of AKT at serine 473 
(S473) in screened HeLa cells. Therefore, we screened a collection of 7,450 
shRNAs in an arrayed format to identify kinases or GTPases whose 
depletion could alter PI3K-dependent AKT phosphorylation. 
 
2.3  METHODS AND MATERIALS 
2.3.1  Cell lines and tissue culture 
The following cell lines were obtained from American Type Culture 
Collection (ATCC): 22Rv1 (CRL-2505), 786-O kidney adenocarcinoma 
(CRL-1932), ACHN kidney adenocarcinoma (CRL-1611), HeLa cervical 
adenocarcinoma cells (CCL-2), Caki-2 renal adenocarcinoma (HTB-47), HT-
29 colon adenocarcinoma (HTB-38), NIH-3T3 murine fibroblasts (CRL-
1658), PC3 prostate adenocarcinoma (CRL-1435), SK-CO-1 colorectal 
adenocarcinoma (HTB-39), and SW620 colorectal adenocarcinoma (CCL-
227). SN12C kidney carcinoma cells were obtained from the Developmental 
Therapeutics Program, NCI/NIH. HEK-293E cells were a generous gift to the 
Sabatini lab from Dr. John Blenis (Harvard Medical School). All human cells 
were cultured at 37° C (5% CO2) in high-glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
penicillin-streptomycin and glutamate. NIH-3T3 murine fibroblasts were 
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cultured in DMEM with 10% bovine calf serum (BCS) from Colorado Serum 
Company. All cells were passaged every 3 days as previously described 
[208].  
 
2.3.2  Antibodies 
The goat anti-RICTOR S-20 antibody was from Santa-Cruz 
Biotechnology (sc-50678), the anti-p85 antibody was from Millipore (04-196), 
the anti-FLAG M2 antibody was from Sigma-Aldrich (F1804), and the anti-
RAB35 antibody was from Proteintech (11329-2-AP). All other antibodies 
were from Cell Signaling Technologies: anti-phospho S473 AKT (4060), anti-
phospho T308 AKT (2965), anti-total pan AKT (2920), anti-phospho T346 
NDRG1 (5482), anti-phospho T24/32 FOXO1/3A (9464), anti-RICTOR 
(2140), anti-mTOR (2998), anti-p110α (4249), anti-p85 (4257), anti-PARP 
(9532), anti-cleaved Caspase 3 (9664), and anti-HA (3724). Secondary 
antibodies used for quantitative immunoblotting were obtained from LiCor 
Biosciences: IRDye 800CW goat anti-rabbit IgG (926-32211), IRDye 800CW 
goat anti-mouse IgG (926-32210), IRDye 680RD goat anti-mouse (926-
68170). 
 
2.3.3  Chemicals, ligands and small molecules 
Insulin (I9278) and polybrene (AL-118) were purchased from Sigma-
Aldrich. Dimethylsulfoxide (DMSO, BP231-4) was purchased from Fisher 
Scientific. Puromycin (ant-pr-1) and Hygromycin B (ant-hm-1) were from 
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InvivoGen. Epidermal Growth Factor (EGF, AF-100-15), Platelet Derived 
Growth Factor AA (PDGF-AA, 100-13A), Insulin-like Growth Factor I (IGF-I, 
100-11) and Vascular Endothelial Growth Factor (VEGF, 100-20) were 
purchased from Peprotech. Torin1 (S2827), rapamycin (S1039), PIK-90 
(S1187) and GDC-0941 (S1065) were all purchased from Sellekchem. Each 
drug was resuspended to 10 mM in DMSO, aliquoted and stored at -20° C 
until use. 100% Triton TX-100 was purchased from Roche (11 332 481 001). 
 
2.3.4  RNAi screens 
High-throughput lentiviral-short hairpin RNA (shRNA) screens were 
performed at The RNAi Consortium (TRC) at the Broad Institute as 
previously described [303]. The shRNA library screened contained shRNAs 
targeting control genes (LUC, GFP, RFP and LACZ), and between 5-15 
individual shRNAs targeting each human kinase or GTPase for a total of 
7,774 shRNAs targeting 1,012 genes (Table 1). 1 day before infection, 300 
HeLa cells were seeded in each well of glass bottomed 384-well plates 
(Costar 9120) in 50 µL of regular DMEM. 24 hours later, the medium was 
removed and replaced with 50 µL DMEM containing 8 µg/mL polybrene. 1 
hour later, 1µL of viral supernatant containing one individual shRNA-
expressing lentivirus was aliquoted into each well, and the plates were 
incubated at 37° C. Each individual plate was performed in triplicate, and 
each plate contained 15-20 control hairpins (shLUC, shGFP, shRFP, 
shLACZ) distributed throughout each plate, 2 shRAPTOR_65 and 2 
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shRICTOR_25 control hairpins, 4 or more empty wells as selection controls 
and ~350 shRNA reagents targeting human kinases or GTPases. 24h later, 
the media in each well was gently aspirated and replaced with DMEM 
supplemented with 1 µg/mL puromycin. Screen plates were incubated at 37° 
C for 3 days, treated for 15 minutes with DMEM containing 100 ng/mL 
insulin, then immediately processed for immunofluorescence. 
 
2.3.5  Immunofluorescence for RNAi screens 
After treatment with insulin, plate media was aspirated, and the cells 
were fixed for 15 min. at room temperature with 50 µL 4% 
paraformaldehyde. Plates were then washed with PBS 3 times, then 
permeabilized with 50 µL 0.1% Triton X-100 in PBS for 15 min, and washed 
once again with PBS 3 times. The last rinse was aspirated, and 12.5 µL of 
anti-phospho-S473 AKT antibody mix was added to each well (Cell Signaling 
Technology #4060, diluted 1:100 in 0.1% TX-100 PBS). Plates were briefly 
centrifuged, then incubated overnight at 4° C. The next day, primary 
antibody buffer was aspirated, the plates were washed 3 times with PBS, 
and the plates were then incubated at room temperature for 2 hours with a 
secondary immunofluorescence cocktail of goat anti-rabbit 800 nm antibody 
(1:1000) and Sapphire 700 nm whole cell stain (LiCor 928-40022 , 1:1000) in 
0.1% TX-100 PBS. Finally, secondary reagents were aspirated, the wells 
were washed 3 times with PBS, and each well was filled with 50 µL PBS 
after the final wash. Plates were then imaged at 700 nm and 800 nm 
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wavelengths using a LiCor Odyssey near-infrared scanner and LiCor 
Odyssey software. For each well, the integrated signal intensity in the 700 
nm (nuclear and whole-cell stain) and 800 nm (phospho-S473 AKT) 
channels were quantified using the LiCor Odyssey software, and a 
normalized phospho-AKT signal of each well was calculated by dividing the 
signal value for the 800 nm channel by that of the 700 nm channel. These 
values were then used to calculate Z-scores for each well within its plate as 
compared to control shRNA reagents.  
 
2.3.6  Phospho-AKT and viability Z-score calculation  
In order to compare phospho-AKT levels between different plates, we 
converted the normalized phospho-AKT from each well to a Z-score [320] 
with the formula z = (x - µ)/σ (x, normalized phospho-AKT signal for a well; µ 
and σ, mean and standard deviation (respectively) of the normalized 
phospho-AKT values for all shLUC, shRFP, shGFP and shLACZ shRNAs in 
an individual plate). Once normalized, we averaged the values of each well 
for replicate plates to generate a mean phospho-AKT Z-score for every 
screened shRNA reagent. The same calculation was used to score 
viability/cell count for each well using the 700 nm whole-cell stain values. 
Viability and phospho-AKT Z-scores for each screened shRNA are listed in 





2.3.7  RNAi screen data analysis and hit selection  
After generating averaged phospho-AKT Z-scores for each hairpin as 
described above, we ranked our entire dataset from smallest to largest 
average phospho-AKT Z-score. We chose -1.50 and +1.50 as cutoff points 
to call shRNAs as hits, thus we discarded from this list any shRNA reagents 
with a phospho-AKT Z-score greater than -1.50 and less than +1.50. We 
chose to impose a 40% shRNA hit-rate requirement for each gene. Thus, for 
a gene represented by 5 hairpins, 2 of those average hairpins must return 
phospho-AKT Z-scores below -1.50 or above +1.50 to be considered a hit. 
Similarly, genes with 10 screened hairpins must return 4 shRNAs as hits. 
shRNAs were only considered for our 40% hit-rate if they scored in the same 
direction. Further, to exclude shRNAs that induced undue toxicity, we 
excluded shRNAs that caused a decrease of -6.0 or greater in the viability Z-
score. Thus, our primary hit list was comprised of shRNAs that were both 
non toxic and scored as hits at a rate of 40% or greater per gene, which are 
listed in Appendix B. We next used quantitative RT-PCR data generated by 
The RNAi Consortium to further curate our hits. A secondary hit-list was 
generated by removing any shRNA that failed to knock down its target 
mRNA by more than 50%. Genes that retained a 40% shRNA hit-rate after 
this step are listed as secondary hits in supplemental Table 3. We next 
excluded from our hits any gene that has been linked to PI3K/AKT signaling 
in the literature. This was accomplished by searching NCBI PubMed for PI3K 
or AKT and the name of each gene. For example, a PubMed search for 
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“AKT and RAB35” returns no publications and RAB35 would therefore be 
retained in our tertiary list of hits. Genes with no prior link to PI3K/AKT 
signaling thus comprised our tertiary list of hits and are reported in Table 4. 
Finally, tertiary hits were curated for alterations in human tumors and cancer 
cell lines as described in the next section.  
 
2.3.8 Identification of hit gene mutations and genomic alterations in human 
cancers 
To identify genes with mutations or alterations in human cancers we 
utilized the MSKCC cBio genomics portal (http://www.cbioportal.org/public-
portal) [321-322], the Sanger Catalog of Somatic Mutations in Cancer 
(COSMIC) (http://cancer.sanger.ac.uk/cancergenome/projects/COSMIC/) 
[323-326], and the Broad Institute/Novartis Cancer Cell Line Encyclopedia 
(CCLE) (http://www.broadinstitute.org/ccle/home) [327-329]. To identify hit 
genes mutated in cancers within these databases, we considered 
meaningful mutations to be either 1.) recurrent mutations, or 2.) mutations 
that resembled known mutations in similar genes that altered protein 
function. For example, a Q->L mutation in the catalytic domain of an 
uncharacterized hit GTPase that resembles the canonical transforming 
KRASQ61L mutation would be considered meaningful even if it was not 
recurrent. For copy number alterations, we considered genes to be altered if 
they were focally amplified or deleted. For example, a hit gene was not 
considered to be “altered” in its copy number if the deletion containing it was 
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comprised of the loss of an entire chromosome arm. We did not inspect 
genes for alterations in their mRNA expression levels. Tertiary hits that were 
found to be altered in human tumors or cancer cell lines and their respective 
alterations comprised our list of prioritized hits and are reported in Table 5. 
 
2.3.9  Cell lysis 
Cell lysis and immunoprecipitations were performed as previously 
described with some modifications [208]. All cells were rinsed once with ice-
cold PBS before lysis. Unless otherwise noted, cells were lysed with Triton 
X-100 lysis buffer (40 mM HEPES [pH 7.4], 2 mM 
ethylenediaminetetraacetic acid [EDTA], 10 mM sodium pyrophosphate, 10 
mM sodium glycerophosphate, 50 mM NaF, 150 mM NaCl, 1% Triton X-
100). 25 mL of lysis buffer was supplemented with one cOmplete EDTA-free 
protease inhibitor chip (Roche, 13971800). The lysates were incubated at 4° 
C for 15 minutes, the insoluble fraction was spun in a microcentrifuge at 
14,000 rpm for 15 minutes at 4° C, and lysates were collected. The protein 
concentrations of cell lysates were then determined using Bio-Rad Bradford 
assay reagent (500-0001) and an Eppendorf Biophotometer by reading the 
absorption of each sample at 600 nm. Lysates were then mixed with 
Laemmli’s buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 100 mM 
2-mercaptoethanol, 0.1% bromophenol blue) so that the final protein 
concentration in each sample was 1-3 µg/µL, boiled for five minutes, and 
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used for sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) as described below. 
 
2.3.10 Immunoprecipitations  
Cells were lysed in CHAPS-containing lysis buffer (40 mM HEPES 
[pH 7.4], 5 mM MgCl2, 10 mM sodium pyrophosphate, 10 mM sodium 
glycerophosphate, 50 mM NaF, 0.3% CHAPS). 25 mL of lysis buffers were 
supplemented with one EDTA-free protease inhibitor chip. Proteins were 
immunoprecipitated from 1000 µg of cell lysates with 1 µg of primary 
antibody for 2 hours or overnight at 4° C. 15 µL of a 50% slurry of Protein G-
agarose beads (Pierce) was then added to each tube, and the 
immunoprecipitations were incubated for another hour at 4° C with rotation. 
Immunoprecipitates were then centrifuged at 5,000 rpm for one minute and 
washed 3 times with CHAPS lysis buffer. On the final wash, the lysis buffer 
was aspirated completely and 15 µL 1X SDS loading buffer was added to the 
beads, which were then boiled for 5 minutes. The immunoprecipitates were 
then analyzed by SDS-PAGE as described below. 
 
2.3.11 SDS-PAGE 
10-20 µg of protein lysates or immunoprecipitates were loaded onto 4-
12% Bis-Tris gels (Novex) and resolved by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) as previously described 
[330]. Proteins were then transferred to Immobilon-FL nitrocellulose 
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membranes (0.45 µm pore size) from Millipore (IPFL00010), and then 
processed for immunoblotting.  
 
2.3.12 Immunoblotting  
All western blots were processed using the LiCor Odyssey near-
infrared system. After transferring to membranes, blots were rinsed for 1 
hour in Odyssey blocking buffer (927-40000) diluted in 50% PBS, then 
incubated with primary antibody (1:1000) in antibody incubation buffer 
(Odyssey blocking buffer, 50% PBS-T) overnight at 4° C or 2 hours at room 
temperature. Blots were then washed 3 times (5 minutes each) in PBS-T 
(Tween, 0.1%), and incubated with secondary antibodies (1:10,000, goat 
anti-rabbit or mouse conjugated to 700 nm or 800 nm IR-dye) in secondary 
antibody incubation buffer (Odyssey blocking buffer, 50% PBS-T, 0.01% 
SDS) for 1 hour at room temperature. The blots were rinsed 3 more times in 
PBS-T, rinsed with deionized H2O, washed for 5 minutes in PBS, and then 
imaged on the LiCor Odyssey near-infrared scanner (resolution 84 µm, 
intensity of 7 on both 700 and 800 nm channels). Images were saved, 
processed, and quantitated using the LiCor Odyssey software. 
 
2.3.13 Plasmids, cDNA manipulations and mutagenesis 
The following plasmids were purchased from Addgene: lentiviral 
(psPAX2) and retroviral (pUMVC) packaging plasmids (12260 and 8449, 
respectively), pVSV-G (8454), pBabe HA-PIK3CA H1047R (12524), and 
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pBabe KRAS G12V (9052). pMSCV plasmids coding for murine AKT1 
(wildtype and S473D) were generous gifts from Dr. Dos Sarbassov (M.D. 
Anderson Cancer Center, Houston TX). RAB35 was synthesized by 
Genscript (Piscataway, NJ) and subcloned into the SalI-NotI sites in the 
pLJM60 vector to generate a plasmid that would express N-terminal FLAG-
tagged RAB35 protein [208], then transformed into TOP10 E. coli cells 
(Invitrogen). Mutagenesis of pLJM60 FLAG-RAB35 and pMSCV mAkt1 
cDNAs was performed as previously described using the Stratagene 
QuickChange II XL site-directed mutagenesis kit (200521) [330]. 
 
2.3.14 Lentiviral and retroviral production 
Lentiviral particles expressing shRNA hairpins or cDNAs were 
generated as previously described using HEK-293CT cells (Clontech). 
500,000 HEK-293CT cells were seeded in 5 mL of DMEM containing 10% 
IFS and 0.1X penicillin-streptomycin in 6 cm dishes. The next day, each 
plate was transfected with 1 µg of pLKO or pLJM60 plasmid expressing the 
desired shRNA or gene, 100 ng of pVSV-G plasmid, and 900 ng of psPAX2 
packaging plasmid mixed with 6 µL FugeneHD transfection reagent 
(Promega, E2311). Retroviral particles expressing cDNAs were generated 
similarly, except that 900 ng pUMVC was used for packaging 1 µg pBabe or 
pMSCV reagents. 24 hours after transfection, the media on each plate was 
aspirated and replaced with regular DMEM supplemented with 10% FBS and 
1.1% BSA. Media containing viruses was harvested 24 and 48 hours 
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afterwards. This supernatant was then clarified of cells by filtration through a 
0.22 µm Steri-Flip filter (Millipore). Supernatants containing virus were frozen 
at -80° C until use or concentrated as described below.  
 
2.3.15 Lentivirus and Retrovirus concentration 
Because viral titers from lentiviruses and retroviruses expressing 
genes are often low, we concentrated each using Lenti-X and Retro-X 
reagents from Clontech (631231 and 631455, respectively). Briefly, viral 
supernatants were mixed 4:1 with the appropriate concentration reagent and 
incubated at 4° C overnight. The next day, virus was spun at 1,500g for 45 
minutes, and the clarified supernatant was gently aspirated. Viral pellets 
were resuspended to 1/50th their original volume in fresh DMEM (with 10% 
FBS and 1.1% BSA), aliquoted, and stored at -80° C until use. 
 
2.3.16 Lentiviral shRNA experiments 
Lentiviral transduction of cells for shRNA experiments was performed 
as previously described [119, 291, 303, 331]. Human or mouse cells were 
seeded at 50,000 cells per well in 2 mL of media in 6 well plates. The next 
day, media was removed and replaced with media containing 8 µg/mL 
polybrene. 1 mL of unconcentrated shRNA-expressing lentivirus was then 
added to each well. 24 hours later, the media and virus was removed and 
replaced with fresh medium containing 1 µg/mL puromycin. Cells were then 
cultured for 3 to 5 days, then treated as necessary and lysed.  
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2.3.17 Human and mouse stable cell line generation 
HEK-293E, HeLa and NIH-3T3 cell lines stably expressing FLAG-
RHEBwt, FLAG-RAB35wt, FLAG-RAB35Q67L, FLAG-RAB35S22N, FLAG-
RAB35A151T, FLAG-RAB35F161L, HA-p110αH1047R, mAkt1wt, mAkt1S473D, 
mAkt1T308D, or FLAG-AKT1myr were generated as previously described [332]. 
Briefly, 10,000 cells were seeded into one well of a 6-well plate in 2 mL 
media. The next day, the media in each well was supplemented with 8 
µg/mL polybrene. 1 mL of concentrated lentivirus (FLAG-RHEB or the FLAG-
RAB35 alleles) or retrovirus (HA-p110αH1047R, mAkt1wt, mAkt1S473D, 
mAkt1T308D, KRASG12V or FLAG-AKT1myr) was then added to each well. 24 
hours later, the media was aspirated and replaced with fresh media 
containing the appropriate selection reagent (1 µg/mL puromycin or 100 
ng/mL hygromycin B). Cells were grown to 80% confluence, then passaged, 
expanded further, and preserved at -80° C as frozen aliquots in media 
containing 10% DMSO and 40% serum. 
 
2.3.18 Lentiviral RNAi reagents 
We found that the shLUC_221 hairpin served as the best control 
hairpin for our experiments because it was not toxic towards cells and did 
not alter protein levels or phosphorylation under a number of different 
conditions. Thus, we used shLUC_221 as the preferred shRNA control 
hairpin for our low-throughput shRNA experiments. 
shLUC: shLUC_221: TRCN0000072246; promegaLuc_221s1c1 
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The human shRICTOR_25 and shRAPTOR_65 shRNAs used as 
control hairpins in the RNAi screen and throughout this paper can be 
obtained from Addgene (Plasmids 1853 and 1857, respectively).  
Human shRICTOR_25: Sense: 
CCGGTACTTGTGAAGAATCGTATCTTCTCGAGAAGATACGATTCTTCAC
AAGTTTTTTG 
Human shRAPTOR_65: Sense: 
CCGGAGGGCCCTGCTACTCGCTTTTCTCGAGAAAAGCGAGTAGCAGGG
CCCTTTTTTG 
TRC reagents were obtained either directly from the Broad Institute 
RNAi Consortium or ordered from Sigma-Aldrich. The TRC identifications for 
the shRNAs used here are as follows and can be used to query individual 
hairpins in The RNAi Consortium’s public data portal 
(http://www.broadinstitute.org/rnai/public/gene/search): 
The five shRAB35 reagents screened in our RNAi screen were:  
Human shRAB35_207: TRCN0000047796; NM_006861.4-207s1c1 
Human shRAB35_451: TRCN0000047793; NM_006861.4-451s1c1 
Human shRAB35_486: TRCN0000307737; NM_006861.4-486s1c1 
Human shRAB35_649: TRCN0000047794; NM_006861.4-649s1c1 
Human shRAB35_709: TRCN0000047797; NM_006861.4-709s1c1 
Additionally, we tested the following nine shRAB35 reagents that were 




Human shRAB35_207b: TRCN0000291620; NM_006861.4-207s21c1 
Human shRAB35_260: TRCN0000331177; NM_006861.4-260s21c1 
Human shRAB35_359: TRCN0000331153; NM_006861.4-359s21c1 
Human shRAB35_453: TRCN0000380080; NM_006861.4-453s21c1 
Human shRAB35_475: TRCN000038033; NM_006861.4-475s21c1 
Human shRAB35_486: TRCN0000307737; NM_006861.4-486s21c1 
Human shRAB35_537: TRCN0000297015; NM_006861.4-537s21c1 
Human shRAB35_565: TRCN0000379410; NM_006861.4-565s21c1 
Human shRAB35_601: TRCN0000380003; NM_006861.4-601s21c1 
We found that three particular shRAB35 reagents were the most 
reliable in both depleting RAB35 protein levels and suppressing AKT 
phosphorylation. The three hairpins used throughout this paper for all 
experiments after validation of RAB35 as our primary hit are represented with 
simplified numbers (1, 2, and 3): 
shRAB35_1: Human shRAB35_709: TRCN0000047797; NM_006861.4-
709s1c1 
shRAB35_2: Human shRAB35_475: TRCN000038033; NM_006861.4-
475s21c1 
shRAB35_3: Human shRAB35_601: TRCN0000380003; NM_006861.4-
601s21c1 
shRNAs targeting murine RICTOR and human PIK3CA were 
purchased from Sigma-Aldrich: 
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shPIK3CA_1: Human shPIK3CA_3234: TRCN0000010407; NM_006218.x-
3234s1c1 
shPIK3CA_2: Human shPIK3CA_3254: TRCN0000195304; NM_006218.2-
3254s1c1 
shRICTOR_1: Mouse shRICTOR_5030: TRCN0000123398; NM_030168.2-
5030s1c1 
shRICTOR_2: Mouse shRICTOR_5031: TRCN0000123395; NM_030168.2-
5031s1c1 
 
2.3.19 mTORC2 in vitro kinase assays 
mTORC2 kinase assays were performed in vitro as described 
previously [119, 333]. Briefly, cells grown in 15 cm plates were serum 
starved overnight, then stimulated, washed once in ice-cold PBS and lysed 
in 1 mL 0.3% CHAPS lysis buffer. Lysates were incubated at 4° C for 15 
minutes, centrifuged at 14,000 rpm for 15 minutes, the soluble fraction was 
collected and the protein concentration was determined. 1000 µg of protein 
in a final volume of 750 µL was then used for each immunoprecipitation. 15 
µL of goat anti-RICTOR antibody (Santa Cruz) was added to each tube, and 
tubes were incubated at 4° C overnight with rotation. The next day, 15 µL of 
a 50% slurry of agarose Protein G beads (Pierce) was added to each tube 
and incubated for an additional hour with rotation. Immunoprecipitates were 
then washed three times with CHAPS lysis buffer, and once with 1X 
mTORC2 kinase buffer (25 mM HEPES [pH 7.5], 100 mM potassium 
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acetate, 1 mM MgCl2). The kinase buffer was then completely aspirated and 
the following was immediately added: 7.5 µL 2X mTORC2 kinase buffer, 250 
ng inactivated AKT1/PKBα (Millipore, #14-279), 0.75 µL 10 mM ATP, and 
the reaction volume was then brought up to 15 µL with dH2O. The reactions 
were then incubated at 37° C for 20 minutes with gentle agitation (300 rpm). 
Every five minutes, the tubes were gently flicked to resuspend the agarose 
beads within the reactions. The kinase assay was then stopped with the 
addition of 200 µL of 1X Laemmli’s loading buffer, the tubes were boiled for 
five minutes, and 20 µL of each reaction was then analyzed by SDS-PAGE.  
 
2.3.20 PI3-kinase in vitro kinase assays 
We used Echelon Biosciences PI3K kinase assay ELISA “pico” kits 
(K-1000s) for in vitro PI3K reactions using purified p85-p110α. Cells were 
lysed in 0.3% CHAPS lysis buffer as described above and PI3K was 
immunopurified from 1000 µg of clarified cell lysates using 20 µL agarose-
conjugated anti-p85 antibody (Millipore, 16-107) overnight at 4° C. 
Immunoprecipitates were then washed three times in CHAPS lysis buffer 
and once in KBZ buffer (Echelon). After the final wash, KBZ buffer was 
completely aspirated and 30 µL of KBZ buffer supplemented with 5 mM DTT 
and 150 µM ATP was immediately added to the immunoprecipitates. 30 µL 
of 100 µM phosphatidylinositol 4, 5-bisphosphate (PIP2) and either DMSO or 
PIK-90 were then added to the reaction. Final kinase assay buffer was thus 
comprised of KBZ buffer, 50 µM PIP2, 2.5 mM DTT, 75 µM ATP, DMSO or 
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500 µM PIK-90, and 20 µL of agarose anti-p85 beads. Reactions were then 
incubated at 37° C and tubes were gently tapped every 15 minutes to 
resuspend the agarose beads in the reaction. After 3 hours, reactions were 
stopped with the addition of 60 µL KBZ buffer supplemented with 4 mM 
EDTA. The reactions were then centrifuged, and the supernatants were 
removed and frozen at -20° C. The PIP3 competitive ELISA assay kit was 
then used as per the manufacturer’s instructions to determine the 
concentration of PIP3 generated in each kinase reaction. The supernatant 
from each reaction was split between two individual ELISA wells and each 
reaction was run in duplicate, thus each kinase assay condition was assayed 
in quadruplicate.  
 
2.3.21 Apoptosis assays of NIH-3T3 cell lines 
NIH-3T3 cells were assayed for apoptosis by both western blotting of 
whole cell lysates and by cell counting methods. Briefly, cells were split and 
each cell line was seeded at 1 million cells per well of a 6-well plate in 2 mL 
of DMEM supplemented with 10% BCS. After 6 hours at 37° C, 3 wells of 
each plate were aspirated, washed once with serum-free DMEM, and the 
media was replaced with serum-free DMEM and the plates were returned to 
37° C. 4 hours later, the cells were lysed in TX-100 lysis buffer and cell 
lysates were analyzed by immunoblotting. For cell count assays, each cell 
line was seeded and treated as just described. Instead of lysis, after 4 hours 
of serum withdrawal, cells were rinsed once with PBS, briefly trypsinized with 
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500 µL of trypsin, dissociated into a single cell suspension, resuspended to 
1000 µL with 500 µL of DMEM and collected. 500 µL of each cell suspension 
was then counted on a Beckman-Dickinson Vi-Cell XR, and the total number 
of viable cells per mL was recorded. Each condition (serum complete and 
serum withdrawn) was performed in triplicate (3 wells each). Serum 
withdrawn cell counts for each cell line were then normalized to their 
respective serum complete cell count to arrive at a % of viable cells. Mean 
and standard deviation values for each condition were then calculated and 
graphed in Microsoft Excel. 
 
2.3.22 NIH-3T3 focus formation assays 
Focus formation assays with NIH-3T3 stable cell lines were performed 
as previously described [334-335]. For each focus formation assay, freshly 
thawed, low-passage NIH-3T3 stable cell lines were used. Briefly, NIH-3T3 
cells stably expressing genes indicated throughout this paper were seeded 
in 6-well plates in 2 mL of 10% BCS DMEM at 20,000 cells per well. The 
next day, the media was aspirated and replaced with 2 mL 2% BCS DMEM 
containing either DMSO or 250 nM GDC-0941. Cells were then cultured at 
37° C for 4 weeks with media changes every 3 days. After 4 weeks, cells 
were fixed and processed for crystal violet staining as follows. Cells were 
rinsed once with PBS and fixed for 10 minutes at room temperature in 1 mL 
70% EtOH. Next, EtOH was aspirated and cells were stained with crystal 
violet reagent (0.5% crystal violet, 25% EtOH) for 10 minutes. Crystal violet 
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was then removed, and each well was rinsed gently with dH2O until 
background stain was removed. The plates were then imaged using an 
Oxford Optronix plate imager. Because the qualitative aspects of foci formed 
by different oncogenes varies widely (i.e. fewer but larger ones for 
RAB35Q67L and many small ones for AKTmyr, etc.) and because colony 
counting is a subjective process, we chose to quantify the amount of crystal 
violet stain in each well as a way of objectively measuring the total amount of 
cells present in our focus formation assays. To extract crystal violet from 
stained cells, we incubated each well overnight at room temperature in 1 mL 
of Sorenson’s buffer (50 mM sodium citrate, 50 mM citric acid, 50% EtOH) 
with gentle agitation. The next day, extractions were collected and the 
absorbance at 590 nm was recorded using a spectrophotometer. These 
values were tabulated in Microsoft Excel, and the values for all samples 
were normalized to the average absorbance of DMSO treated FLAG-
RAB35wt NIH-3T3 cells. 
 
2.4  RESULTS  
2.4.1 A quantitative, immunofluorescent assay for AKT phosphorylation  
To quantitatively assess PI3K/AKT signaling in cultured cells, we designed 
an immunofluorescence-based assay that detects levels of AKT 
phosphorylation at S473. mTORC2 phosphorylates AKT at this site in a 
PI3K-dependent manner, a phosphorylation which both reflects PI3K activity 
and is required for full activation of AKT itself [119]. To probe for AKT 
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phosphorylation in HeLa cells grown in 384-well plates, we probed fixed cells 
with a monoclonal rabbit antibody directed against AKT phosphorylated at 
S473 (Figure 2.1). This antibody was probed with a secondary antibody 
tagged with an 800 nm 
fluorophore (green), and the cells were counterstained with a 700 nm whole 
cell stain (red). We imaged and quantified these two signals with a near-
infrared scanner. These signals could be divided by one another to yield a 
normalized value for each well that represents phospho-AKT levels (see 
methods for a more complete description of this assay). This assay was 
sensitive to inhibition with PI3K and mTOR kinase inhibitors. Thus, we 
 
Figure 2.1: An immunofluorescent assay for phospho-S473 AKT 
quantitatively reflects PI3K activity. HeLa cells grown in 384-well 
plates were serum starved overnight, treated with PIK-90 and insulin as 
indicated, then fixed and processed for immunofluorescence with a 
whole cell stain (red) and an anti-phospho-S473 AKT monoclonal 
antibody (green) (top). Signals were imaged and quantified with a LiCor 
Odyssey near-infrared scanner, and the phospho-AKT signal intensity 
was divided by the whole-cell stain signal intensity to calculate a 




developed a robust assay for PI3K/AKT activity that we next deployed in a 
high-throughput screen.  
 
2.4.2 An RNAi screen identifies RAB35 as a novel regulator of PI3K/AKT 
signaling 
We defined phospho-AKT Z-scores -1.50 and +1.50 as the cutoffs 
beyond which individual shRNAs would be considered as low or high hits, 
respectively. Fortunately, shRNAs targeting genes whose knockdown should 
suppress AKT phosphorylation—RICTOR, PIK3CA, PIK3CB, AKT1, and 
 
Figure 2.2: An arrayed lentiviral loss-of-function RNA interference 
screen identifies known and novel regulators of the PI3K/AKT axis. 
Averaged phospho-AKT Z-scores of screened shRNAs. HeLa cells were 
plated in 384-well plates, transduced with lentiviral reagents expressing 
control shRNAs or shRNAs targeting human kinases and GTPases, then 
processed as in Figure 2.1. Phospho-AKT Z-scores for each shRNA were 
then calculated, averaged (n=3), and arranged in increasing order. Low 
hits (Z-score < -1.50) are indicated in red, high hits (Z-score > 1.50) are 
indicated in green. Hit genes that are known to regulate PI3K/AKT 
signaling are indicated in red or green boxes. For a full list of non-lethal 
hit genes please see Appendix B.  
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 AKT3—all diminished AKT phosphorylation and scored as low hits (Figure 
2.2, Appendix B). Conversely, shRNAs targeting genes whose protein 
products inhibit AKT signaling—such as RAPTOR and RHEB—elevated 
phospho-AKT levels and scored as high hits. Since this assay successfully 
identified known regulators of PI3K/AKT signaling, we were confident that 
our screening approach was a valid method for discovering new members of 
the this pathway.   
To reduce the number of shRNAs and genes in our primary hit list to a 
manageable number, we discarded shRNAs that were toxic or did not knock 
down their target mRNA, and considered as hits only genes for which 40% 
or more of the screened hairpins scored in our assay (Table 2.1, Appendix 
B). Further, we discarded hit genes that were not ubiquitously expressed or 
had been previously studied in the context of PI3K/AKT signaling (Appendix  
D). Finally, we used publicly available oncogenomic databases to annotate 
the remaining hit genes and discarded any genes that were not altered in 
human tumor samples or cell lines. Thus we prioritized our hits for validated, 
non-toxic shRNAs that targeted genes with no previous link to PI3K/AKT 
signaling that were altered in human cancers. This left us with a manageable 
list of 29 genes with which we could perform low-throughput loss-of-function 




Table 2.2: RNAi screen hit genes that are widely expressed and altered 
in human tumor samples or cancer cell lines. We used oncogenomic 
databases to identify hit genes from Appendix D that are mutated in human 
tumors or cancer cell lines. See methods for description of data collection 





Recurring mutations from 
COSMIC, cBio 
Other COSMIC or 
cBio mutations of 
interest 
Knockdown of the following 3 genes elevated phospho-AKT Z-score 
PRKAR1B V100M (3), A67V (3) P87T/fs (5)   
Table 2.1: Criteria for selecting hit shRNAs and genes.  
 Criteria Genes shRNAs Table 
Genes 
screened 
All known human GTPases and 
kinases 




1. 40% of shRNAs per gene score 
with an average phospho-AKT Z-
score of greater than -/+ 1.50 
2. Hit shRNAs are nonlethal 




1. Primary hit genes whose shRNAs 
knock down target mRNA transcript 
by 50% or more 
2. 40% of shRNAs meet secondary 
hit criteria #1 (above) 




1. Secondary hits with no known link 
to PI3K/AKT signaling in the 
literature 
2. Expression of genes is not cell-line 
or tissue-specific 




Tertiary hits that are altered in human 
tumors and cancer cell lines 





Table 2.2 (continued) 
GRK1 L180M, G213S, R19Q (4) 
G137E (2), V251M (2), T298M 
(2)   






Recurring mutations from 
COSMIC, cBio 
Other COSMIC or 
cBio mutations of 
interest 
Knockdown of the following 26 genes diminished phospho-AKT Z-score 
PKN2 P914, L384del (25) Q199L/H (2)   
SRP54 no E34* (2), L69V (2), K373N (2)   
TAF1 A1527, R1034H 
R1068H (3), R843W (3), 
E651G (3), E651K (2), R843Q 
(2), R854C (2), R996C (2), 
R1126W (2), R1221Q (2), 
R1376Q (2), I1741V (2), G626C 
(2), R539Q (2), P438S (2), 
R342C (2), G688* (2), K644fs 







N622K (7), p848fs (3)   
RAB35 R27H R27H (2), A151T (2) A151T, F161L (COSMIC) 
RND1 no C19F (2), E48K (2), D75N (2), R130Q (2)   
GTPBP2 no E132D (2), D319N (2), E400V (2), R575L/W (3)   
RAB39A no R80Q (2), A84C/H (2), R119W (4),   
CABC1 
(ADCK3) 
F81L (3), P188H 
(2) 
F81L, V85M (3), D117N (2), 





T414S (3), P1299L (2), R1254C 
(2), P1803L (2)   
TAOK1 none 
R492W (2), R562*/Q (2), R605* 
(2), N639S (2), E719* (2), 
R759Q (2), R832H (2), R833K 
(2), V891A (2), G975V/W (2), 
N639S (2) 
  





Table 2.2 (continued) 
ALPK1 T1150fs (6), S942del (12) 
V62M (3), A86T (2), A144S (2), 
A152S (2), N175D (3), D253N 
(2), V296M (2), S832F/N/T (4), 
I1124M (2), K1125E (2), P293L 
(2) 
  
RAB1B no E35K/Q (2), G42W (2), R79fs (2) A152T (COSMIC) 
ADPGK no L176I (2), K450fs (3), R475*/Q (3)   
GSG2 no R82C (18), K358fs* (2)   
POMK 
(SGK196) R15Q, T146N A13T (5)   
PKDCC E408G (9) V131I (2)   
RASEF no R262C (2), R332Q (3), H350R (2), R706* (2), G792W (2)   





S424C (4), A681E (3), S108P 
(3), S708P (3), R438*, P389H 
(2), R1911Q (3) 
  
STK32C S392Y (3) G282W (2), S482L (2)   
TSSK4 T338del (12) R281C (2)   
NEK8 G602E (2) A206T (2), L621F (2), G605D (2), V690fs (2)   
RABL3 no R107C (2)   
NME9 no E75K (5), R221W (5), G270D (2), E53K (5), G209D (2)   
 
Next, we were curious as to the types of genes that were present in 
this enriched hit list, and whether they shared any functional characteristics. 
Because this list was largely comprised of low hits (26 of 29) and because 
we were interested in identifying positive (i.e. oncogenic) regulators of 
PI3K/AKT signaling, we focused on only the 26 low hit genes from Table 2.2. 
We used literature searches to identify the molecular function—or, failing 
that, the broader organismal function—of these 26 genes, then asked which 
molecular function was the most prominently represented (Figure 2.3A). 
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Interestingly, 5 of these 26 low hit genes were RAB GTPases, which 
suggested to us that there may be a previously unappreciated role for RAB 
proteins in oncogenic growth factor signaling. 
 
Of the five RAB proteins in this list (RAB1B, RAB35, RAB39, RASEF 
and RABL3), we prioritized RAB35 for further study because 1.) it is 
somatically mutated in human cancers (Figure 2.3B) and 2.) it is well-
characterized in recycling endosome biology and has widely available 
reagents and tools. A member of the RAB family of GTPases, RAB35 has 
 
Figure 2.3: RAB proteins are prevalent in the enriched RNAi screen 
hitlist, and RAB35 is somatically mutated in human cancers. (A) 
The 26 hit genes that reduced AKT phosphorylation, are expressed 
widely, and are mutated in human cancers were grouped by their 
annotated function from the literature.  (B) Mutations found in 
oncogenomic databases that are predicted to have a medium (black) or 





been described as a regulator of cytoskeletal organization and trafficking at 
the recycling endosome [336-339]. While a number of regulators and 
effectors of RAB35 have been identified, we did not find any evidence in the 
literature to suggest that RAB35 plays a central role in growth factor 
signaling [340]. Further, although several RAS family members have been 
implicated in cancer, there is little evidence that suggests that RAB proteins 
possess oncogenic potential. Thus, we reasoned that RAB35 was the most 
promising candidate for further study.   
To confirm that RAB35 depletion with the screened shRNAs could 
inhibit AKT phosphorylation, we transduced HeLa cells with lentiviruses 
expressing shRNAs targeting luciferase (as a control), the mTORC2 
component RICTOR, or RAB35. Indeed, three of the shRAB35 hairpins 
simultaneously reduced RAB35 protein levels and diminished the 
phosphorylation of AKT and the AKT substrate FOXO1/3A in response to 
stimulation with serum (Figure 2.4). Similarly, shRAB35 hairpins that were 
not included in our screen that depleted RAB35 protein levels also 
suppressed AKT phosphorylation (Data not shown).  
67 
 
 2.4.3 RAB35 is necessary for full activation of PI3K/AKT signaling in 
response to serum 
To ensure that the effect of RAB35 knockdown on AKT signaling was 
not cell-type specific, we depleted RAB35 protein in two human (HeLa, HEK-
293E) and one mouse (NIH-3T3) cell line(s) (Figure 2.4). Knockdown of 
 
Figure 2.4: Validation of RAB35 as a bona fide hit from our RNAi 
screen. (A) Phenotype-knockdown correlation of RAB35 mRNA levels 
and phospho-S473 AKT Z-scores.  (B) shRNAs that deplete RAB35 
protein levels also suppress phosphorylation of AKT and the AKT 
substrate FOXO1/3A. HeLa cells were transduced lentiviruses 
expressing the indicated shRNAs, starved overnight, stimulated as 
indicated with medium containing serum, lysed, then lysates were 




 RAB35 protein with two different shRNAs diminished AKT phosphorylation 
at S473 and T308 more potently than did RICTOR knockdown in both 
human and mouse cells. Further, the PI3K-dependent phosphorylation of 
two proteins—the AKT substrate FOXO1/3A and the SGK1 substrate 
 
Figure 2.5: RAB35 is necessary for serum-induced PI3K/AKT 
signaling. (A, B) Depletion of RAB35 inhibits serum-induced activation of 
AKT. (A) HeLa and HEK-293E cells were transduced with lentiviral 
reagents expressing the indicated shRNAs. Cells were serum starved 
overnight, treated as indicated with fetal bovine serum (FBS), lysed, and 
cell lysates were then analyzed by immunoblotting. (B) Murine NIH-3T3 
cells were serum starved then treated as indicated with bovine calf serum 
(BCS) and analyzed as in (A). 
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NDRG1—was also decreased in cells depleted of RAB35.  The same 
experiment performed in a variety of cancer cell lines with different 
mutational backgrounds (oncogenic PIK3CA or KRAS, deleted PTEN, 
mutated NF2 or TP53) yielded similar results (Figures 2.6, 2.7). Thus, 
RAB35 is broadly necessary for the efficient activation of PI3K/AKT signaling 




Figure 2.6: Depletion of RAB35 in cell lines with various genetic 
backgrounds inhibits PI3K/AKT signaling. Cell lines of the indicated 
mutational backgrounds were transduced with lentiviruses expressing the 
indicated shRNAs, serum starved overnight, treated as indicated and 
analyzed as in Figure 2.5. The categories of cell line mutational 
backgrounds and their relevant cancer gene mutations were obtained from 
the Sanger COSMIC database and are listed as follows: (A) Cell lines with 
non-PI3K/PTEN alterations: SN12C (NF2 and TP53 mutations) and Caki-2 
(VHL inactivating nonsense mutation). (B) Cell line with a KRAS activating 






Figure 2.7: Depletion of RAB35 in cell lines with activating PIK3CA 
or inactivating PTEN mutations suppresses PI3K/AKT signaling in 
response to serum. (A) Cell lines with PIK3CA mutations: 22Rv1 
(PIK3CA activating mutation, TP53 mutation) and HT-29 (APC 
inactivating mutations, BRAF activating mutation, PIK3CA mutation, 
TP53 mutation) (B) cell lines with PTEN inactivation: 786-0 (PTEN 
nonsense mutation, CDKN2A deletions, VHL deletion, TP53 mutation) 
and PC-3 (PTEN and TP53 deletions). Cells were treated and analyzed 





2.4.4  RAB35 is sufficient to activate PI3K/AKT signaling 
To ask whether RAB35 could activate the PI3K/AKT axis, we 
generated human cell lines that stably expressed either a wildtype allele of 
the GTPase RHEB (RHEBwt) as a control, wildtype RAB35 (RAB35wt), or the 
dominant active GTPase-deficient, GTP-bound RAB35 Q67L mutant 
(RAB35Q67L). Stable expression of either RHEBwt or RAB35wt did not alter 
the regulation of growth factor signaling to AKT (Figure 2.8). However, stable 
expression of the active RAB35Q67L allele rendered AKT phosphorylation 
constitutively elevated and refractory to growth factor deprivation. Not 
surprisingly, the phosphorylation of FOXO1/3A was also elevated in lysates 
from serum-deprived cells expressing RAB35Q67L. Furthermore, neither 
expression of RAB35wt or RAB35Q67L altered the phosphorylation of the 
protein kinase ERK (Figure 2.9). Therefore, the expression of GTP-bound 
 
Figure 2.8: GTPase-deficient RAB35Q67L is sufficient to activate 
PI3K/AKT signaling. GTPase-deficient RAB35Q67L activates PI3K/AKT 
signaling. HeLa and HEK-293E cells were stably transduced with 
lentiviruses expressing FLAG-tagged RHEBwt, RAB35wt or RAB35Q67L. 
Cells were serum starved overnight, treated as indicated and lysates 




RAB35 is sufficient to activate PI3K/AKT signaling in cells in the absence of 
growth factors.  
 
2.4.5 RAB35 depletion inhibits mTORC2 kinase activity towards AKT/PKB 
in vitro 
Because these data thus far did not indicate where in the pathway 
RAB35 might be acting, we asked whether RAB35 regulates AKT activation 
via either of the two kinases that phosphorylate AKT—PDK1 and mTORC2 
[341-342]. Because one of our motivations for performing our RNAi screen 
was to identify regulators of mTORC2, the first question we asked was 
whether depletion of RAB35 could inhibit mTORC2 kinase activity in vitro 
(Figure 2.10). We generated HeLa cells stably expressing a control shRNA 
or shRNAs targeting either RICTOR, PIK3CA, or RAB35, then 
immunopurified mTORC2 with an anti-RICTOR antibody and assayed the in 
vitro kinase activity of mTORC2 against recombinant, inactivated AKT [333, 
341, 343-345]. Not surprisingly, the ability of immunopurified mTORC2 to 
 
Figure 2.9: Stable expression of dominant active, GTPase-deficient 
RAB35Q67L does not activate ERK signaling. HEK-293E and HeLa 
cells transduced with FLAG-tagged RHEBwt, RAB35wt, or RAB35Q67L from 
Fig. 2C were treated as indicated, lysed, and cell lysates were analyzed 





phosphorylate AKT in vitro was activated by growth factors, ablated by 
RICTOR depletion, and inhibited by PI3Kα depletion. Further, we found that 
depletion of RAB35 with two different hairpins also markedly reduced 
mTORC2’s kinase activity in vitro. Taken with the data in section 2.3, these 
data suggest that RAB35 is necessary for full activation of mTORC2. 
However, this did not indicate whether RAB35 was directly regulating 
mTORC2 or was acting further upstream of it. Because we were unable to 
 
Figure 2.10: RAB35 depletion inhibits the in vitro kinase activity of 
immunopurified mTORC2 towards AKT. HeLa cells were stably 
transduced with lentiviruses expressing the indicated shRNAs, serum 
starved overnight, stimulated with serum where indicated, then lysed. 
Cell lysates were then used for immunoprecipitations with the indicated 
antibodies, and the immunoprecipitates were used for in vitro mTORC2 
kinase assays using 100 ng of purified, inactivated AKT1 as a substrate. 
Kinase reactions were then analyzed by immunoblotting analysis for 
AKT phosphorylation and mTORC2 components as indicated (top). 





identify any interaction between endogenous or recombinant RAB35 and 
components of mTORC2 (data not shown), we reasoned that RAB35 could 
be regulating mTORC2 indirectly. We next sought to delineate whether 
RAB35 was regulating both PDK1 and mTORC2 by acting on their common 
regulator PI3K. 
 
2.4.6 RAB35 functions above PDK1 and mTORC2 
To place RAB35 within the pathway, we asked if RAB35 regulates AKT 
activation via either of the two kinases that phosphorylate AKT—PDK1 on 
T308 and mTORC2 on S473 [341-342]. Determining whether a particular gene 
or small molecule functions through either PDK1 or mTORC2 is challenging 
because the phosphorylation states of T308 and S473 in wildtype cells are 
influenced by one another [119, 134, 346]. We took advantage of cells that 
stably expressed alleles of murine Akt1 (mAkt1) where either T308 or S473 
were mutated to phosphomimetic aspartate residues [344] (Figure 2.11) to ask 





As expected, mTOR blockade with the ATP-competitive inhibitor Torin1 
or RICTOR depletion suppressed S473 phosphorylation on mAkt1 that had an 
intact mTORC2 site (mAkt1wt and mAkt1T308D) (Figure 2.12). Further, in cells 
without a regulatable mTORC2 site (mAkt1S473D), RICTOR depletion did not 
depress T308 phosphorylation, and treatment with Torin1 elevated 
phosphorylation at T308. Interestingly, depletion of RAB35 decreased S473 
phosphorylation in mAkt1wt and mAkt1T308D cells as well as T308 
phosphorylation in mAkt1wt and mAkt1S473D cells. Together, these data 
suggested that RAB35 signals to AKT by acting upstream of both PDK1 and 
mTORC2.  
 
Figure 2.11: AKT phosphomimetic mutants to delineate between 
regulators of PDK1 and mTORC2. Because phosphorylation of the 
T308 and S473 sites on AKT can affect one another, determining 
whether an unknown regulator or perturbogen functions by controlling 
PDK1, mTORC2, or p110α is challenging. By locking one residue into a 
phosphomimetic state by mutating it to an aspartate, the phosphorylation 
state of the other can be probed without concern that it is being 
influenced by the other site. (A) S473D mutation allows measurement of 
T308 phosphorylation to reflect only PDK1 activity. (B) T308D mutation 






2.4.7 RAB35 depletion upregulates protein levels of the mTORC1/2 
inhibitor DEPTOR 
In addition to the “biochemical epistasis” experiment described in 
Figure 2.12, we performed further experiments to confirm that RAB35 was 
acting upstream of mTOR. One indicator of both mTORC1 and mTORC2 
activity is the stability of DEPTOR, a negative regulator of both mTOR 
complexes [208, 343, 347-349]. In addition to regulating mTOR, DEPTOR is 
itself an mTOR substrate, and phosphorylation by mTOR reduces the 
stability of DEPTOR protein. Thus, inhibition of PI3K or mTOR—by 
pharmacological means or via deprivation of growth factors—leads to 
accumulation of DEPTOR levels. Similarly, depletion of PI3K/mTOR pathway 
 
Figure 2.12: RAB35 acts upstream of both PDK1 and mTORC2. HeLa 
cells stably expressing murine Akt1wt, Akt1S473D or Akt1T308D were treated 
as indicated with shRNA-expressing lentiviruses and Torin1. Cells were 
then lysed and cell lysates were analyzed by immunoblotting. 
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components can lead to increased DEPTOR stability. We reasoned that if 
RAB35 was regulating PI3K and/or mTOR that RAB35 depletion in the 
presence of growth factors would result in increased DEPTOR protein levels. 
Indeed, serum deprivation, RICTOR, PI3Kα or RAB35 depletion—in the 
presence of complete media—all lead to DEPTOR accumulation (Figure 
2.13). This further suggested to us that RAB35 regulates PI3K/mTOR 
signaling upstream of mTOR. 
 
2.4.8 Depletion of RAB35 blunts mTORC1 inhibitor-induced PI3K/AKT 
activation 
Next, we reasoned that if RAB35 was involved in PI3K/AKT/mTOR 
signaling, depletion of this protein would blunt the activation of PI3K/AKT 
 
Figure 2.13: Serum deprivation, depletion of RICTOR, p110α, or 
RAB35 all lead to accumulation of the mTORC1 and mTORC2 
inhibitor Deptor. HeLa cells were transduced with lentivirus expressing 
the indicated shRNAs, then were serum starved for 30 hours and either 
lysed or re-stimulated with serum for 12 hours, lysed, and lysates were 




signaling that is induced by rapamycin. As reviewed in chapter 1 of this 
thesis, there exists a negative feedback circuit between mTORC1/S6K1 and 
upstream components of PI3K signaling—namely through proteins like IRS-1 
and GRB10 [218-220, 350-354]. Under regular conditions, mTORC1 and its 
substrate S6K1 phosphorylate and inhibit negative regulatory components of 
PI3K/AKT signaling like GRB10, or destabilize positive regulators like IRS1. 
Thus, mTORC1 inhibition with rapamycin induces an increase in AKT and 
AKT substrate phosphorylation. Even mTORC1/2 inhibition with ATP-
competitive mTOR kinase inhibitors potently upregulates PI3K activity and 
leads to activation of PI3K, PIP3 accumulation, and hyperphosphorylation of 
T308 on AKT even when mTORC2 is disabled [208, 355-356].  
 We therefore reasoned that if RAB35 was a positive regulator of 
signaling from PI3K/AKT to either PDK1 or mTORC2 (or both), then the 
increase in AKT phosphorylation induced by mTORC1 inhibition with 
rapamycin should be blunted with RAB35 inactivation (Figure 2.14). Not 
surprisingly, we found that depletion of the mTORC2 component RICTOR in 
HeLa cells prevented any increase of AKT phosphorylation at both T308 and 
S473 after 18 hours of mTORC1 inhibition. Consistent with our data that 
indicated that RAB35 lay upstream of both mTORC2 and PDK1, depletion of 
RAB35 blunted AKT activation by rapamycin to the same extent as did 
RICTOR knockdown. Thus, RAB35 likely functions proximally to RTKs and 




2.4.9  RAB35 is necessary for full activation of PI3K kinase activity in vitro 
We reasoned that if RAB35 acts upstream of both PDK1 and 
mTORC2, it may be controlling their common regulator PI3K. Therefore, we 
asked whether RAB35 is necessary for PI3K kinase activity in vitro (Figure 
2.15). As expected, PI3K immunopurified from cells depleted of PI3Kα—but 
not RICTOR—had significantly reduced in vitro kinase activity towards PIP2. 
Further, PI3K purified from cells depleted of RAB35 had approximately 50% 
less in vitro PI3K kinase activity. These data indicate that RAB35 regulates 
PI3K/AKT signaling upstream of PI3K. 
 
Figure 2.14: Depletion of RAB35 prevents PI3K/AKT activation in 
response to mTORC1 inhibition. HeLa cells were transduced with 
lentivirus expressing the indicated shRNAs, treated with 100 nM 






2.4.10 RAB35 is necessary for activation of PI3K/AKT signaling in response 
to growth factor receptor stimulation 
Next, we investigated whether RAB35 acts downstream of any 
particular growth factor receptor. Not surprisingly, depletion of RICTOR or 
PI3Kα in cells reduced the phosphorylation of AKT in response to treatment 
with insulin-like growth factor (IGF-I), epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF-AA) and vascular endothelial growth 
factor (VEGF) (Figure 2.16A). Further, depletion of RAB35 also prevented 
AKT activation by IGF-I, EGF, PDGF-AA or VEGF. Interestingly, RAB35 
depletion did not dramatically alter phosphorylation of ERK or tyrosine 
phosphorylation of IGFR, EGFR, PDGFR or VEGFR (Figure 2.16B). Taken 
together, the data in Figures 2.10-2.16 suggest that RAB35 functions 
 
Figure 2.15: RAB35 depletion inhibits the kinase activity of 
immunopurified PI3K in vitro. HEK-293E cells stably expressing 
shRNAs targeting Luciferase, RICTOR, PI3Kα or RAB35 were treated 
as indicated. Cells were then lysed, PI3K was immunopurified with an 
anti-p85 antibody, and purified PI3K was analyzed for in vitro kinase 




upstream of PI3K and downstream of growth factor receptor tyrosine 
kinases. 
 
2.4.11 RAB35 is mutated in human tumors 
Like the other genes on our prioritized hit list in Table 2.2, we found 
that RAB35 was mutated in human tumor samples (Table 2.3). Although 
none of the RAB35 mutations that we observed were recurrent, two of the 
 
Figure 2.16: RAB35 depletion inhibits PI3K signaling to AKT 
downstream of multiple growth factor receptors. (A) HeLa cells 
were transduced with the indicated shRNA-expressing lentiviruses, 
serum starved overnight, treated as indicated with either insulin-like 
growth factor I (IGF-I), epidermal growth factor (EGF), platelet derived 
growth factor AA (PDGF-AA) or vascular endothelial growth factor 
(VEGF), then lysed and analyzed by immunoblotting. (B) Lysates from 
(A) were analyzed by immunoblotting for tyrosine phosphorylation of 




mutations in RAB35—A151T and F161L—occurred at residues that are 
conserved in RAS-like GTPases. We noticed that the A151T and F161L 
mutations in RAB35 were strikingly similar to KRAS mutations (A146T and 
F156L) that have been previously identified from human tumor samples 
(Figure 2.17) [357-358]. While they are not “canonical” KRAS- activating 
mutations, stable expression of these two KRAS mutants was sufficient to 
activate ERK signaling and transform NIH-3T3 cells in vitro. We therefore 
reasoned that the two similar mutations in RAB35 might also be gain-of-





Table 2.3: The TCGA, COSMIC and MSKCC cBIO databases reveal 
somatic RAB35 mutations in human cancers. The Cancer Genome Atlas 
(TCGA), Catalogue of Somatic Mutations in Cancer (COSMIC), the 
International Cancer Genomics Consortium (ICGC) and MSKCC 
computation biology (cBio) data portal web sites were used to search for 
mutations in RAB35 in human tumor samples. Mutations are listed in order 
of the amino acid residue that they occur at. Predicted change in protein 
function was assessed by the cBio mutational assessor with the exception of 
F161L, whose change in function was predicted manually by literature 
survey (asterisk).  

















cBio, COSMIC R27C 1 of 60 (1.67%) Medium 
Stomach COSMIC, TCGA R27H 1 of 386 (0.26%) Medium 
Lung COSMIC, ICGC A29V 1 of 488 (0.2%) Neutral 
Breast cBio, COSMIC, 
TCGA 
F45L 1 of 772 (0.1%) Medium 




cBio, TCGA T76 
splice 






G80E 1 of 60 (1.67%) Medium 
Adrenal cBio, TCGA H82Y 1 of 179 (0.56%) Medium 
Medulla COSMIC, ICGC V90I Unknown NP 
Colon COSMIC, TCGA E94K 1 of 600 (0.17%) NP 
Skin cBio S95F 1 of 228 (0.44%) NP 
Lung COSMIC, TCGA R101Q 1 of 173 (0.58%) Neutral 
Breast cBio V129G 1 of 1061 (0.09%) Medium 
Liver cBio Y136C 1 of 268 (0.37%) Neutral 
Colon COSMIC A139V 1 of 2132 (0.05%) NP 
Uterus cBio, COSMIC, 
TCGA 




cBio, COSMIC A151T 1 of 60 (1.67%) High 




Table 2.3 (continued) 
Prostate cBio, COSMIC, 
TCGA 
N156S 1 of 425 (0.24%) Medium 
Lung cBio, COSMIC F161L 1 of 183 (0.5%) High* 
Stomach cBio, TCGA K173fs 1 of 295 (0.34%) NP 











Figure 2.17: RAB35 mutants identified in human tumors are 
similar to known activating mutations in KRAS. Two mutations in 
RAB35 that code for amino acid changes A151T and F161L were 
identified in the MSKCC cBio and COSMIC datasets. Alignment of 




2.4.12 Mutant RAB35 from human tumors can activate PI3K/AKT signaling 
To ask whether stable expression of RAB35 with the A151T and 
F161L substitutions could activate PI3K/AKT signaling, we generated NIH-
3T3 cells stably expressing either RAB35wt, GTPase-deficient RAB35Q67L, or 
the RAB35A151T or RAB35F161L alleles identified from the COSMIC database. 
While expression of RAB35wt did not activate AKT phosphorylation during 
serum deprivation, stable expression of the GTPase-deficient RAB35Q67L or 
the naturally occurring RAB35A151T and RAB35F161L mutants elevated AKT 
phosphorylation levels even in the absence of growth factors (Figure 2.18). 
Thus, stable expression of the GTPase-deficient RAB35Q67L mutant or the 





Figure 2.18: Mutant RAB35 alleles from human tumors can 
activate PI3K/AKT signaling. NIH-3T3 mouse fibroblasts stably 
expressing the indicated RAB35 alleles were serum starved for 4 
hours, left unstimulated or treated with bovine calf serum (BCS), lysed, 





2.4.13 Stable expression of mutant alleles of RAB35 suppresses apoptosis 
Because PI3K/AKT signaling inhibits apoptosis, we next examined 
whether cells expressing mutant alleles of RAB35 were resistant to 
apoptosis triggered by growth factor withdrawal. 4 hours of serum 
deprivation of NIH-3T3 cells stably expressing RAB35wt was sufficient to 
elevate cleaved levels of the apoptotic markers PARP and Caspase3 (Figure 
2.19A). In comparison, cells stably expressing all three RAB35 mutants or 
oncogenic p110αH1047R had decreased levels of cleaved PARP and cleaved 
Caspase3 following serum withdrawal. Further, while cells expressing 
RAB35wt were sensitive to cell death in response to serum deprivation, cells 
expressing mutant alleles of RAB35 or p110αH1047R exhibited significantly 
improved cell viability when deprived of growth factors (Figure 2.19B). 
Together, these data suggest that mutant RAB35 proteins can suppress cell 







Figure 2.19: Expression of RAB35 mutants suppresses apoptosis. 
(A) NIH-3T3 cells stably expressing the indicated proteins were plated 
then treated as indicated for 4 hours with or without serum-containing 
medium. Cells were then lysed and the cell lysates were immunoblotted 
for the indicated proteins. (B) NIH-3T3 cells were treated as in (A), 
trypsinized and the number of viable cells was counted. Cell counts for 
each cell line were normalized to the number of viable cells for each cell 
line from non serum starved conditions. Asterisks indicate p-value <0.05.  
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2.4.14 Mutant alleles of RAB35 transform NIH-3T3 cells in vitro in a PI3K-
dependent manner 
To determine if the mutant alleles of RAB35 are oncogenic, we asked 
whether they could transform non-cancerous NIH-3T3 cells in a focus-
formation assay—a standard in vitro model of density-independent growth 
and thus tumorigenicity [334-335]. Indeed, NIH-3T3 cells expressing 
oncogenic p110αH1047R, AKT1myr or the three mutant alleles of RAB35—but 
not RAB35wt—formed foci (Figure 2.20). Moreover, we found that when 
cultured in medium containing 250 nM of the pan-class I PI3K inhibitor GDC-
0941 [359], cells expressing RAB35 mutants and p110αH1047R were unable to 
form foci. Not surprisingly, GDC-0941did not inhibit the growth of cells 
transduced with AKT1myr. Thus, expression of RAB35 mutants identified from 







Figure 2.20: RAB35 mutants can transform cells in vitro in a PI3K-
dependent manner. (A) NIH-3T3 cells stably expressing the indicated 
RAB35 alleles, HA-p110αH1047R, or myristoylated FLAG-AKT1myr were 
cultured for 4 weeks in medium containing 2% BCS with either DMSO 
or 250 nM GDC-0941, then fixed, stained with crystal violet, and 
imaged. (B) Crystal violet stain from each well was then solubilized in 






We identify here the small GTPase RAB35 as a positive regulator of 
PI3K signaling (Figure 2.21). Although the precise mechanism of how 
RAB35 transduces upstream signals to PI3K remains unclear, our data 
demonstrate a previously unappreciated role for RAB35 in regulating growth 
 
factor signaling to PI3K/AKT. Further, the ability of mutant alleles of RAB35 
found in human cancers to activate PI3K/AKT signaling, protect cells from 
apoptosis and transform cells in vitro suggests that RAB35 may be a proto-
oncogene. Finally, that a RAB protein that regulates endomembrane 
trafficking possesses oncogenic potential suggests that dysregulation of 
membrane trafficking in cells could itself serve as a driver in the 
development and survival of tumor cells.   
 
Figure 2.21: RAB35 regulates PI3K signaling to AKT either 
through PI3K or growth factor receptors. The data presented in 
this chapter suggest that RAB35 controls PI3K signaling by regulating 
signaling at the level of growth factor receptor tyrosine kinases 





RAB35 REGULATES THE PI3K/AKT PATHWAY VIA THE PLATELET-
DERIVED GROWTH FACTER RECEPTOR TYROSINE KINASE 
3.1 ABSTRACT 
 The data described in Chapter 2 of this thesis suggest that RAB35 is 
a bona fide positive regulator of PI3K signaling. Here, we suggest that 
RAB35 regulates this pathway specifically via the platelet-derived growth 
factor receptor α (PDGFRα). GTPase-deficient RAB35 Q67L potently activates 
PI3K/AKT signaling by specifically activating PDGFRα. Further, dominant 
active RAB35 constitutively localizes PDGFRα—but not receptor tyrosine 
kinases like EGFR—to RAB7-positive late endosomes, which is the same 
compartment that active, liganded PDGFRα localizes to after internalization 
in cells that express wildtype RAB35. Finally, blockade of PDGFRα kinase 
activity with the PDGFRα-specific inhibitor Crenolanib suppresses AKT 
activation in cells that express dominant active RAB35Q67L. Thus, RAB35 
signals to PI3K/AKT primarily through PDGFRα, likely by serving to traffic 
PDGFRα to a RAB7-positive endomembrane where it is active. 
 
3.2 INTRODUCTION 
Thus far, our data suggest that RAB35 is a positive regulator of 
PI3K/AKT signaling (Chapter 2) [360]. We used loss-of-function studies to 
demonstrate that RAB35 is necessary for activation of the PI3K/AKT 
pathway. Further, our gain-of-function experiments with a constitutively 
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activated allele of RAB35 provided evidence that RAB35 is a positive 
regulator of PI3K/AKT signaling. Finally, biochemical epistasis experiments 
strongly suggest that RAB35 functions upstream of PI3K itself. 
Because 1.) our data strongly implicate RAB35 as a positive regulator 
of PI3K signaling, 2.) RAB35 is well documented to be involved in the 
trafficking of several cargoes between endocytic compartments and the cell 
membrane, and 3.) growth factor receptors and their associated signaling 
machinery are known to actively signal after internalization to 
endomembranes, we reasoned that RAB35 might serve to activate or retain 
RTK-PI3K complexes in a cellular compartment where they transmit 
signaling to PI3K/AKT effectors. Thus, we asked whether RAB35 signaling is 
transduced through any particular RTK-PI3K complexes. We investigated 
whether these complexes were altered in their trafficking by activated RAB35 
proteins. Interestingly, the data we describe in this chapter suggests that 
RAB35 activates PI3K through a particular RTK and at a specific 
endomembrane within the cell.  
 
3.3 METHODS 
3.3.1 In vitro PI3K-RAB35 interaction assays 
In vitro interaction assays between immunoprecipitated PI3K and 
FLAG-purified RAB35 were adapted from previously described protocols 
[183-184, 361-362]. First, we affinity purified FLAG-GTPases as follows. 
HEK-293E cell lines stably expressing either FLAG-tagged RHEBwt, 
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RAB35wt, or RAB35Q67L were lysed in 1% TX-100 lysis buffer as described in 
Chapter 2.2 of this thesis. The lysates were clarified, and 40 µL of mouse 
anti-FLAG M2 antibody conjugated to agarose beads was added to tubes 
containing 2 µg of cell lysates. The lysate/antibody mix was incubated over 
night at 4° C. The next day, the agarose beads were washed three times 
with TX-100 lysis buffer, then twice more with RHEB GTPase buffer (20 mM 
HEPES [pH 8.0], 200 mM NaCl, 5 mM MgCl2) [178]. The GTPase buffer was 
aspirated completely and 100 µL of 10 mM FLAG peptide in GTPase buffer 
was added to the beads. This mixture was then incubated at room 
temperature for 1 hour to elute the FLAG-GTPases from the agarose beads. 
The eluates were then collected and pooled. To remove the FLAG peptide 
and concentrate the GTPases, the pooled eluates were filtered with a 10 
kDa Amicon Ultra 0.5 mL centrifuge filter (Millipore, UFC501008).  
The same day that FLAG-GTPase expressing cells were lysed, 
wildtype HEK-293E cells cultured in complete medium were lysed in 0.3% 
CHAPS buffer, and 1 µg of cell lysates were incubated overnight with 20 µL 
of anti-p85 antibody conjugated agarose beads. The next day, the complex 
of agarose/antibody and immunoprecipitated PI3K was washed three times 
with CHAPS lysis buffer. 
Prior to combining the immunopurified PI3K and GTPases, FLAG-
RHEB or FLAG-RAB35 were loaded with either GDP or guanosine 5’-3-O-
(thio) triphosphate (GTPγS) as follows [178]. FLAG-RHEB or FLAG-RAB35 
GTPases were incubated with 10 mM EDTA and either 1 mM GDP or 0.1 
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mM GTPγS at 30° C for 10 minutes, then 20 mM MgCl2 was added and the 
proteins were kept on ice until use. 
Once PI3K was immunopurified and washed and FLAG-GTPases 
were loaded with either GDP or GTPγS, 40 µL of purified, nucleotide loaded 
GTPase was added to each individual PI3K IP. This mixture was incubated 
at room temperature for 30 minutes, and then washed three times with 
GTPase storage buffer. Finally, the last wash was aspirated, beads were 
resuspended in 20 µL Laemmli’s buffer, boiled, resolved by SDS-PAGE and 
then analyzed by immunoblotting as described in Chapter 2.  
 
3.3.2 Immunofluorescence for microscopy 
Immunofluorescence was performed as described previously [363]. 
Millicell EZ slide 4-well chamber slides (Millipore, PEZGS0416) were coated 
for 30 minutes with 0.01 mg/mL human fibronectin (Calbiochem, 341635) in 
PBS, rinsed once with PBS, and seeded with 100,000 HEK-293E cells. 
Immediately following the indicated treatments and/or stimulations, slides 
were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, 15714-
S) in PBS for 15 minutes at room temperature. The slides were then rinsed 3 
times in PBS for 5 minutes each, permeabilized with 0.05% Triton TX-100 in 
PBS for 1 minute at room temperature, then rinsed three more times in PBS. 
Next, each well was incubated with primary antibody at a dilution of 1:100 in 
5% normal goat serum (Vector Laboratories, S-1000) in PBS overnight at 4° 
C. When Alexa Fluor 488 conjugated mouse anti-myc antibody (Cell 
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Signaling Technology, 2279) was necessary, it was used at a 1:50 dilution 
and incubated as indicated overnight. The next day, the slides were rinsed in 
PBS 3 times at room temperature, and incubated for 1 hour at room 
temperature with the following mixture: the appropriate fluorophore-
conjugated secondary antibody (either goat anti-rabbit Alexa Fluor 488 nm 
(Invitrogen, A11070), goat anti-mouse Alexa Fluor 488 nm (Invitrogen, 
A11029), goat anti-mouse Alexa Fluor 555 nm (Invitrogen, A21424), or goat 
anti-rabbit Alexa Fluor 555 nm (Invitrogen, A21429)) at a 1:200 dilution, and 
Hoechst 33342 (Invitrogen, H3570) at a 1:10,000 dilution. When actin 
staining with fluorophore-conjugated phalloidin was performed, Alexa Fluor 
594 conjugated phalloidin (Invitrogen, A12381) was included in the 
secondary staining mix at a dilution of 1:200. After incubation, the slides 
were rinsed 4 times in room temperature PBS, the slide chambers were 
removed, slides were mounted with 100 µL ProLong Gold anti-fade reagent 
(Invitrogen, P36930) and glass coverslips (Fisher Scientific, 12-545-88). 
Slides were then sealed with Sally Hansen® “Super Shine” Shiny Top Coat 
(Sally Hansen, 2290), air dried, then stored at 4° C until imaging. Slides were 
imaged with an Axio Imager 2 widefield microscope (Zeiss) and AxioVision 





3.3.3 Immunoprecipitation/mass spectroscopy for the identification of PI3K 
interacting proteins 
Immunoprecipitations of PI3K were carried out as described in the 
previous chapter. Immunoprecipitates were then resolved by SDS-PAGE 
and the gel was stained with Novex Simply Blue stain (Invitrogen, PART #). 
The gel was then submitted to the Memorial Sloan-Kettering Cancer Center 
Microchemistry and Proteomics Core Facility. The lanes of the gel containing 
the immunoprecipitated proteins were then cut into sections, digested with 
trypsin, and subjected to mass spectroscopic analysis as previously 
described [364-366]. Results of the MS run were analyzed using the 
program Scaffold v4.2.1 (Proteome Software). Only peptides of >90% 
certainty with 1 or more peptide fragments present were considered in 
analysis of MS data.  
 
3.4 RESULTS 
3.4.1 RAB35 interacts with PI3K in a nucleotide-dependent manner 
The data described in Chapter 2 suggest that RAB35 regulates PI3K 
signaling either 1.) at PI3K itself or 2.) at the interface between growth factor 
receptor tyrosine kinases and PI3K. However, those data do not delineate 
whether RAB35 regulates PI3K directly or indirectly. To first ask whether the 
two proteins interact, we used an anti-p85 antibody to immunopurify PI3K 
from cells stably expressing FLAG-tagged alleles of RHEB (as a control) or 
RAB35 (Figure 3.1). Indeed, we found that FLAG-RAB35wt—but not FLAG-
98 
 
RHEB—co-immunopurified with PI3K. Further, the dominant active GTPase 
deficient RAB35Q67L mutant was present in the PI3K immunoprecipitates to a 
higher extent than was the wildtype allele. Further, the GDP-bound mutant—
RAB35S22N—was barely detectable in PI3K immunoprecipitates from HEK-
293E cells that stably expressed FLAG-RAB35S22N.  
In addition to these data, we also found that transiently expressed 
myc-tagged RAB35—but not myc-tagged RHEB—immunoprecipitated with 
endogenous PI3Kα (Figure 3.2). Consistent with the interaction data from 
the stable cell lines in Figure 3.1, myc-RAB35S22N was nearly undetectable in 
PI3K IPs. Taken together, these data suggested to us that RAB35 interacts 
with PI3K. However, whether RAB35 interacts with PI3K directly—as has 
 
Figure 3.1: Stably expressed RAB35 interacts with endogenous 
PI3K in a nucleotide-dependent fashion. HEK-293E cells stably 
expressing the indicated FLAG-GTPases were serum starved 
overnight, treated with serum, lysed, and PI3K was immunopurified with 
an anti-p85 antibody. Lysates and immunoprecipitates were then 




been demonstrated for GTPases like KRAS—or does so through other 
proteins remained unclear [94-95, 97-99, 101, 367-370].  
We next sought to validate the PI3K-RAB35 interaction with an in vitro 
interaction assay. PI3K immunopurified from HEK-293E cells was incubated 
with either purified FLAG-tagged RHEB loaded with the GTP-analogue 
GTPγS or purified FLAG-RAB35 loaded with GDP or GTPγS (Figure 3.3) 
 
Figure 3.2: Transiently expressed RAB35 interacts with 
endogenous PI3K in a nucleotide-dependent fashion. HEK-293E 
cells stably expressing the indicated FLAG-GTPases were serum 
starved overnight, treated with serum, lysed, and PI3K was 
immunopurified with an anti-p85 antibody. Lysates and 
immunoprecipitates were then analyzed by immunoblotting. Signal 
intensities of the bands were quantified using the LiCor Odyssey 
software, then the signal intensity of each immunoprecipitated myc 
band (top) was divided by that of the corresponding myc band in the 





[183-184, 361, 371-373]. After incubation together, the agarose beads 
bound to PI3K were washed and the remaining proteins were analyzed by 
immunoblotting for the presence of FLAG-RAB35wt. Indeed, the only PI3K 
immunoprecipitates that retained bound RAB35 were those that had been 
incubated with GTP-loaded FLAG-RAB35 wt. These data indicate that PI3K 
and RAB35 interact in a GTP-dependent manner. However, because the 
PI3K used in this experiment had been immunopurified from cells, it is 
possible that adapter proteins or growth factor receptors that associate with 
PI3K could serve to interact with RAB35. Thus, whether RAB35 interacts 
directly with PI3K remains unclear.  
 
 
Figure 3.3: Immunopurified PI3K interacts with purified GTPγS-
RAB35 but not GDP-RAB35. FLAG-tagged RHEB or RAB35 were 
affinity purified from lysates of cells stably expressing either GTPase, 
loaded with either GDP or GTPγS as indicated. Endogenous PI3K 
was immunopurified from wildtype HEK-293E cells with an agarose-
conjugated anti-p85 antibody, washed, and then incubated with the 
GTPases as indicated above. The GTPase-PI3K complexes were 




3.4.2 GTPase-deficient RAB35 specifically activates the platelet-derived 
growth factor receptor 
In probing the interaction of RAB35 with PI3K, we noticed that a 
prominent phospho-tyrosine signal was present in immunoprecipitates of 
PI3K from cells stably expressing GTPase-deficient RAB35Q67L (Figure 3.4). 
In cells stably expressing RAB35wt, this signal is strongest in PI3K 
immunoprecipitates from cells that have been treated with growth factors or 
serum. Interestingly, this signal is elevated in PI3K immunoprecipitates from 
cells expressing RAB35Q67L regardless of whether cells had been serum 
starved or not. Indeed, this signal was apparent even in the lysates of cells 
expressing RAB35Q67L but not RHEB or RAB35wt.  
The protein responsible for the elevated phospho-tyrosine signal in 
PI3K immunoprecipitates and whole cell lysates from cells expressing 
 
Figure 3.4: PI3K immunoprecipitated from cells stably expressing 
RAB35Q67L is associated with a constitutively elevated phospho-
tyrosine signal. HEK-293E cells stably expressing FLAG GTPases 
were serum starved overnight, treated as indicated with FBS, lysed, 
and PI3K was immunopurified from the lysates. Immunoprecipitates 
and whole cell lysates were then analyzed by immunoblotting. White 




dominant active RAB35 was of a relatively high molecular weight (175-200 
kDa). Given the prominence of tyrosine phosphorylation in the activation of 
receptor tyrosine kinases and their substrates, we thus reasoned that this 
signal might be emanating from either a receptor tyrosine kinase (EGFR, 
PDGFR, IGF-IR, etc.) or an RTK substrate of a high molecular weight (such 
as IRS-1, etc.). Further, we speculated that this was likely one individual 
protein, as there were not other phosphotyrosine signals present in lysates 
from cells expressing GTPase-deficient RAB35Q67L.  
 We next asked which growth factor receptor tyrosine kinase might be 
the source of the phosphotyrosine signal in cells stably expressing GTP-
bound RAB35Q67L. Once activated, RTKs auto-phosphorylate numerous 
tyrosine residues in trans, and tyrosine phosphorylation of the catalytic 
domain tyrosines is necessary for activation of most receptor tyrosine 
kinases [374-378]. In contrast, the other auto-phosphorylation tyrosine sites 
on RTKs serve as sites for adaptor proteins—such as IRS1/2, p85, GRB2, 
etc.—to interact with active RTKs. Because each receptor has multiple 
binding domains that contain phosphorylatable tyrosine residues, we 
reasoned that the most effective way to identify the source of this elevated 
phosphotyrosine signal would be to probe lysates for phosphorylation of the 
catalytic domain tyrosine residues of different growth factor receptors. Thus, 
we probed for multiple RTK catalytic domain phosphorylation levels in 
lysates from cells expressing FLAG-tagged RHEBwt, RAB35wt and 
RAB35Q67L that had been either serum starved or stimulated with serum 
103 
 
(Figure 3.5). Interestingly, we found that only the phosphorylation levels of 
Y849/857 on PDGFRα/β were constitutively elevated in cells expressing 
RAB35Q67L. The catalytic domain tyrosine phosphorylation sites on other 
receptors were either normally activated by serum in all three cell lines (IGF-
IRβ, EGFR, MET) or equally constitutively active in all three cell lines 
regardless of serum deprivation/stimulation (VEGFR, FGFR). We also 
probed for phosphorylation of other tyrosine kinases (c-Kit, SRC, etc.) and 
did not find any difference in phosphotyrosine levels between the three cell 
lines examined in Figure 3.5 (data not shown).   
 
 
Figure 3.5: The platelet-derived growth factor receptor—but not other 
growth factor receptors—is hyper-phosphorylated at a catalytic 
domain tyrosine residue in cells stably expressing GTPase-deficient 
RAB35Q67L. HEK-293E cells expressing the indicated FLAG-GTPases 
were starved overnight, stimulated with FBS as indicated, lysed, and 
lysates were analyzed by immunoblotting with the indicated antibodies. 
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3.4.3 Pharmacological inhibition of PDGFRα/β but not PDGFRβ inhibits 
PI3K/AKT signaling in cells stably expressing GTPase-deficient 
RAB35Q67L 
 Because the upregulation of growth factor receptors by dominant 
active RAB35 seemed so specific to PDGFR, we next asked whether 
pharmacological blockade of PDGFR could inhibit PI3K/AKT signaling. Our 
first course of action was to attempt PDGFR inhibition with the well 
characterized pan-tyrosine kinase inhibitor imatinib/gleevec [278, 379-381], 
but this molecule failed to suppress PI3K/AKT signaling in cells that 
expressed GTP-bound RAB35Q67L (data not shown). This could be 
accounted for by the fact that: 1.) the affinity of imatinib for PDGFR is 
relatively low, or 2.) the activated PDGFR is locked in an imatinib-resistant 
conformation.  
 We next asked whether more potent, isoform specific PDGFR 
inhibitors could block PDGFR signaling to PI3K/AKT (Figure 3.6A). Indeed, 
in cells stably expressing RAB35Q67L the phosphorylation of the PDGF 
receptor, AKT, and FOXO1/3A were not suppressed by treatment with the 
PDGFRβ-specific small molecule CP-673451[382]. However, an inhibitor 
that specifically targets PDGFRα and PDGFRβ with similar potency—CP-
868596 (Crenolanib®) [383-387]—was more effective at suppressing the 
phosphorylation of PDGFR, AKT and FOXO1/3A. To ensure that the majority 
of the signal through the PI3K/AKT 
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pathway was originating from the mutant allele of RAB35, these experiments 
were performed in serum-free conditions. Interestingly, in the same 
experiment performed in cells stably expressing RAB35wt in serum replete 
conditions, we found that PDGFRα/β inhibition failed to suppress AKT 
phosphorylation (Figure 3.6B). This suggests that PDGFR inhibition on its 
own in the presence of serum is not sufficient to inhibit PI3K/AKT signaling 
(Figure 3.6B). 
 Finally, to check whether other RTKs might be involved in the 
regulation of PI3K/AKT by RAB35, we also tested a number of lipid kinase 
and tyrosine kinase inhibitors (TKI’s) on cells expressing GTPase deficient, 
 
Figure 3.6: Pharmacological blockade of PDGFRα/β inhibits PI3K/AKT 
signaling in cells stably expressing GTPase-deficient RAB35Q67L. (A) 
Cells stably expressing RAB35Q67L were serum starved and treated 
overnight with either vehicle (DMSO), the pan-Class I PI3K inhibitor GDC-
0941 (0.5 µM), the PI3Kα-specific BYL-719 (1 µM), the PDGFRβ inhibitor 
CP-673451 (PDGFRβi, 1 µM), or the PDGFRα/β inhibitor CP-868596 
(PDGFRα/βi, 1 µM). Cells were then lysed and lysates were analyzed by 
immunoblotting. (B) Cells stably expressing RAB35wt were treated 
overnight as indicated in serum replete medium, then lysed and analyzed 




dominant active RAB35Q67L (Figure 3.7 and data not shown). As expected, 
the PI3K inhibitors GDC-0941 and BYL-719 suppressed AKT 
 
Figure 3.7: Non-PDGFR targeting kinase inhibitors do not reduce 
PI3K/AKT signaling in cells expressing GTPase-deficient 
RAB35Q67L. (A) Cells stably expressing RAB35wt were serum starved 
and treated with either DMSO or the indicated drugs overnight as noted. 
The next day, the cells were stimulated with DMEM containing 10% FBS 
and the indicated inhibitors. (B) Cells stably expressing RAB35Q67L were 
treated overnight in serum free medium as indicated. Cells were then 




phosphorylation in cells expressing RAB35Qwt or RAB35Q67L. Further, EGFR 
inhibitors like Erlotinib and Lapatinib failed to suppress AKT phosphorylation 
in cells expressing GTPase-deficient RAB35Q67L. Further, VEGFR-specific 
molecules had little to no effect on AKT phosphorylation in cells expressing 
RAB35Q67L.  
 
3.4.4 RAB35wt and GTPase-deficient RAB35Q67L interact with PDGFRα and 
PDGFRβ 
As demonstrated earlier in this chapter, we had found that RAB35 
interacts with PI3K in a GTP-dependent manner. This led us to wonder 
whether RAB35 was interacting with PI3K in a manner analogous to how the 
GTPase KRAS interacts with PI3K—i.e. directly and in a way that activates 
the kinase activity of PI3K. However, our findings that 1.) the expression of 
dominant active RAB35Q67L specifically upregulates the tyrosine 
phosphorylation of PDGFRα/β (Figure 3.5) and 2.) a PDGFRα/β specific 
kinase inhibitor suppresses RAB35Q67L-driven PI3K/AKT activity suggested 
to us that RAB35 might be acting directly on PDGFR.  
To ask whether RAB35 might be interacting with PDGFR, we 
transfected cDNAs expressing either myc-tagged PDGFRα or β into cells 
stably expressing either RHEBwt, RAB35wt or RAB35Q67L. After lysing these 
cells, we then immunopurified either PI3K (using an anti-p85 antibody) or 
myc-PDGFR (using an anti-myc antibody) and asked whether FLAG-tagged 
RAB35 co-immunoprecipitated with these proteins (Figure 3.8). Not 
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surprisingly, we found that both PDGFRα and β immunoprecipitated with 
PI3K, and that FLAG-tagged RAB35wt and RAB35Q67L—but not RHEBwt—
was also present in these purifications (Figure 3.8A). These data were 
consistent with 1.) the fact that PDGFRα/β is a well-characterized interaction 




Figure 3.8: RAB35wt and GTPase-deficient RAB35Q67L interact with 
PDGFRα and PDGFRβ. (A) HEK-293E cells stably expressing FLAG-
tagged RHEBwt, RAB35wt or RAB35Q67L were transfected with cDNA 
encoding for either myc-PDGFRα or myc-PDGFRβ. Cells were then lysed 
and PI3K was immunopurified with an anti-p85 antibody. (B) myc-PDGFR 




We also immunopurified myc-PDGFRα or β using an anti-myc 
antibody. As with our PI3K purifications, we found that both the p85 and 
p110α subunits of PI3K were present in both PDGFRα and β 
immunoprecipitates (Figure 3.8B). We also found that both alleles of FLAG-
tagged RAB35 were also present in these purifications. Interestingly, the 
FLAG-RAB35 signal present in PDGFR purifications was consistently 
stronger than the FLAG-RAB35 signal in our PI3K purifications, which 
suggested to us that the PDGFR-RAB35 interaction may be more robust 
than the PI3K-RAB35 interaction. This is reinforced by the fact that in cells 
expressing RAB35Q67L, less p85 and p110α purify with both PDGFRα and β, 
but the amount of FLAG-RAB35Q67L is not diminished in these 
immunoprecipitations. This suggests to us that the interaction of PI3K and 
RAB35 may be indirect and due to the fact that both are interacting with 
PDGFR. However, whether RAB35 interacts with PDGFR directly or via 
another protein remains unclear.   
 
3.4.5 GTPase-deficient RAB35Q67L constitutively localizes PDGFRα to an 
internal compartment 
Because RAB35 is a RAB GTPase, we had previously considered 
that its role in PI3K/AKT signaling could be due to endomembrane trafficking 
of either PDGFR, PI3K or AKT itself. Since we had evidence that dominant 
active RAB35Q67L is exerting its effects via PDGFRα—and because 
trafficking of RTKs is a well documented phenomenon [388-391]—we next 
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asked whether expression of dominant active, GTPase-deficient RAB35Q67L 
was altering the localization of PDGFRα  (Figure 3.9). We transiently 
transfected cDNAs coding for myc-tagged PDGFRα into cells that 
 
stably expressed either RAB35wt or RAB35Q67L and asked whether the 
localization of the receptor was altered by GTPase-deficient RAB35. Not 
surprisingly, in cells expressing RAB35wt, PDGFRα was diffusely localized in 
the absence of growth factors but reorganized into discreet internalized 
punctate structures after 15 minutes of treatment with PDGF-AA. However, 
in cells expressing RAB35Q67L, PDGFRα was constitutively internalized 
regardless of whether the cells had been stimulated with PDGF or not. Thus, 
GTPase-deficient RAB35Q67L dyslocalizes PDGFRα to compartments inside 
the cell regardless of growth factor stimulation. 
 
Figure 3.9: Dominant active, GTPase-deficient RAB35Q67L 
constitutively internalizes PDGFRα. HEK-293E cells stably 
expressing FLAG-tagged RAB35wt or RAB35Q67L were transiently 
transfected with cDNAs expressing myc-tagged PDGFRα, then 
starved, treated with 100 ng/mL PDGF-AA for 15 minutes and 
processed for immunofluorescence with an anti-myc antibody and 





Although our biochemical evidence and experiments with small 
molecules already suggested that RAB35-mediated activation of PI3K/AKT 
signaling was explicitly through PDGFRα, we wanted to ask whether 
trafficking of RTKs was generally deranged in cells with activated 
RAB35Q67L. The epidermal growth factor receptor (EGFR) is well-
characterized in terms of its internalization and recycling after stimulation 
with EGF. Thus, we performed a similar experiment to the one in Figure 3.9 
using myc-tagged EGFR to visualize EGFR trafficking in cells expressing 
either RAB35wt or RAB35Q67L (Figure 3.10). Unlike our observations with 
PDGFRα, we did not see any difference in the EGF-stimulated 
internalization of EGFR between the two cell lines, which suggested to us 




Figure 3.10: Dominant active RAB35Q67L does not alter the 
localization of the epidermal growth factor receptor (EGFR). HEK-
293E cells stably expressing the indicated FLAG-RAB35 alleles were 
transiently transfected with cDNAs expressing the indicated receptor 
tyrosine kinases, starved overnight, treated with the indicated ligands 





Interestingly, the localization of other growth factor receptors also did 
not appear to be grossly altered in cells that stably expressed RAB35Q67L 
(data not shown). These data are consistent with our biochemical evidence 
that PDGFR is the only RTK that is hyper-phosphorylated due to expression 
of RAB35Q67L. This further suggested to us that the influence of RAB35 on 
PI3K/AKT signaling is transduced by PDGFRα but not other RTKs.  
 
3.4.6 RAB35Q67L sequesters PDGFRα to RAB7-positive endomembranes 
We were curious as to whether or not the localization of PDGFRα in 
cells that expressed GTP-bound RAB35Q67L was either due to 1.) excessive 
accumulation of the receptor in a compartment that PDGFR normally traffics 
through, or 2.) aberrant trafficking of the receptor into an abnormal 
endomembrane compartment. We thus asked two questions: 1.) which 
endosomal compartment is internalized PDGFRα normally associated with 
after PDGF-treatment in cells that express RAB35wt? and 2.) which 
endosomal compartment PDGFRα is localized to in cells expressing 
activated RAB35Q67L? Although endosomes are a diverse population of 
endomembrane compartments, they can be roughly functionally categorized 
by the populations of proteins that they contain [392-395]. For example, early 
endosomes contain early endosomal antigen 1 (EEA1) and the GTPase 
RAB5 [396-402], while late endosomes contain RAB7 [403-404], recycling 
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endosomes are marked by RAB11a and RAB11b [405-411], and lysosomes 
contain RAB7 and LAMP1 [412-413].  
We found that 15 minutes after PDGF-AA treatment in cells expressing 
wildtype RAB35, transiently expressed myc-tagged PDGFRα is localized in 
part to a RAB7-positive compartment within the cell (Figure 3.11A). This is 
not surprising, as RAB proteins (RAB4, in particular) have been implicated in 
PDGFR trafficking previously [414]. Interestingly, in cells stably expressing 
RAB35Q67L, myc-PDGFRα was also localized to RAB7-positive 
compartments even in the absence of stimulation with PDGF-AA (Figure 
3.11B). These data suggested to us that RAB35Q67L may be retaining active 
PDGFRα in a RAB7-positive compartment.  
 
 
Figure 3.11: PDGF-stimulated PDGFRα localizes to a RAB7-
positive compartment in cells stably expressing RAB35wt or in 
PDGF-deprived cells stably expressing RAB35Q67L. HEK-293E 
cells stably expressing FLAG-RAB35wt were transfected with myc-
PDGFRα, treated with PDGF-AA for 15 minutes, then processed for 





 We also asked whether PDGFRα localized to other compartments 
that are marked by the RAB proteins RAB5 (present in early endosomes) or 
RAB11 (present in recycling endosomes). Interestingly, myc-PDGFRα did 
not localize to RAB5 or RAB11-containing compartments in RAB35wt cells 
that had been treated with PDGF-AA or in RAB35Q67L expressing cells that 
had been deprived of growth factors. This indicated to us that the 









Figure 3.12: PDGFRα does not localize to RAB5 or RAB11-
positive endomembranes in cells expressing RAB35wt or 
RAB35Q67L. (A) HEK-293E cells stably expressing FLAG-RAB35wt 
were transfected with myc-PDGFRα, serum starved overnight, then 
treated with 100 ng/mL PDGF-AA for 15 minutes and processed for 
immunofluorescence with the indicated antibodies. (B) HEK-293E cells 
stably expressing FLAG-RAB35Q67L were transfected with cDNA 
expressing myc-PDGFRα, serum starved overnight, then processed 




 Our data suggest that RAB35 interacts with PI3K, and that this 
interaction is at least partially GTP-dependent. In searching for mechanisms 
by which RAB35 regulates PI3K, we identified PDGFR as aberrantly 
activated in cells that stably express a dominant active allele of RAB35. 
Further, small molecule inhibitor experiments suggest that RAB35 likely 
regulates PI3K/AKT signaling through PDGFRα, although the “division of 
labor” between PDGFRα and β when regulated by RAB35 remains unclear.  
In addition to the biochemical evidence that RAB35 regulates PI3K via 
the PDGFRs, we find that expression of activated RAB35Q67L retains 
PDGFRα in a RAB7-positive endomembrane compartment. Interestingly, 
this is similar to the location of liganded PDGFRα in cells expressing 
wildtype RAB35. Thus, it appears that dominant active RAB35Q67L is not 
trafficking PDGFRs to an inappropriate or abnormal endomembrane, rather 
retaining these RTKs in a location that they likely inhabit only temporarily 
under normal conditions. Whether this RAB7-positive location in the cell is 
an unidentified endosome, a late endosome [404], or the lysosome [415] is 
at present unclear. 
 Rab proteins like RAB35 are primarily thought to regulate 
endomembrane trafficking, and growth factor receptor trafficking is a 
mechanism of regulating RTK signaling. Thus, we hypothesize that GTP-
loaded RAB35 traffics activated PDGFRs to endomembranes where the 
PDGFR-PI3K complexes sustain localized PI3K signaling. Although our data 
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do support such a hypothesis, many questions about the nature of this 
relationship remain unanswered. For instance, whether—and to what 
extent—RAB35 is a normal physiological regulator of PDGFRα trafficking is 
unclear. Further, whether PDGFRα is a direct cargo of RAB35 or merely a 
“hitchhiker” on RAB35-positive endosomes is also unknown. These 
questions can be answered as more is learned about the trafficking life cycle 
of PDGFRα itself and as the relationship between RAB35 and PI3K 





RAB35, CANCER, AND THE ONCOGENIC POTENTIAL OF THE 
ENDOMEMBRANE TRAFFICKING SYSTEM 
4.1 THE SMALL GTPASE RAB35 IS A REGULATOR OF ENDOSOMAL 
TRAFFICKING AND CYTOSKELETAL ORGANIZATION 
4.1.1 RAB35 regulates endomembrane trafficking at the recycling 
endosome 
RAB35 was at first thought to be a member of the RAB1 sub-family of 
RAB GTPases by virtue of its amino acid sequence, and it was initially called 
Ray/RAB1C [416-417]. However, it was soon appreciated that despite 
sequence similarity, RAB35 was functionally distinct from RAB1A and 
RAB1B, which regulate vesicular trafficking between the endoplasmic 
reticulum and the golgi apparatus [417-420]. The first endomembrane 
trafficking function ascribed to RAB35 was fast endocytic recycling, which is 
necessary for the terminal steps of cytokinesis in dividing cells [421]. Other 
early studies of RAB35 localization indicated that although RAB35 is 
localized to recycling endosomes, it is located at other endosomes as well as 
at the plasma membrane [336, 421-422]. Considering the different effectors 
of RAB35 that will be reviewed here, it is likely that there exist within the cell 
many distinct cellular pools of RAB35 that allow for fine-tuning of RAB35’s 
functions. Thus, the functions of RAB35 are very likely to be quite diverse.  
In addition to regulating the recycling endosome, RAB35 has also 
been implicated in exosome regulation. One group recently described 
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RAB35 as a positive regulator of exosome secretion, where RAB35 is 
necessary for the normal release of exosomes from oligodendrocytes into 
the intracellular space [423]. Hsu et. al. further described the proteins 
TBC1D10A-C as  RAB35 GTPase activating proteins that inhibit RAB35 
GTP-loading and exosome release. Further, TBC1D10C has been shown to 
negatively regulate the export of transferrin from the recycling endosome 
pathway, as well as T-cell receptor (TCR) recycling at the immunological 
synapse [373]. Recent data also suggest that GTP-bound RAB35 serves to 
retain cadherin molecules at the surface of cells, which promotes cell-to-cell 
adhesion [424-426].  
RAB35 has also been demonstrated to play a role at the early 
endosome. Both RAB35 and its positive regulator DENND1A (a guanine 
nucleotide exchange factor (GEF) [427]) have been shown to regulate 
trafficking at the early endosome [337]. Specifically, RAB35 and DENND1A 
recruit the tubular endosome protein EHD1 to EEA1-positive early 
endosomes. Further, the RAB35 GAP Skylwalker—a Drosophila homologue 
of the TBC1D10A-C proteins in humans—regulates the pool of synaptic 
endosomes in neurons [428].  Thus, in addition to regulating the recycling of 
cargoes through the recycling endosome, RAB35 functions at several other 
endomembrane sites in a variety of different cellular contexts. 
Interestingly, RAB35 can regulate the endosomal localization and 
activation of other small GTPases. For example, GTP-bound RAB35 can 
activate centaurin-β2 GAPs that negatively regulate the GTPase ARF6 [429], 
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which in turn downregulates ARF6-dependent recycling of β1-integrins and 
EGFRs [426]. Conversely, GTP-bound ARF6 can activate the RAB35 GAP 
TBC1D10B, which downregulates RAB35-dependent signaling and prevents 
loading of RAB35 into the endocytic pathway [430]. More recent evidence 
from the Fukuda lab suggests that RAB35 recruits RAB8, RAB13 and 
RAB36 to recycling endosomes via the scaffold protein MICAL-L1 [431] 
It also appears that the recruitment of the Rho GTPases RAC1 and 
CDC42 to phagosomes is dependent on GTP-bound RAB35 [432]. Further, 
Shim et. al. suggest that RAB35 is necessary for actin remodeling by RAC1 
and CDC42. Thus, the regulation of actin/the cytoskeleton and membrane 
trafficking can actually be seen as overlapping functions, as RAB35 
regulates the localization of several GTPases that directly govern 
cytoskeletal shape.  
 
4.1.2 RAB35 regulates actin cytoskeletal dynamics and cell shape 
 In addition to its role in trafficking cargoes through the recycling 
endosome, RAB35 regulates the shape of the actin cytoskeleton [338]. The 
same group that described RAB35 as a regulator of cytokinesis has also 
described RAB35 as a regulator of the 5’-OH phosphatase OCRL, which 
localizes phosphatidylinositol 4, 5-bisphosphate and F-actin to the cellular 
bridge during the abscission steps of cytokinesis [336]. Activated RAB35 has 
also been described as a positive regulator of the actin remodeling that 
drives neurite outgrowth [433-435]. Indeed, several groups have found that 
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expression of dominant active GTP-bound RAB35 caused remodeling of the 
cytoskeleton into spindly, neurite-like portions of cell membrane. Indeed, 
stable expression of RAB35Q67L in our hands yielded the same phenotype. 
Interestingly, we found that this was PI3K-dependent, as treatment with PI3K 
inhibitors reversed this RAB35Q67L-dependent spindly actin phenotype (data 
not shown).  
It also appears that RAB35 regulates actin via a direct interaction. In 
Drosophila and mammalian cells, GTP-bound RAB35 interacts with the 
actin-bundling protein fascin to locally recruit actin [339]. These studies are 
supported by data from other groups that also identify the DENND1A-C 
proteins as guanine nucleotide exchange factors (GEFs) that activate the 
actin-related functions of RAB35 [433]. 
In summary, RAB35 performs a number of functions in a diverse set 
of biological pathways. In most cases, these appear to share a similar 
mechanism, where GTP-bound RAB35 recruits its effectors to various 
cellular locales. The effectors and regulators of RAB35 discussed in this 






Figure 4.1: RAB35 regulates the recycling endosome and actin 
cytoskeletal dynamics.  GDP-bound RAB35 is inactive and does not bind 
effectors. GDP is exchanged for GTP on RAB35 by the guanine nucleotide 
exchange factors (GEFs) DENND1A-C (left), which activates RAB35. RAB35 
GTPase activity is activated by the GTPase activating proteins (GAPs) 
TBC1D10A-C. GTP-bound RAB35 then regulates a diverse set of effectors by 
recruiting them to different cellular locations. OCRL, oculocerebral syndrome 
of Lowe; TCR, T-cell receptor; EHD1, EH-domain containing 1; EE, early 




4.2  PDGFR TRAFFICKING, RAB35, PI3K/AKT SIGNALING, AND 
CANCER 
4.2.1 Growth factor receptor tyrosine kinases are trafficked via the 
endomembrane system 
After growth factor stimulation, RTKs are internalized and either 
inactivated and returned to the membrane, allowed to signal in various 
subcellular locations, or targeted for destruction by the lysosome and 
proteasome system [389]. This mechanism is likely common to  
most growth factor receptors, but the epidermal growth factor receptor 
(EGFR) is the most thoroughly investigated receptor with regards to its 
internalization and trafficking after activation [389]. Because we found that 
RAB35 regulates the intracellular location of PDGFRα, it is important to 
consider how RTKs are trafficked by the cell after internalization.  
One mechanism by which growth factor receptors are downregulated 
is through ubiquitinization by the E3 ubiquitin ligase CBL [389, 436-437]. 
RTKs like EGFR [438], IGFIR [439], PDGFR [440-441], MET [442], KIT 
[443], VEGFR [444], and the Ephrin receptors [445-446] are all regulated by 
CBL in a similar process. Activated RTKs are internalized by clathrin-coated 
pieces of membrane, which often includes the recruitment of CBL to the RTK 
or its associated proteins. CBL then mono- and di-ubiquitinylates the target 
RTK, which tags the kinase for degradation at the lysosome and/or 
proteasome. Alternatively, receptors can be de-liganded, de-ubiquitinylated, 
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and recycled back to the cell membrane where they can be re-activated 
later. These scenarios are illustrated in Figure 4.2. 
 
The trafficking and degradation of receptors like EGFR has been 
understood for some time, but recent data have demonstrated that instead of 
simply being internalized and turned off, EGFR can actively signal while it is 
associated with endosomes [389, 391, 447-449] (See example in Figure 
4.2). The signaling of internalized EGFR from endomembrane compartments 
suggests a mechanism by which the cell can exquisitely govern the spatial 
 
Figure 4.2 The fates of internalized growth factor receptor tyrosine 
kinases. Once growth factor receptor tyrosine kinases (RTKs) are 
activated by their growth factor ligands, they initiate signaling at the cell 
membrane via PI3K and other effectors. They are then trafficked into the 
cell by endocytosis. Signaling can be attenuated by lysosomal destruction 
of the RTK, or by de-liganding and recycling the RTK back to the cell 
membrane. Alternatively, the RTK/PI3K complex can continue to actively 




and temporal activity of signal transduction. Interestingly, similar studies 
conducted with respect to PDGFR suggest that much of the signaling 
downstream of this receptor occurs after PDGFR is internalized to 
endosomes [390].  
We speculate that much of the PI3K-dependent signaling by PDGFR 
actually happens while receptors are trafficked intracellularly. Interestingly, 
we have found that the inhibition of endocytosis with the dynamin GTPase 
inhibitor Dynasore [450-453] or N-ethylmaleimide (NEM, which inhibits 
vesicular trafficking) [454-456] spares the initial activation of PI3K/AKT by 
growth factors (0-5 minutes), but blocks signaling that occurs 15 minutes to 
several hours after initial stimulation (data not shown). Given that RTKs are 
internalized within minutes after their initial stimulation, this suggests to us 
that RTK signaling to oncogenic pathways such as PI3K/AKT is dependent 
upon vesicular trafficking.  
 
4.2.2  RAB35 regulates the PI3K/AKT signaling axis by controlling the 
intracellular location of PDGFRα 
With the data presented in Chapters 2 and 3 of this thesis, we have 
provided evidence that GTP-bound RAB35 retains the PDGFRα in a RAB7-
positive endosome where it can drive PI3K/AKT signaling. Because 
depletion of RAB35 suppressed AKT and FOXO/NDRG1 phosphorylation in 
response to serum and individual growth factors, our data suggested that 
RAB35 might function downstream of multiple growth factor receptors. Our 
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first suspicion was that RAB35 either functioned at PI3K or was a general 
regulator of RTK activation of PI3K. However, our gain-of-function 
experiments indicate that RAB35 might function specifically through 
PDGFRα. 
 Localization studies in cell lines stably expressing wildtype RAB35 
suggested to us that PDGFRα is normally trafficked to RAB7-positive 
endomembranes after PDGF stimulation. Further, in cells expressing GTPase-
deficient RAB35Q67L, PDGFRα is trafficked to RAB7-positive endomembranes 
in the absence of PDGF. Although our data do not indicate whether or not 
RAB35 is required for the trafficking of PDGFRα to a RAB7-positive 
compartment, it appears that GTP-bound RAB35 somehow retains PDGFRα 
at this location, where it actively drives PI3K/AKT signaling in the absence of 
ligand. Whether RAB35 is necessary for trafficking PDGFRα to a RAB7-
positive endomembrane will be addressed with RAB35 loss-of-function 
studies. Further, it is unclear whether RAB35Q67L is itself driving PDGFRα to 
RAB7-positive compartments, or preventing the efficient exit from these 
compartments.  
It is also possible that GTP-bound RAB35Q67L inhibits a negative 
regulator of PDGFR signaling, trafficking, or degradation. For example, 
RAB35Q67L could inhibit the ability of the protein tyrosine phosphatase Src 
homology 2 domain-containing phosphatase 1 (SHP-1) to dephosphorylate 
the phospho-tyrosine residues on PDGFRs [457]. Alternatively—considering 
that RAB35 has been demonstrated to negatively regulate GTPases such as 
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ARF6 [426, 430]— RAB35Q67L may inhibit a RAB or ARF GTPase that 
determines the trafficking fate(s) of PDGFRs. Finally, RAB35Q67L may 
prevent ubiquitin ligases like CBL or CBL2 from ubiquitinylating PDGFRs 
[441, 458], which could lead to accumulated, phosphorylated and activated 
PDGFRs on endomembranes that can sustain signaling to PI3K/AKT.  
Although it is interesting to postulate various scenarios by which 
RAB35 may regulate PDGFRα, we suspect that the indirect scenarios 
outlined above are less likely, given that we have detected interactions 
between wildtype and mutant RAB35 and both PI3Kα and PDGFRα. We 
propose that the PDGFRα/PI3Kα complex is bound directly by RAB35, 
preferentially when it is loaded with GTP. The data presented in Figure 3.8—
where RAB35 co-purified more robustly with PI3K immunoprecipitates than it 
did with PDGFRα immunoprecipitates—suggest to us that RAB35 interacts 
with PI3Kα, which interacts with PDGFRα (Figure  
4.3). Thus, we suspect that GTP-bound RAB35 directly binds PI3K and 
serves to localize PDGFRα/PI3Kα to RAB7-containing endomembranes, 
either by “steering” PDGFRα/PI3Kα to this compartment or “trapping” it 
there. Whether the exit of PDGFRα from this compartment is dependent on 
hydrolysis of the GTP of activated RAB35 is an interesting question that 
could be addressed with loss-of-function experiments that ask whether 
perturbation of the known RAB35 GAPs (TBC1D10A-C) and GEFs 




4.2.3 Is RAB35 a physiological regulator of PDGFRα/PI3K signaling, and 
are oncogenic mutant alleles of RAB35 hypermorphic or neomorphic? 
 At first glance, our gain-of-function data—that RAB35 signal to PI3K 
by activating PDGFRα—did not fit with our loss-of-function data, which 
suggested that RAB35 was required for PI3K/AKT activation in response to 
non-PDGF ligands like VEGF, IGF-I or EGF (Figure 2.16). However, recent 
data from the Kwiatkowski lab strongly suggests that these other ligands 
actually require PDGFRα/β to efficiently signal to the PI3K/AKT machinery 
 
Figure 4.3: A model for regulation of PDGFRα-PI3K signaling by the 
small GTPase RAB35.  Following stimulation with PDGF-AA, actively 
signaling PDGFRα/PI3K is internalized to RAB7-positive 
endomembranes. RAB35 interacts with the PDGFRα/PI3K complex, likely 
by direct interaction with PI3K (left). In cells that express GTPase-
deficient, dominant active RAB35Q67L, PDGFRα/PI3K is retained at RAB7-
positive endosomes within the cell even in the absence of ligand, where it 
constitutively signals to AKT (right).  
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[459]. These findings confirmed earlier ones that indicated that PDGFRs are 
activated in a “lateral signaling” fashion: stimulation of IGF-IRs with IGF, for 
example, activates a Src-dependent activation of PDGFRs, which then 
signal along with IGF-IR to PI3K [460-463]. Further, PDGFR and EGFR can 
heterodimerize to activate one another in response to EGF stimulation [464]. 
Thus, the loss-of-function data that suggests that RAB35 is necessary for 
EGF, IGF, PDGF and VEGF-mediated PI3K/AKT activation do not 
necessarily conflict with the gain-of-function data that suggest that RAB35 
regulation of PI3K/AKT is primarily accomplished via PDGFRα.  
 It is also interesting to speculate over the nature of the gain-of-
function phenotype we observed in the GTPase-deficient allele of RAB35. 
Mutations that alter protein function can be inactivating (hypomorphic), 
hyperactivating (hypermorphic), or confer new functions to that protein 
altogether (neomorphic) [465]. For example, mutations that result in a 
truncated and inactive PTEN protein are hypomorphic, while mutations that 
generate constitutively active alleles displaying normal function—like 
activating mutations in PI3K—are hypermorphic. Occasionally, mutations 
can confer altogether neomorphic functions on proteins. For example, the 
PIK3R1/p85 adaptor subunit of PI3K actually serves to inhibit the lipid kinase 
activity of PI3K. However, mutations in the PIK3R1 gene have been 
identified from human tumors that confer a novel, activating capacity of 
PIK3R1 towards PI3K activity [466].  
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The data presented in this thesis suggest that RAB35 is a 
physiological regulator of PDGFR-PI3K-AKT signaling and that the 
internalization and activation of PDGFRα and PI3K/AKT signaling by 
dominant active RAB35Q67L is a hypermorphic—not neomorphic—
phenomenon. We suspect that if the regulation of PDGFRα/PI3K by 
RAB35Q67L was non-physiological—i.e. neomorphic—that depletion of 
wildtype RAB35 in loss-of-function experiments would not block PI3K/AKT 
signaling. Indeed, as demonstrated in Chapter 2, depletion of RAB35 in a 
number of contexts serves to blunt the activation of PI3K/AKT as potently as 
does the depletion of other core PI3K/AKT signaling components.  
 Further, our gain-of-function experiments using GTPase-deficient 
RAB35Q67L also suggest that the phenotype demonstrated by RAB35Q67L is 
an exaggerated and unregulated version of the normal signaling phenotype 
of RAB35wt. The internalization of PDGF-stimulated PDGFRα in cells 
expressing RAB35wt appears virtually identical to the internalization of 
unliganded PDGFRα in cells expressing RAB35Q67L. In both cases, PDGFRα 
localizes to RAB7-positive endosomes. If RAB35Q67L were conferring a truly 
neomorphic function to PDGFRα signaling in cells, we would expect it to be 
re-trafficked into different compartments from those normally occupied by 
liganded PDGFRα.  
 A full assessment of the hypermorphic vs. neomorphic nature of 
oncogenic alleles of RAB35 will be further clarified by studying the 
relationship between wildtype RAB35 and PDGFRα trafficking. This would 
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likely include loss-of-function experiments using both RNAi and small 
molecule inhibitors.  
 
4.3 CONCLUDING REMARKS 
4.3.1 RAB35, cancer and why “private mutations” matter 
 This thesis began with a desire to use RNAi screens to identify novel 
regulators of PI3K/AKT signaling. While we used this loss-of-function 
screening approach to identify candidate genes that might regulate 
PI3K/AKT signaling, we prioritized hit genes that were mutated in a way that 
might alter their function (Table 2.2). Although we are interested in 
identifying any new members of the PI3K/AKT pathway, we hoped that such 
an approach would allow us to identify novel PI3K/AKT components that play 
an role in oncogenesis.  
 As described in Chapter 2 of this thesis, the mutations that we 
identified and characterized in RAB35 were not recurrent. Indeed, the 
RAB35 mutations that we identified in human tumors (A151T and F161L) 
were not canonical mutations that are known to lock RAB35 in a GTP-bound 
state (e.g. Q67L).  Nevertheless, the fact that the RAB35A151T and 
RAB35F161L mutant proteins could activate PI3K/AKT signaling and transform 
cells suggests that these mutations are not “passenger” mutations, but that 
they instead played a role in the development of the tumors in which they 
were found. Recent findings that the same mutations in KRAS at similar 
residues are transforming suggest further that these two RAB35 mutations 
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are functionally relevant to tumorigenesis [357-358, 467]. Thus, rare 
mutations in proteins like RAB35 that regulate growth factor signaling can 
activate oncogenic signaling. 
 The possibility that RAB35 mutations in patients are activating 
PI3K/AKT signaling and aiding in tumor formation or progression could have 
actionable clinical implications. For example, patients with activating 
mutations in PIK3CA would likely benefit from PI3Kα inhibitors, similar to 
BRAFV600E-positive melanoma patients treated with vemurafenib [468-470]. 
Thus, given that PDGFRα/PI3K/AKT is hyperactivated byRAB35A151T and 
RAB35F161L, patients with these mutations could benefit from PI3K-inhibitors.
 The scenario outlined above underscores the importance of finding, 
identifying, and characterizing rare but biologically relevant mutations in 
genes that regulate cell survival pathways. These so-called “private 
mutations” [471-473] are the subject of considerable discussion within the 
oncology community [474][475] because the number of patients with them is 
relatively small. We suggest that the identification of RAB35 as a regulator of 
PI3K signaling that is mutated in cancers thus serves as an example for why 
rarer “private” mutations should be investigated and understood.  
 
4.3.2 Endomembrane trafficking as an oncogenic force 
 The concept of dysregulated endomembrane trafficking in cancer is 
not a novel one [476]. Indeed, many investigators have documented 
dysregulated membrane organization and trafficking downstream of various 
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oncogenic forces. For example, it is well documented that the membrane 
polarity of tumor cells is deranged in many contexts [477-479]. In addition, it 
has recently been reported that some oncogenic mutations in MET disrupt 
the normal trafficking of the receptor [480]. This enhances the oncogenic 
potential of MET by preventing its degradation and localizing the protein to 
endosomes where it actively signals. Further, as mentioned earlier, 
mutations that derange CBL function can also lead to aberrant RTK 
localization and signaling.  
However, the notion that the direct dysregulation of endomembrane 
trafficking may itself lead to transformation is relatively unexamined. We 
reason that the oncogenic capability of mutant RAB35 proteins is likely due 
to dysregulated membrane trafficking of PDGFRα/PI3K signaling machinery, 
which allows sustained oncogenic signaling. The idea that dysregulation of 
endomembrane trafficking—in this case by RAB35—could be an oncogenic 
force is novel and indeed tantalizing. Further, the fact that the majority (5 of 
7) of the GTPases that were tertiary hits in our screen were RAB proteins 
(RAB35, RAB1B, RAB39, RASEF, and RABL3) begs further examination of 
this idea.  If dysregulated endomembrane trafficking possesses tumorigenic 





APPENDIX A: Human kinases and GTPases targeted by shRNA screen. 
 
NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
25 ABL1  818 CAMK2G  1606 DGKA 
27 ABL2  914 CD2  1607 DGKB 
90 ACVR1  983 CDC2  1608 DGKG 
91 ACVR1B  984 CDC2L1  1609 DGKQ 
92 ACVR2A  985 CDC2L2  1613 DAPK3 
93 ACVR2B  1017 CDK2  1633 DCK 
94 ACVRL1  1018 CDK3  1716 DGUOK 
132 ADK  1019 CDK4  1739 DLG1 
156 ADRBK1  1020 CDK5  1740 DLG2 
157 ADRBK2  1021 CDK6  1741 DLG3 
203 AK1  1022 CDK7  1760 DMPK 
204 AK2  1024 CDK8  1841 DTYMK 
205 AK3L1  1025 CDK9  1859 DYRK1A 
207 AKT1  1111 CHEK1  1956 EGFR 
208 AKT2  1119 CHKA  1969 EPHA2 
238 ALK  1120 CHKB  2011 MARK2 
269 AMHR2  1147 CHUK  2041 EPHA1 
369 ARAF  1152 CKB  2042 EPHA3 
472 ATM  1158 CKM  2043 EPHA4 
545 ATR  1159 CKMT1B  2044 EPHA5 
558 AXL  1160 CKMT2  2045 EPHA7 
613 BCR  1163 CKS1B  2046 EPHA8 
640 BLK  1164 CKS2  2047 EPHB1 
657 BMPR1A  1195 CLK1  2048 EPHB2 
658 BMPR1B  1196 CLK2  2049 EPHB3 
659 BMPR2  1198 CLK3  2050 EPHB4 
660 BMX  1263 PLK3  2051 EPHB6 
673 BRAF  1326 MAP3K8  2064 ERBB2 
676 BRDT  1399 CRKL  2065 ERBB3 
695 BTK  1432 MAPK14  2066 ERBB4 
699 BUB1  1436 CSF1R  2081 ERN1 
701 BUB1B  1445 CSK  2185 PTK2B 
780 DDR1  1452 CSNK1A1  2241 FER 
801 CALM1  1453 CSNK1D  2242 FES 
805 CALM2  1454 CSNK1E  2260 FGFR1 
808 CALM3  1455 CSNK1G2  2261 FGFR3 
814 CAMK4  1456 CSNK1G3  2263 FGFR2 
815 CAMK2A  1457 CSNK2A1  2264 FGFR4 
816 CAMK2B  1459 CSNK2A2  2268 FGR 
817 CAMK2D  1460 CSNK2B  2321 FLT1 
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
2322 FLT3  3815 KIT  5063 PAK3 
2324 FLT4  3932 LCK  5105 PCK1 
2395 FXN  3984 LIMK1  5106 PCK2 
2444 FRK  3985 LIMK2  5127 PCTK1 
2475 FRAP1  4058 LTK  5128 PCTK2 
2534 FYN  4067 LYN  5129 PCTK3 
2580 GAK  4117 MAK  5156 PDGFRA 
2584 GALK1  4139 MARK1  5157 PDGFRL 
2585 GALK2  4140 MARK3  5159 PDGFRB 
2645 GCK  4145 MATK  5163 PDK1 
2710 GK  4214 MAP3K1  5164 PDK2 
2712 GK2  4215 MAP3K3  5165 PDK3 
2868 GRK4  4216 MAP3K4  5166 PDK4 
2869 GRK5  4217 MAP3K5  5170 PDPK1 
2870 GRK6  4233 MET  5207 PFKFB1 
2872 MKNK2  4293 MAP3K9  5208 PFKFB2 
2931 GSK3A  4294 MAP3K10  5209 PFKFB3 
2932 GSK3B  4296 MAP3K11  5210 PFKFB4 
2965 GTF2H1  4342 MOS  5211 PFKL 
2984 GUCY2C  4354 MPP1  5213 PFKM 
2986 GUCY2F  4355 MPP2  5214 PFKP 
2987 GUK1  4356 MPP3  5218 PFTK1 
3000 GUCY2D  4486 MST1R  5230 PGK1 
3055 HCK  4593 MUSK  5232 PGK2 
3098 HK1  4598 MVK  5255 PHKA1 
3099 HK2  4638 MYLK  5256 PHKA2 
3101 HK3  4750 NEK1  5257 PHKB 
3480 IGF1R  4751 NEK2  5260 PHKG1 
3551 IKBKB  4752 NEK3  5261 PHKG2 
3611 ILK  4830 NME1  5286 PIK3C2A 
3643 INSR  4831 NME2  5287 PIK3C2B 
3645 INSRR  4832 NME3  5288 PIK3C2G 
3654 IRAK1  4833 NME4  5289 PIK3C3 
3656 IRAK2  4881 NPR1  5290 PIK3CA 
3702 ITK  4882 NPR2  5291 PIK3CB 
3705 ITPK1  4914 NTRK1  5292 PIM1 
3706 ITPKA  4915 NTRK2  5293 PIK3CD 
3707 ITPKB  4916 NTRK3  5294 PIK3CG 
3716 JAK1  4919 ROR1  5295 PIK3R1 
3717 JAK2  4920 ROR2  5296 PIK3R2 
3718 JAK3  4921 DDR2  5297 PI4KA 
3791 KDR  5058 PAK1  5298 PI4KB 
3795 KHK  5062 PAK2  5305 PIP4K2A 
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
5313 PKLR  5601 MAPK9  6725 SRMS 
5315 PKM2  5602 MAPK10  6732 SRPK1 
5328 PLAU  5603 MAPK13  6733 SRPK2 
5347 PLK1  5604 MAP2K1  6787 NEK4 
5361 PLXNA1  5605 MAP2K2  6788 STK3 
5362 PLXNA2  5606 MAP2K3  6789 STK4 
5364 PLXNB1  5607 MAP2K5  6790 AURKA 
5365 PLXNB3  5608 MAP2K6  6792 CDKL5 
5394 EXOSC10  5609 MAP2K7  6793 STK10 
5562 PRKAA1  5610 EIF2AK2  6794 STK11 
5563 PRKAA2  5613 PRKX  6795 AURKC 
5564 PRKAB1  5616 PRKY  6850 SYK 
5565 PRKAB2  5631 PRPS1  6872 TAF1 
5566 PRKACA  5634 PRPS2  6885 MAP3K7 
5567 PRKACB  5681 PSKH1  7006 TEC 
5568 PRKACG  5747 PTK2  7010 TEK 
5571 PRKAG1  5753 PTK6  7016 TESK1 
5573 PRKAR1A  5754 PTK7  7046 TGFBR1 
5575 PRKAR1B  5756 TWF1  7048 TGFBR2 
5576 PRKAR2A  5832 ALDH18A1  7049 TGFBR3 
5577 PRKAR2B  5871 MAP4K2  7075 TIE1 
5578 PRKCA  5891 RAGE  7083 TK1 
5579 PRKCB  5894 RAF1  7084 TK2 
5580 PRKCD  5979 RET  7175 TPR 
5581 PRKCE  5987 TRIM27  7204 TRIO 
5582 PRKCG  6011 GRK1  7272 TTK 
5583 PRKCH  6041 RNASEL  7273 TTN 
5584 PRKCI  6046 BRD2  7294 TXK 
5585 PKN1  6093 ROCK1  7297 TYK2 
5586 PKN2  6098 ROS1  7301 TYRO3 
5587 PRKD1  6102 RP2  7371 UCK2 
5588 PRKCQ  6195 RPS6KA1  7443 VRK1 
5590 PRKCZ  6196 RPS6KA2  7444 VRK2 
5591 PRKDC  6197 RPS6KA3  7465 WEE1 
5592 PRKG1  6198 RPS6KB1  7525 YES1 
5593 PRKG2  6199 RPS6KB2  7535 ZAP70 
5594 MAPK1  6259 RYK  7786 MAP3K12 
5595 MAPK3  6300 MAPK12  7867 MAPKAPK3 
5596 MAPK4  6347 CCL2  8019 BRD3 
5597 MAPK6  6351 CCL4  8295 TRRAP 
5598 MAPK7  6416 MAP2K4  8317 CDC7 
5599 MAPK8  6446 SGK1  8382 NME5 
5600 MAPK11  6714 SRC  8394 PIP5K1A 
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
8395 PIP5K1B  9113 LATS1  10420 TESK2 
8396 PIP4K2B  9149 DYRK1B  10461 MERTK 
8408 ULK1  9162 DGKI  10494 STK25 
8428 STK24  9175 MAP3K13  10519 CIB1 
8444 DYRK3  9201 DCLK1  10595 ERN2 
8445 DYRK2  9212 AURKB  10645 CAMKK2 
8476 CDC42BPA  9223 MAGI1  10654 PMVK 
8491 MAP4K3  9252 RPS6KA5  10733 PLK4 
8503 PIK3R3  9261 MAPKAPK2  10746 MAP3K2 
8525 DGKZ  9262 STK17B  10769 PLK2 
8526 DGKE  9263 STK17A  10783 NEK6 
8527 DGKD  9344 TAOK2  10922 FASTK 
8536 CAMK1  9414 TJP2  11011 TLK2 
8550 MAPKAPK5  9448 MAP4K4  11035 RIPK3 
8558 CDK10  9451 EIF2AK3  11040 PIM2 
8566 PDXK  9467 SH3BP5  11113 CIT 
8569 MKNK1  9475 ROCK2  11139   
8573 CASK  9578 CDC42BPB  11183 MAP4K5 
8576 STK16  9625 AATK  11184 MAP4K1 
8621 CDC2L5  9641 IKBKE  11200 CHEK2 
8649 MAPKSP1  9706 ULK2  11213 IRAK3 
8711 TNK1  9748 SLK  11284 PNKP 
8737 RIPK1  9807 IP6K1  11329 STK38 
8767 RIPK2  9829 DNAJC6  11344 TWF2 
8780 RIOK3  9833 MELK  22848 AAK1 
8798 DYRK4  9874 TLK1  22853 LMTK2 
8814 CDKL1  9891 NUAK1  22858 ICK 
8844 KSR1  9942 XYLB  22868 FASTKD2 
8851 CDK5R1  9943 OXSR1  22901 ARSG 
8859 STK19  9950 GOLGA5  22928 SEPHS2 
8877 SPHK1  10000 AKT3  22983 MAST1 
8895 CPNE3  10020 GNE  23012 STK38L 
8899 PRPF4B  10087 COL4A3BP  23031 MAST3 
8941 CDK5R2  10110 SGK2  23043 TNIK 
8986 RPS6KA4  10114 HIPK3  23049 SMG1 
8997 KALRN  10128 LRPPRC  23097 CDC2L6 
8999 CDKL2  10154 PLXNC1  23129 PLXND1 
9020 MAP3K14  10188 TNK2  23139 MAST2 
9024 BRSK2  10201 NME6  23178 PASK 
9060 PAPSS2  10221 TRIB1  23227 MAST4 
9061 PAPSS1  10290 SPEG  23235 SIK2 
9064 MAP3K6  10295 BCKDK  23300 ATMIN 
9088 PKMYT1  10298 PAK4  23387   
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
23396 PIP5K1C  51347 TAOK3  56848 SPHK2 
23476 BRD4  51422 PRKAG2  56911 C21orf7 
23533 PIK3R5  51447 IP6K2  56924 PAK6 
23552 CCRK  51678 MPP6  56997 CABC1 
23604 DAPK2  51701 NLK  57118 CAMK1D 
23617 TSSK2  51727 CMPK1  57143 ADCK1 
23636 NUP62  51755 CRKRS  57144 PAK7 
23654 PLXNB2  51765    57147 SCYL3 
23677 SH3BP4  51776    57172 CAMK1G 
23678 SGK3  53354 PANK1  57396 CLK4 
23683 PRKD3  53632 PRKAG3  57410 SCYL1 
23729 SHPK  53834 FGFRL1  57538 ALPK3 
25778 DSTYK  53904 MYO3A  57551 TAOK1 
25865 PRKD2  53944 CSNK1G1  57729   
25989 ULK3  54101 RIPK4  57761 TRIB3 
26007 DAK  54103 PION  57787 MARK4 
26289 AK5  54822 TRPM7  58538 MPP4 
26353 HSPB8  54861 SNRK  60493 FASTKD5 
26524 LATS2  54899 PXK  64080 RBKS 
26576 SRPK3  54963 UCKL1  64089 SNX16 
26750 RPS6KC1  54981 C9orf95  64122 FN3K 
27010 TPK1  54986 ULK4  64149 C17orf75 
27102 EIF2AK1  55224 ETNK2  64398 MPP5 
27148 STK36  55229 PANK4  64768 IPPK 
27231 ITGB1BP3  55277 FGGY  64781 CERK 
27330 RPS6KA6  55300 PI4K2B  65018 PINK1 
27347 STK39  55312 RFK  65061 PFTK2 
28951 TRIB2  55351 STK32B  65125 WNK1 
28996 HIPK2  55359 STYK1  65220 NADK 
29110 TBK1  55361 PI4K2A  65266 WNK4 
29904 EEF2K  55437 STRADB  65267 WNK3 
29922 NME7  55500 ETNK1  65268 WNK2 
29941 PKN3  55558 PLXNA3  65975 STK33 
29959 NRBP1  55561 CDC42BPG  79012 CAMKV 
30811 HUNK  55577 NAGK  79072 FASTKD3 
30849 PIK3R4  55589 BMP2K  79646 PANK3 
50488 MINK1  55681 SCYL2  79672   
50808 AK3  55728 N4BP2  79675 FASTKD1 
51086 TNNI3K  55750 AGK  79705 LRRK1 
51135 IRAK4  55781 RIOK2  79834   
51231 VRK3  55872 PBK  79837 PIP4K2C 
51265 CDKL3  56155 TEX14  79858 NEK11 
51314 TXNDC3  56164 STK31  79877 DCAKD 
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
79906 MORN1  112858 TP53RK  221823 PRPS1L1 
79934 ADCK4  114783 LMTK3  225689 MAPK15 
80025 PANK2  114836 SLAMF6  253430 IPMK 
80122 YSK4  115701 ALPK2  255239 ANKK1 
80201 HKDC1  117283 IP6K3  256356 GK5 
80216 ALPK1  120892 LRRK2  260425 MAGI3 
80271 ITPKC  122011 CSNK1A1L  282974 STK32C 
80347 COASY  122481 AK7  283455 KSR2 
80851 SH3BP5L  124923    283629 TSSK4 
81629 TSSK3  127933 UHMK1  284086 NEK8 
81788 NUAK2  130106 CIB4  284656 EPHA10 
83440 ADPGK  130399 ACVR1C  285220 EPHA6 
83549 UCK1  131890 GRK7  285962   
83694 RPS6KL1  132158 GLYCTK  340156 MYLK4 
83732 RIOK1  136332 LRGUK  340371 NRBP2 
83903 GSG2  138429 PIP5KL1  341676 NEK5 
83931 STK40  138474 TAF1L  344387 CDKL4 
83942 TSSK1B  139189 DGKK  347359 BMP2KL 
83983 TSSK6  139728 PNCK  347736 NME9 
84033 OBSCN  140469 MYO3B  374872 C19orf35 
84197 POMK   140609 NEK7  375133 PI4KAP2 
84206 MEX3B  140803 TRPM6  375298 CERKL 
84254 CAMKK1  140901 STK35  375449 MAST4 
84284 C1orf57  143098 MPP7  378464 MORN2 
84433 CARD11  146057 TTBK2  387851 AK3L2 
84446 BRSK1  147746 HIPK4  388228 SBK1 
84451    149420 PDIK1L  388259   
84630 TTBK1  150094 SIK1  388957   
84930 MASTL  152110 NEK10  389840 MAP3K15 
85366 MYLK2  157285    389906   
85443 DCLK3  158067 C9orf98  390877   
85481 PSKH2  160851 DGKH  391295   
89882 TPD52L3  166614 DCLK2  391533   
90381 C15orf42  167359    392226   
90956 ADCK2  169436 C9orf96  392265   
91156 IGFN1  197258 FUK  392347   
91419 XRCC6BP1  197259 MLKL  400301   
91461    200576 PIP5K3  402289   
91584 PLXNA4  202374 STK32A  402679   
91754 NEK9  203054 ADCK5  415116 PIM3 
91807 MYLK3  203447 NRK  440275 EIF2AK4 
92335 STRADA  204851 HIPK1  440345   
93627    220686    441047   
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
441655    2773 GNAI3  5879 RAC1 
441708    2774 GNAL  5880 RAC2 
441777    2775 GNAO1  5881 RAC3 
441971    2776 GNAQ  5898 RALA 
442075    2778 GNAS  5899 RALB 
442313    2779 GNAT1  5901 RAN 
442558    2780 GNAT2  5906 RAP1A 
57521 RAPTOR  2781 GNAZ  5908 RAP1B 
253260 RICTOR  2782 GNB1  5911 RAP2A 
373 TRIM23  2783 GNB2  5912 RAP2B 
375 ARF1  2784 GNB3  6009 RHEB 
377 ARF3  2785 GNG3  6014 RIT2 
378 ARF4  2786 GNG4  6016 RIT1 
379 ARL4D  2787 GNG5  6236 RRAD 
381 ARF5  2788 GNG7  6237 RRAS 
382 ARF6  2791 GNG11  6729 SRP54 
387 RHOA  2792 GNGT1  6734 SRPR 
388 RHOB  2793 GNGT2  7284 TUFM 
389 RHOC  3265 HRAS  7879 RAB7A 
390 RND3  3266 ERAS  8153 RND2 
391 RHOG  3845 KRAS  8766 RAB11A 
399 RHOH  4218 RAB8A  8934 RAB7L1 
400 ARL1  4261 CIITA  9077 DIRAS3 
402 ARL2  4599 MX1  9230 RAB11B 
403 ARL3  4600 MX2  9363 RAB33A 
989 39698  4733 DRG1  9364 RAB28 
998 CDC42  4735 39693  9367 RAB9A 
1731 39692  4893 NRAS  9545 RAB3D 
1759 DNM1  4976 OPA1  9567 GTPBP1 
1785 DNM2  5413 39696  9609 RAB36 
1819 DRG2  5414 39695  9630 GNA14 
1915 EEF1A1  5861 RAB1A  9886 RHOBTB1 
1917 EEF1A2  5862 RAB2A  9927 MFN2 
1968 EIF2S3  5864 RAB3A  10059 DNM1L 
2633 GBP1  5865 RAB3B  10123 ARL4C 
2634 GBP2  5867 RAB4A  10124 ARL4A 
2635 GBP3  5868 RAB5A  10139 ARFRP1 
2669 GEM  5869 RAB5B  10325 RRAGB 
2767 GNA11  5870 RAB6A  10633 RASL10A 
2768 GNA12  5872 RAB13  10670 RRAGA 
2769 GNA15  5873 RAB27A  10672 GNA13 
2770 GNAI1  5874 RAB27B  10681 GNB5 
2771 GNAI2  5878 RAB5C  10801 39700 
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NCBI ID GENE ID  NCBI ID GENE ID  NCBI ID GENE ID 
10890 RAB10  54509 RHOF  91608 RASL10B 
10966 RAB40B  54622 ARL15  94235 GNG8 
10981 RAB32  54676 GTPBP2  115273 RAB42 
11020 RABL4  54734 RAB39  115361 GBP4 
11021 RAB35  54769 DIRAS2  115362 GBP5 
11031 RAB31  55207 ARL8B  115761 ARL11 
11158 RABL2B  55288 RHOT1  115827 RAB3C 
11159 RABL2A  55647 RAB20  116442 RAB39B 
11321 XAB1  55669 MFN1  116986 CENTG1 
22800 RRAS2  55752 39702  116987 CENTG2 
22808 MRAS  55964 39694  116988 CENTG3 
22931 RAB18  55970 GNG12  121268 RHEBL1 
23011 RAB21  56269 IRGC  127829 ARL8A 
23157 39697  56681 SAR1A  132946 ARL9 
23221 RHOBTB2  57111 RAB25  142684 RAB40A 
23433 RHOQ  57381 RHOJ  148252 DIRAS1 
23551 RASD2  57403 RAB22A  151011 39701 
23560 GTPBP4  57521 KIAA1303  158158 RASEF 
23682 RAB38  57580 PREX1  161253 REM2 
25837 RAB26  57799 RAB40C  171177 RHOV 
26052 DNM3  57826 RAP2C  200894 ARL13B 
26164 GTPBP5  58477 SRPRB  221079 ARL5B 
26225 ARL5A  58480 RHOU  285282 RABL3 
26284 ERAL1  58528 RRAGD  285598 ARL10 
27289 RND1  59345 GNB4  326624 RAB37 
27314 RAB30  64121 RRAGC  338382 RAB7B 
28511 NKIRAS2  64223 GBL  339122 RAB43 
28512 NKIRAS1  64284 RAB17  344988 SAR1P3 
28954 REM1  64792 RABL5  347517 RAB41 
29984 RHOD  65997 RASL11B  376267 RAB15 
51062 SPG3A  79109 MAPKAP1  387496 RASL11A 
51128 SAR1B  79899 FLJ14213  387751 GVIN1 
51209 RAB9B  80117 ARL14  401409 RAB19 
51285 RASL12  81876 RAB1B 
51552 RAB14  83452 RAB33B 
51560 RAB6B  83871 RAB34 
51655 RASD1  84084 RAB6C 
51715 RAB23  84100 ARL6 
51762 RAB8B  84335 AKT1S1 
51764 GNG13  84705 GTPBP3 
53916 RAB4B  84932 RAB2B 
53917 RAB24  85004 RERG 
54331 GNG2  89941 RHOT2 
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APPENDIX B: Non-lethal shRNAs with phospho-AKT Z-scores greater than -
/+ 1.50. 






 207 AKT1 NM_005163.x-642s1c1 -2.23 10% A-431 
207 AKT1 NM_005163.x-1044s1c1 -1.52 14% A-431 
207 AKT1 NM_005163.1-1410s1c1 -1.69 48% A-431 
207 AKT1 NM_005163.x-981s1c1 -2.02 17% A-431 
207 AKT1 NM_005163.x-642s1c1d2 -1.55 16% A431 
207 AKT1 NM_005163.x-1044s1c1d1 -1.70 14% A431 
373 TRIM23 NM_001656.3-655s1c1d1 -2.07 37% Jurkat 
373 TRIM23 NM_001656.3-301s1c1d1 -1.67 65% Jurkat 
378 ARF4 NM_001660.2-614s1c1d2 2.55 1% A549 
378 ARF4 NM_001660.2-296s1c1d2 4.14 68% A549 
387 RHOA NM_001664.1-382s1c1d2 -2.51 16% A549 
387 RHOA NM_001664.1-616s1c1d2 -2.78 3% A549 
387 RHOA NM_001664.1-300s1c1d2 -2.67 15% A549 
387 RHOA NM_001664.1-199s1c1d2 -2.51 5% A549 
388 RHOB NM_004040.2-839s1c1d2 4.69 5% A549 
388 RHOB NM_004040.2-452s1c1d2 -1.91 12% A549 
388 RHOB NM_004040.2-461s1c1d2 -1.80 22% A549 
388 RHOB NM_004040.2-623s1c1d2 -2.74 65% A549 
389 RHOC NM_175744.3-539s1c1d3 -1.50 13% A549 
389 RHOC NM_175744.3-328s1c1d2 -1.77 12% A549 
390 RND3 NM_005168.2-557s1c1d2 -2.61 103% A549 
390 RND3 NM_005168.2-338s1c1d2 -2.61 32% A549 
391 RHOG NM_001665.2-273s1c1d2 -3.16 #N/A #N/A 
391 RHOG NM_001665.2-616s1c1d2 -2.47 #N/A #N/A 
391 RHOG NM_001665.2-192s1c1d2 -1.81 #N/A #N/A 
399 RHOH NM_004310.2-1177s1c1d2 -2.15 #N/A #N/A 
399 RHOH NM_004310.2-828s1c1d2 -2.19 #N/A #N/A 
400 ARL1 NM_001177.3-374s1c1d2 -3.57 #N/A #N/A 
400 ARL1 NM_001177.3-190s1c1d2 -2.25 #N/A #N/A 
402 ARL2 NM_001667.1-531s1c1d3 -1.88 54% A549 
402 ARL2 NM_001667.1-182s1c1d3 -2.09 11% A549 
403 ARL3 NM_004311.2-480s1c1d3 -2.65 13% A549 
403 ARL3 NM_004311.2-290s1c1d3 -1.57 3% A549 
472 ATM NM_000051.2-9211s1c1 -1.81 0% MCF7 
472 ATM NM_000051.2-9380s1c1 -2.57 0% MCF7 
472 ATM NM_000051.2-1717s1c1 -1.76 0% MCF7 
472 ATM NM_000051.2-1974s1c1 -2.39 75% MCF7 
545 ATR NM_001184.x-3426s1c1 -1.78 33% A549 
640 BLK NM_001715.x-1031s1c1 -2.41 16% Jurkat 
640 BLK NM_001715.2-746s1c1 -2.12 30% Jurkat 
640 BLK NM_001715.2-1626s1c1 -1.66 43% Jurkat 
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640 BLK NM_001715.x-1200s1c1 -2.03 29% Jurkat 
676 BRDT NM_001726.1-629s1c1 1.98 36% A549 
676 BRDT NM_001726.2-2905s1c1 2.15 80% A549 
676 BRDT NM_001726.1-2954s1c1 2.95 36% A549 
780 DDR1 NM_001954.x-961s1c1 2.00 20% MCF7 
780 DDR1 NM_001954.x-3795s1c1 1.64 100% A549 
983 CDC2 NM_001786.x-820s1c1 -1.76 10% A549 
983 CDC2 NM_001786.x-906s1c1 -2.31 52% A549 
983 CDC2 NM_001786.2-748s1c1 -1.92 51% A549 
998 CDC42 NM_001791.2-493s1c1d2 -1.73 73% A549 
998 CDC42 NM_001791.2-328s1c1d2 -2.18 24% A549 
1119 CHKA NM_001277.1-1557s1c1 1.98 71% A549 
1119 CHKA NM_001277.1-1136s1c1 2.11 92% A549 
1152 CKB NM_001823.3-1250s1c1 -2.50 8% MCF7 
1152 CKB NM_001823.3-877s1c1 -1.70 35% MCF7 
1152 CKB NM_001823.3-722s1c1 -2.70 34% MCF7 
1152 CKB NM_001823.3-326s1c1 -1.68 60% MCF7 
1152 CKB NM_001823.3-1251s1c1 -1.80 20% MCF7 
1453 CSNK1D NM_139062.x-991s1c1 2.52 74% A549 
1453 CSNK1D NM_139062.x-1027s1c1 2.11 85% A549 
1453 CSNK1D NM_001893.x-991s1c1 2.57 58% A549 
1453 CSNK1D NM_001893.x-1027s1c1 3.61 69% A549 
1606 DGKA NM_001345.4-592s1c1 2.41 22% Jurkat 
1606 DGKA NM_001345.4-382s1c1 2.52 42% Jurkat 
1633 DCK NM_000788.x-252s1c1 -2.09 113% MCF7 
1633 DCK NM_000788.x-440s1c1 -1.60 0% MCF7 
1915 EEF1A1 NM_001402.4-807s1c1d1 -1.76 2% A549 
1915 EEF1A1 NM_001402.4-338s1c1d1 -2.53 4% A549 
1968 EIF2S3 NM_001415.2-1225s1c1d1 -4.87 136% A549 
1968 EIF2S3 NM_001415.2-646s1c1d1 -1.85 11% A549 
1968 EIF2S3 NM_001415.2-782s1c1d1 -2.28 45% A549 
2041 EPHA1 NM_005232.2-3118s1c1 -1.94 8% MCF7 
2041 EPHA1 NM_005232.2-2176s1c1 -2.01 61% MCF7 
2049 EPHB3 NM_004443.3-3611s1c1 2.14 43% MCF7 
2049 EPHB3 NM_004443.3-1895s1c1 1.58 46% MCF7 
2050 EPHB4 NM_004444.x-459s1c1 -1.76 27% A549 
2050 EPHB4 NM_004444.x-2076s1c1 -1.55 8% A549 
2064 ERBB2 NM_004448.x-1214s1c1 -2.37 0% A-431 
2064 ERBB2 NM_004448.x-1365s1c1 -2.23 37% A-431 
2064 ERBB2 NM_004448.1-466s1c1 -1.78 135% A549 
2260 FGFR1 NM_000604.2-2340s1c1 1.99 56% MCF7 
2260 FGFR1 NM_000604.2-1013s1c1 1.67 121% MCF7 
2260 FGFR1 NM_000604.2-1237s1c1 1.77 38% MCF7 
2321 FLT1 NM_002019.2-5483s1c1 -2.57 #N/A #N/A 
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2321 FLT1 NM_002019.2-4063s1c1 -2.92 #N/A #N/A 
2321 FLT1 NM_002019.2-654s1c1 -2.56 #N/A #N/A 
2321 FLT1 NM_002019.x-2722s1c1 2.94 133% MCF7 
2321 FLT1 NM_002019.2-3492s1c1 -3.01 #N/A #N/A 
2321 FLT1 NM_002019.x-1340s1c1 1.91 47% MCF7 
2321 FLT1 NM_002019.x-5356s1c1 1.58 2203% MCF7 
2324 FLT4 NM_002020.x-3875s1c1 1.54 28% A549 
2324 FLT4 NM_002020.x-2503s1c1 -1.70 71% A549 
2324 FLT4 NM_002020.1-3989s1c1 1.57 81% MCF7 
2444 FRK NM_002031.x-1177s1c1 1.55 0% A549 
2444 FRK NM_002031.x-1620s1c1 2.68 270% A549 
2475 FRAP1 NM_004958.2-640s1c1 1.72 14% A549 
2475 FRAP1 NM_004958.2-7897s1c1 2.56 21% A549 
2475 FRAP1 NM_004958.2-4662s1c1 2.21 21% A549 
2475 FRAP1 NM_004958.2-3425s1c1 2.73 35% A549 
2475 FRAP1 NM_004958.2-3425s1c1d2 2.54 25% Jurkat 
2710 GK NM_000167.3-3396s1c1 -1.95 74% 293T 
2710 GK NM_000167.3-814s1c1 -1.64 40% 293T 
2770 GNAI1 NM_002069.4-1208s1c1d1 -1.69 #N/A #N/A 
2771 GNAI2 NM_002070.1-870s1c1d1 -1.83 28% #N/A 
2785 GNG3 NM_012202.1-326s1c1d1 1.86 #N/A #N/A 
2785 GNG3 NM_012202.1-288s1c1d1 2.31 #N/A #N/A 
2791 GNG11 NM_004126.2-502s1c1d1 2.49 47% A549 
2791 GNG11 NM_004126.2-437s1c1d1 2.73 32% A549 
2870 GRK6 NM_002082.2-1407s1c1 1.70 52% Jurkat 
2870 GRK6 NM_002082.x-545s1c1 1.87 6% MCF7 
2870 GRK6 NM_002082.2-2152s1c1 1.73 56% Jurkat 
2931 GSK3A NM_019884.1-1173s1c1 -2.44 9% MCF7 
2931 GSK3A NM_019884.x-1428s1c1 -2.10 0% MCF7 
2965 GTF2H1 NM_005316.2-1316s1c1 -2.98 40% MCF7 
2965 GTF2H1 NM_005316.2-1755s1c1 -1.78 25% MCF7 
2965 GTF2H1 NM_005316.2-1228s1c1 2.01 38% MCF7 
2965 GTF2H1 NM_005316.2-2502s1c1 3.33 91% MCF7 
2984 GUCY2C NM_004963.x-3280s1c1 1.87 #N/A #N/A 
2984 GUCY2C NM_004963.1-2425s1c1 2.66 #N/A #N/A 
2984 GUCY2C NM_004963.1-1244s1c1 1.68 #N/A #N/A 
3101 HK3 NM_002115.1-1748s1c1 -1.57 #N/A #N/A 
3101 HK3 NM_002115.1-2902s1c1 -1.56 #N/A #N/A 
3101 HK3 NM_002115.1-932s1c1 -1.77 #N/A #N/A 
3611 ILK NM_004517.2-1136s1c1 -2.55 59% A549 
3611 ILK NM_004517.x-687s1c1 -1.71 22% A549 
3654 IRAK1 NM_001569.3-2873s1c1 -1.69 18% MCF7 
3654 IRAK1 NM_001569.x-1257s1c1 -1.66 115% MCF7 
3706 ITPKA NM_002220.1-539s1c1 -2.37 #N/A #N/A 
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3706 ITPKA NM_002220.1-1420s1c1 -1.94 #N/A #N/A 
3706 ITPKA NM_002220.1-783s1c1 -2.10 #N/A #N/A 
3706 ITPKA NM_002220.1-808s1c1 1.97 #N/A #N/A 
3706 ITPKA NM_002220.1-1076s1c1 3.36 #N/A #N/A 
3706 ITPKA NM_002220.1-368s1c1 3.37 #N/A #N/A 
3717 JAK2 NM_004972.2-3669s1c1 1.66 #N/A #N/A 
3717 JAK2 NM_004972.x-4564s1c1 3.73 23% A549 
3717 JAK2 NM_004972.2-4773s1c1 1.98 #N/A #N/A 
3795 KHK NM_000221.1-359s1c1 -2.19 #N/A #N/A 
3795 KHK NM_000221.1-1328s1c1 -2.83 #N/A #N/A 
3795 KHK NM_000221.1-458s1c1 -3.11 #N/A #N/A 
3984 LIMK1 NM_002314.x-1512s1c1 -2.04 5% MCF7 
3984 LIMK1 NM_002314.x-1374s1c1 -1.78 3% MCF7 
4058 LTK NM_002344.x-2132s1c1 -2.46 0% A549 
4058 LTK NM_002344.x-1509s1c1 -2.00 69% A549 
4058 LTK NM_002344.x-593s1c1 -1.88 99% A549 
4117 MAK NM_005906.x-982s1c1 2.78 #N/A #N/A 
4117 MAK NM_005906.x-2562s1c1 4.33 #N/A #N/A 
4139 MARK1 NM_018650.2-1916s1c1 -1.83 86% A549 
4139 MARK1 NM_018650.2-2586s1c1 -1.58 86% A549 
4139 MARK1 NM_018650.2-2974s1c1 4.07 117% A549 
4139 MARK1 NM_018650.2-1564s1c1 1.59 99% A549 
4140 MARK3 NM_002376.x-518s1c1 -2.69 36% MCF7 
4140 MARK3 NM_002376.x-1363s1c1 -2.47 59% MCF7 
4214 MAP3K1 XM_042066.8-5517s1c1 1.73 173% A549 
4214 MAP3K1 XM_042066.11-7305s1c1 1.53 49% A549 
4294 MAP3K10 NM_002446.x-3247s1c1 -3.27 84% MCF7 
4294 MAP3K10 NM_002446.x-1420s1c1 -2.37 83% MCF7 
4294 MAP3K10 NM_002446.2-1329s1c1 -2.30 #N/A #N/A 
4294 MAP3K10 NM_002446.x-2033s1c1 -1.54 94% MCF7 
4354 MPP1 NM_002436.2-1286s1c1 -3.06 26% A549 
4354 MPP1 NM_002436.2-1216s1c1 -1.73 24% A549 
4355 MPP2 NM_005374.2-178s1c1 1.95 46% Jurkat 
4355 MPP2 NM_005374.2-755s1c1 2.84 57% Jurkat 
4486 MST1R NM_002447.x-4136s1c1 -3.05 58% A549 
4486 MST1R NM_002447.1-2829s1c1 -2.00 57% A549 
4486 MST1R NM_002447.1-2397s1c1 -2.14 20% A549 
4733 DRG1 NM_004147.2-665s1c1d1 1.51 18% A549 
4733 DRG1 NM_004147.2-514s1c1d1 1.89 10% A549 
4750 NEK1 NM_012224.1-1427s1c1 1.52 71% Jurkat 
4750 NEK1 NM_012224.1-2206s1c1 2.59 92% Jurkat 
4750 NEK1 NM_012224.1-2620s1c1 1.55 89% Jurkat 
4832 NME3 NM_002513.2-310s1c1 -1.88 11% 293T 
4832 NME3 NM_002513.2-414s1c1 -2.96 15% 293T 
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4976 OPA1 NM_130832.1-435s1c1d1 -4.29 55% A549 
4976 OPA1 NM_130832.1-434s1c1d1 -2.45 12% A549 
5062 PAK2 NM_002577.x-2531s1c1 2.20 9% MCF7 
5062 PAK2 NM_002577.3-1555s1c1 2.63 7% MCF7 
5062 PAK2 NM_002577.x-454s1c1 2.70 15% MCF7 
5062 PAK2 NM_002577.3-4034s1c1 2.77 96% MCF7 
5165 PDK3 NM_005391.1-1322s1c1 -2.02 83% A549 
5165 PDK3 NM_005391.1-440s1c1 -1.96 16% A549 
5165 PDK3 NM_005391.1-1354s1c1 -1.60 106% A549 
5170 PDPK1 NM_002613.1-1373s1c1 -1.88 86% MCF7 
5170 PDPK1 NM_002613.1-542s1c1 -2.46 118% MCF7 
5170 PDPK1 NM_002613.x-1306s1c1 -1.57 110% MCF7 
5211 PFKL NM_002626.x-1630s1c1 -2.08 10% A549 
5211 PFKL NM_002626.4-2301s1c1 -1.69 11% A549 
5211 PFKL NM_002626.4-2309s1c1 -1.69 0% A549 
5213 PFKM NM_000289.3-1883s1c1 -1.52 35% MCF7 
5213 PFKM NM_000289.3-429s1c1 -2.57 16% MCF7 
5213 PFKM NM_000289.3-1708s1c1 -1.71 #N/A #N/A 
5213 PFKM NM_000289.3-1571s1c1 -3.01 #N/A #N/A 
5291 PIK3CB NM_006219.x-61s1c1 -1.63 40% MCF7 
5291 PIK3CB NM_006219.x-2289s1c1 -1.60 25% MCF7 
5291 PIK3CB NM_006219.x-748s1c1 -1.56 55% MCF7 
5291 PIK3CB NM_006219.x-1306s1c1 -1.57 29% MCF7 
5291 PIK3CB NM_006219.x-61s1c1d2 -1.74 40% MCF7 
5291 PIK3CB NM_006219.x-748s1c1d1 -1.89 56% MCF7 
5347 PLK1 NM_005030.3-1986s1c1 -1.50 48% MCF7 
5347 PLK1 NM_005030.3-1374s1c1 -1.93 35% MCF7 
5347 PLK1 NM_005030.3-1893s1c1 -2.01 25% MCF7 
5347 PLK1 NM_005030.3-1361s1c1 -1.89 0% MCF7 
5361 PLXNA1 NM_032242.2-4255s1c1 2.36 31% A549 
5361 PLXNA1 NM_032242.2-4656s1c1 2.82 38% A549 
5364 PLXNB1 NM_002673.3-6053s1c1 -2.85 43% Jurkat 
5364 PLXNB1 NM_002673.3-1116s1c1 -1.91 66% Jurkat 
5394 EXOSC10 NM_002685.1-1833s1c1 -1.87 24% A549 
5394 EXOSC10 NM_002685.1-1274s1c1 -3.51 7% A549 
5394 EXOSC10 NM_002685.1-2560s1c1 -1.64 25% A549 
5563 PRKAA2 NM_006252.x-2127s1c1 -2.05 #N/A #N/A 
5563 PRKAA2 NM_006252.x-1028s1c1 -2.37 #N/A #N/A 
5575 PRKAR1B NM_002735.1-157s1c1 3.79 #N/A #N/A 
5575 PRKAR1B NM_002735.1-593s1c1 2.77 8% MCF7 
5575 PRKAR1B NM_002735.1-544s1c1 4.01 61% MCF7 
5575 PRKAR1B NM_002735.1-620s1c1 3.24 7% MCF7 
5580 PRKCD NM_006254.3-2389s1c1 -2.77 102% MCF7 
5580 PRKCD NM_006254.x-826s1c1 -2.55 56% A549 
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5580 PRKCD NM_006254.3-1145s1c1 -1.74 57% MCF7 
5586 PKN2 NM_006256.1-2250s1c1 -2.06 39% A549 
5586 PKN2 NM_006256.1-309s1c1 -2.26 28% A549 
5608 MAP2K6 NM_002758.x-592s1c1 1.89 77% MCF7 
5608 MAP2K6 NM_002758.x-503s1c1 1.61 191% MCF7 
5631 PRPS1 NM_002764.x-592s1c1 1.70 42% MCF7 
5631 PRPS1 NM_002764.x-819s1c1 2.05 0% MCF7 
5634 PRPS2 NM_002765.x-871s1c1 1.81 16% MCF7 
5634 PRPS2 NM_002765.x-320s1c1 1.96 13% MCF7 
5832 ALDH18A1 NM_002860.2-568s1c1 -2.13 44% A549 
5832 ALDH18A1 NM_002860.2-658s1c1 -2.59 8% A549 
5861 RAB1A NM_004161.3-698s1c1d1 -3.70 9% A549 
5861 RAB1A NM_004161.3-1607s1c1d1 -2.02 57% A549 
5862 RAB2A NM_002865.1-523s1c1d1 -2.40 143% A549 
5864 RAB3A NM_002866.3-266s1c1d4 -2.11 161% Jurkat 
5864 RAB3A NM_002866.3-447s1c1d2 -1.67 132% Jurkat 
5865 RAB3B NM_002867.x-907s1c1d1 -1.54 6% A549 
5865 RAB3B NM_002867.x-447s1c1d1 -2.71 8% A549 
5865 RAB3B NM_002867.x-446s1c1d1 -2.98 5% A549 
5867 RAB4A NM_004578.2-500s1c1d1 -3.32 71% Jurkat 
5867 RAB4A NM_004578.2-608s1c1d1 -2.33 69% Jurkat 
5867 RAB4A NM_004578.2-346s1c1d3 -2.10 56% Jurkat 
5868 RAB5A NM_004162.3-659s1c1d1 -3.94 46% #N/A 
5868 RAB5A NM_004162.3-2139s1c1d3 -1.86 16% #N/A 
5868 RAB5A NM_004162.3-406s1c1d1 -1.53 69% #N/A 
5870 RAB6A NM_002869.4-824s1c1d3 1.97 103% Jurkat 
5870 RAB6A NM_002869.4-1073s1c1d3 2.07 42% Jurkat 
5872 RAB13 NM_002870.2-336s1c1d2 -3.60 #N/A #N/A 
5872 RAB13 NM_002870.2-196s1c1d2 -2.18 #N/A #N/A 
5873 RAB27A NM_004580.3-735s1c1d2 -1.72 5% A549 
5873 RAB27A NM_004580.3-477s1c1d2 -2.09 25% A549 
5874 RAB27B NM_004163.3-697s1c1d2 -2.83 24% A549 
5874 RAB27B NM_004163.3-217s1c1d2 -1.61 72% A549 
5874 RAB27B NM_004163.3-566s1c1d2 -2.18 133% A549 
5881 RAC3 NM_005052.2-544s1c1d2 -2.77 17% 293T 
5881 RAC3 NM_005052.2-664s1c1d2 -3.31 20% 293T 
5881 RAC3 NM_005052.2-331s1c1d2 -2.78 14% 293T 
6009 RHEB NM_005614.x-624s1c1d2 2.48 #N/A #N/A 
6009 RHEB NM_005614.x-754s1c1d2 2.57 #N/A #N/A 
6009 RHEB NM_005614.2-1100s1c1d2 2.28 #N/A #N/A 
6011 GRK1 NM_002929.x-388s1c1 2.79 #N/A #N/A 
6011 GRK1 NM_002929.x-945s1c1 1.73 #N/A #N/A 
6011 GRK1 NM_002929.2-1682s1c1 2.82 #N/A #N/A 
6011 GRK1 NM_002929.2-463s1c1 1.61 #N/A #N/A 
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6046 BRD2 NM_005104.2-2401s1c1 -2.12 40% 293T 
6046 BRD2 NM_005104.2-2059s1c1 -2.57 21% 293T 
6729 SRP54 NM_003136.2-1839s1c1d1 -2.80 25% A549 
6729 SRP54 NM_003136.2-1903s1c1d1 -2.61 22% A549 
6729 SRP54 NM_003136.2-849s1c1d1 -2.71 15% A549 
6733 SRPK2 NM_003138.1-749s1c1 -1.79 9% MCF7 
6733 SRPK2 NM_003138.1-2730s1c1 -1.61 3% MCF7 
6734 SRPR NM_003139.2-202s1c1d1 -4.08 4% A549 
6734 SRPR NM_003139.2-1086s1c1d1 -1.86 5% A549 
7083 TK1 NM_003258.x-530s1c1 -1.74 14% A549 
7083 TK1 NM_003258.x-610s1c1 -1.94 11% A549 
7083 TK1 NM_003258.x-327s1c1 -1.51 3% A549 
7284 TUFM NM_003321.3-1266s1c1d1 -1.71 2% A549 
7284 TUFM NM_003321.3-668s1c1d1 -2.68 5% A549 
7297 TYK2 NM_003331.x-3209s1c1 -2.87 13% A549 
7297 TYK2 NM_003331.x-4078s1c1 -2.54 15% A549 
7879 RAB7A NM_004637.5-347s1c1d1 -1.96 151% Jurkat 
7879 RAB7A NM_004637.5-781s1c1d1 -2.40 41% Jurkat 
8153 RND2 NM_005440.2-244s1c1d3 -2.11 #N/A #N/A 
8153 RND2 NM_005440.2-189s1c1d2 -2.77 #N/A #N/A 
8153 RND2 NM_005440.2-286s1c1d3 -2.16 #N/A #N/A 
8476 CDC42BPA NM_014826.x-2749s1c1 2.49 3% A549 
8476 CDC42BPA NM_014826.x-4292s1c1 1.55 44% A549 
8476 CDC42BPA NM_003607.x-4535s1c1 2.58 6% A549 
8476 CDC42BPA NM_003607.x-2992s1c1 2.33 5% A549 
8503 PIK3R3 NM_003629.2-752s1c1d1 3.29 #N/A #N/A 
8503 PIK3R3 NM_003629.2-1826s1c1d1 2.82 #N/A #N/A 
8503 PIK3R3 NM_003629.2-1543s1c1d1 5.15 #N/A #N/A 
8503 PIK3R3 NM_003629.2-3516s1c1 1.56 #N/A #N/A 
8503 PIK3R3 NM_003629.2-1826s1c1 2.56 #N/A #N/A 
8503 PIK3R3 NM_003629.2-1126s1c1 1.95 #N/A #N/A 
8526 DGKE NM_003647.1-853s1c1 -1.70 20% MCF7 
8526 DGKE NM_003647.1-952s1c1 -1.54 5% MCF7 
8527 DGKD NM_003648.x-1118s1c1 -1.82 42% Jurkat 
8527 DGKD NM_003648.2-2201s1c1 -1.96 81% Jurkat 
8527 DGKD NM_003648.x-1812s1c1 -1.95 40% Jurkat 
8527 DGKD NM_003648.x-350s1c1 -1.56 56% Jurkat 
8566 PDXK NM_003681.x-889s1c1 -1.81 112% A549 
8566 PDXK NM_003681.x-684s1c1 -1.73 9% A549 
8649 MAPKSP1 NM_021970.2-415s1c1 2.44 40% A-431 
8649 MAPKSP1 NM_021970.2-577s1c1 2.44 69% A-431 
8766 RAB11A NM_004663.3-209s1c1d1 -2.46 #N/A #N/A 
8766 RAB11A NM_004663.3-387s1c1d1 -1.52 #N/A #N/A 
8798 DYRK4 NM_003845.1-1163s1c1 -1.99 21% Jurkat 
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8798 DYRK4 NM_003845.1-1342s1c1 -2.22 37% Jurkat 
8798 DYRK4 NM_003845.1-814s1c1 -1.84 76% Jurkat 
8798 DYRK4 NM_003845.x-1755s1c1 -1.81 94% Jurkat 
8877 SPHK1 NM_182965.1-1640s1c1 -2.43 36% 293T 
8877 SPHK1 NM_182965.1-1116s1c1 -1.68 21% 293T 
8877 SPHK1 NM_182965.1-1063s1c1 -3.09 13% 293T 
8934 RAB7L1 NM_003929.1-533s1c1d2 -2.70 157% A549 
8934 RAB7L1 NM_003929.1-307s1c1d2 -1.66 33% A549 
9060 PAPSS2 NM_004670.2-177s1c1 -1.83 11% MCF7 
9060 PAPSS2 NM_004670.2-1768s1c1 -1.58 7% MCF7 
9064 MAP3K6 NM_004672.3-2887s1c1 -1.61 #N/A #N/A 
9064 MAP3K6 NM_004672.x-3795s1c1 -2.40 24% A549 
9064 MAP3K6 NM_004672.3-4159s1c1 -1.84 #N/A #N/A 
9064 MAP3K6 NM_004672.3-3541s1c1 -1.64 #N/A #N/A 
9223 MAGI1 NM_004742.2-5513s1c1 1.99 91% A549 
9223 MAGI1 NM_004742.2-1636s1c1 2.34 76% A549 
9230 RAB11B NM_004218.1-288s1c1d1 -2.40 #N/A #N/A 
9230 RAB11B NM_004218.1-469s1c1d1 -2.75 #N/A #N/A 
9263 STK17A NM_004760.x-1998s1c1 -1.55 65% A549 
9263 STK17A NM_004760.x-854s1c1 -2.64 150% A549 
9363 RAB33A NM_004794.2-630s1c1d2 -3.23 20% Jurkat 
9363 RAB33A NM_004794.2-778s1c1d2 -2.14 89% Jurkat 
9363 RAB33A NM_004794.2-749s1c1d2 -2.79 55% Jurkat 
9364 RAB28 NM_004249.1-265s1c1d2 -2.74 #N/A #N/A 
9364 RAB28 NM_004249.1-75s1c1d2 -2.85 #N/A #N/A 
9545 RAB3D NM_004283.2-296s1c1d2 -2.10 #N/A #N/A 
9545 RAB3D NM_004283.2-745s1c1d2 -1.67 #N/A #N/A 
9567 GTPBP1 NM_004286.3-884s1c1d2 -4.45 23% 293T 
9567 GTPBP1 NM_004286.3-1015s1c1d2 -1.90 31% 293T 
9567 GTPBP1 NM_004286.3-362s1c1d2 -1.92 61% 293T 
9641 IKBKE NM_014002.x-941s1c1 -2.06 40% MCF7 
9641 IKBKE NM_014002.x-1628s1c1 -2.32 62% MCF7 
9829 DNAJC6 NM_014787.x-355s1c1 -3.04 56% Jurkat 
9829 DNAJC6 NM_014787.x-2453s1c1 -2.01 26% Jurkat 
9891 NUAK1 NM_014840.x-2796s1c1 -2.20 0% A549 
9891 NUAK1 NM_014840.x-1712s1c1 -1.67 56% A549 
9943 OXSR1 NM_005109.x-551s1c1 2.16 #N/A #N/A 
9943 OXSR1 NM_005109.x-1189s1c1 1.52 #N/A #N/A 
9943 OXSR1 NM_005109.x-1969s1c1 2.54 #N/A #N/A 
10000 AKT3 NM_005465.x-569s1c1 -1.82 21% A549 
10000 AKT3 NM_005465.x-770s1c1 -3.04 33% A549 
10000 AKT3 NM_005465.x-1757s1c1 -1.83 47% A549 
10000 AKT3 NM_005465.x-1307s1c1 -1.57 58% A549 
10139 ARFRP1 NM_003224.2-265s1c1d2 4.15 66% A549 
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10139 ARFRP1 NM_003224.2-571s1c1d2 3.86 27% A549 
10154 PLXNC1 NM_005761.1-3289s1c1 -2.25 31% Jurkat 
10154 PLXNC1 NM_005761.1-1236s1c1 -2.26 32% Jurkat 
10221 TRIB1 NM_025195.x-1691s1c1 2.66 95% A549 
10221 TRIB1 NM_025195.x-641s1c1 1.67 60% A549 
10519 CIB1 NM_006384.2-504s1c1 -2.80 7% A549 
10519 CIB1 NM_006384.2-376s1c1 -2.04 31% A549 
10783 NEK6 NM_014397.x-445s1c1 -2.40 3% MCF7 
10783 NEK6 NM_014397.x-484s1c1 -2.11 22% MCF7 
10890 RAB10 NM_016131.2-997s1c1d1 -3.78 #N/A #N/A 
10890 RAB10 NM_016131.2-874s1c1d1 -2.49 #N/A #N/A 
10966 RAB40B NM_006822.1-513s1c1d2 -3.48 40% A549 
10966 RAB40B NM_006822.1-354s1c1d1 -2.30 7% A549 
10966 RAB40B NM_006822.1-243s1c1d1 -2.99 53% A549 
11020 RABL4 NM_006860.2-605s1c1d2 -2.14 #N/A #N/A 
11020 RABL4 NM_006860.2-527s1c1d2 -2.69 #N/A #N/A 
11021 RAB35 NM_006861.4-486s1c1d2 -3.27 27% A549 
11021 RAB35 NM_006861.4-451s1c1d2 -3.67 64% A549 
11021 RAB35 NM_006861.4-207s1c1d2 -2.58 19% A549 
11021 RAB35 NM_006861.4-709s1c1d2 -3.93 37% A549 
11035 RIPK3 NM_006871.x-1280s1c1 -3.02 98% Jurkat 
11035 RIPK3 NM_006871.x-612s1c1 -1.59 104% Jurkat 
11158 RABL2B NM_001003789.1-319s1c1d2 -2.18 #N/A #N/A 
11158 RABL2B NM_001003789.1-270s1c1d2 -2.83 #N/A #N/A 
11158 RABL2B NM_001003789.1-418s1c1d2 -3.69 #N/A #N/A 
11158 RABL2B NM_001003789.1-625s1c1d2 -2.37 #N/A #N/A 
11159 RABL2A NM_007082.2-312s1c1d2 -1.55 #N/A #N/A 
11159 RABL2A NM_007082.2-190s1c1d2 -2.63 #N/A #N/A 
11159 RABL2A NM_007082.2-705s1c1d1 -2.76 #N/A #N/A 
11200 CHEK2 NM_007194.x-2219s1c1 -1.67 110% A549 
11200 CHEK2 NM_007194.x-2394s1c1 -1.70 49% A549 
11321 XAB1 NM_007266.1-835s1c1d2 2.33 4% A549 
11321 XAB1 NM_007266.1-220s1c1d2 2.73 18% A549 
11344 TWF2 NM_007284.3-522s1c1 -2.09 22% A549 
11344 TWF2 NM_007284.3-610s1c1 -1.50 9% A549 
23227 MAST4 XM_291141.3-2703s1c1 -1.95 #N/A #N/A 
23227 MAST4 XM_291141.3-4700s1c1 -2.33 #N/A #N/A 
23433 RHOQ NM_012249.1-96s1c1d1 -3.06 #N/A #N/A 
23433 RHOQ NM_012249.1-385s1c1d1 -2.69 #N/A #N/A 
23560 GTPBP4 NM_012341.1-114s1c1d2 -3.01 #N/A #N/A 
23560 GTPBP4 NM_012341.1-485s1c1d2 -1.51 #N/A #N/A 
23636 NUP62 NM_012346.3-302s1c1 -3.18 50% Jurkat 
23636 NUP62 NM_012346.3-925s1c1 -2.62 110% Jurkat 
23636 NUP62 NM_012346.3-533s1c1 -1.97 87% Jurkat 
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23729 SHPK NM_013276.2-3662s1c1 -2.00 85% Jurkat 
23729 SHPK NM_013276.2-1334s1c1 -1.92 50% Jurkat 
23729 SHPK NM_013276.2-558s1c1 -1.85 18% Jurkat 
25837 RAB26 NM_014353.4-721s1c1d2 -4.06 40% A549 
25837 RAB26 NM_014353.4-512s1c1d2 -2.21 48% A549 
26007 DAK NM_015533.2-1015s1c1 -1.70 10% A549 
26007 DAK NM_015533.2-1597s1c1 -1.51 0% A549 
26164 GTPBP5 NM_015666.2-372s1c1d2 -3.99 #N/A #N/A 
26164 GTPBP5 NM_015666.2-747s1c1d2 -1.77 #N/A #N/A 
26164 GTPBP5 NM_015666.2-1174s1c1d2 -2.10 #N/A #N/A 
26164 GTPBP5 NM_015666.2-1250s1c1d2 -2.00 #N/A #N/A 
26225 ARL5A NM_177985.1-335s1c1d1 1.95 #N/A #N/A 
26225 ARL5A NM_177985.1-556s1c1d1 3.44 #N/A #N/A 
26284 ERAL1 NM_005702.1-539s1c1d1 -2.37 #N/A #N/A 
26284 ERAL1 NM_005702.1-1693s1c1d1 -1.59 #N/A #N/A 
27289 RND1 NM_014470.2-741s1c1d2 -2.73 #N/A #N/A 
27289 RND1 NM_014470.2-285s1c1d2 -1.86 #N/A #N/A 
27289 RND1 NM_014470.2-424s1c1d2 -2.72 #N/A #N/A 
27314 RAB30 NM_014488.3-341s1c1d2 -2.92 26% Jurkat 
27314 RAB30 NM_014488.3-571s1c1d2 -3.07 240% Jurkat 
28996 HIPK2 NM_022740.x-1389s1c1 -1.86 104% A549 
28996 HIPK2 NM_022740.x-1940s1c1 -1.63 227% A549 
28996 HIPK2 NM_022740.x-3587s1c1 -1.53 51% A549 
29110 TBK1 NM_013254.x-1212s1c1 -2.46 35% A549 
29110 TBK1 NM_013254.x-1536s1c1 -1.75 33% A549 
29110 TBK1 NM_013254.x-1773s1c1 -1.98 74% A549 
29904 EEF2K NM_013302.2-281s1c1 -3.44 74% Jurkat 
29904 EEF2K NM_013302.2-1449s1c1 -3.78 136% Jurkat 
51128 SAR1B NM_016103.2-267s1c1d2 -3.50 9% A549 
51128 SAR1B NM_016103.2-569s1c1d2 -1.95 8% A549 
51135 IRAK4 NM_016123.x-2142s1c1 1.64 71% A549 
51135 IRAK4 NM_016123.x-374s1c1 1.88 29% A549 
51135 IRAK4 NM_016123.x-197s1c1 2.81 53% A549 
51135 IRAK4 NM_016123.x-820s1c1 1.53 10% A549 
51209 RAB9B NM_016370.1-444s1c1d2 -3.12 79% Jurkat 
51209 RAB9B NM_016370.1-361s1c1d2 -1.83 63% Jurkat 
51231 VRK3 NM_016440.x-354s1c1 1.74 149% MCF7 
51231 VRK3 NM_016440.x-209s1c1 1.70 11% MCF7 
51285 RASL12 NM_016563.2-1552s1c1d1 2.76 #N/A #N/A 
51285 RASL12 NM_016563.2-341s1c1d1 1.58 #N/A #N/A 
51552 RAB14 NM_016322.2-304s1c1d1 1.50 21% Jurkat 
51552 RAB14 NM_016322.2-505s1c1d1 2.84 55% Jurkat 
51678 MPP6 NM_016447.x-528s1c1 -1.89 14% A549 
51678 MPP6 NM_016447.x-527s1c1 -1.57 27% A549 
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51701 NLK NM_016231.2-2245s1c1 -2.56 #N/A #N/A 
51701 NLK NM_016231.2-3634s1c1 -3.95 #N/A #N/A 
51701 NLK NM_016231.x-1422s1c1 -3.18 60% A549 
51701 NLK NM_016231.x-2413s1c1 -2.86 38% A549 
51715 RAB23 NM_016277.3-1262s1c1d2 -1.96 #N/A #N/A 
51715 RAB23 NM_016277.3-762s1c1d2 -1.69 #N/A #N/A 
53632 PRKAG3 NM_017431.2-1075s1c1 1.56 #N/A #N/A 
53632 PRKAG3 NM_017431.1-564s1c1 2.05 #N/A #N/A 
53632 PRKAG3 NM_017431.2-183s1c1 2.52 #N/A #N/A 
53632 PRKAG3 NM_017431.1-156s1c1 1.92 #N/A #N/A 
53834 FGFRL1 NM_001004356.1-2412s1c1 -2.87 136% Jurkat 
53834 FGFRL1 NM_001004356.1-1103s1c1 -2.25 29% Jurkat 
54509 RHOF NM_019034.2-565s1c1d2 -3.14 #N/A #N/A 
54509 RHOF NM_019034.2-376s1c1d2 -2.90 #N/A #N/A 
54676 GTPBP2 NM_019096.3-1522s1c1d2 -2.27 #N/A #N/A 
54676 GTPBP2 NM_019096.3-464s1c1d2 -1.74 #N/A #N/A 
54676 GTPBP2 NM_019096.3-1308s1c1d2 -4.43 #N/A #N/A 
54734 RAB39 NM_017516.1-1624s1c1d2 -2.80 #N/A #N/A 
54734 RAB39 NM_017516.1-533s1c1d2 -1.81 #N/A #N/A 
54734 RAB39 NM_017516.1-485s1c1d2 -1.71 #N/A #N/A 
55277 FGGY NM_018291.2-1232s1c1 1.73 58% Jurkat 
55277 FGGY NM_018291.2-863s1c1 2.03 45% Jurkat 
55288 RHOT1 NM_018307.2-900s1c1d2 -2.05 17% Jurkat 
55288 RHOT1 NM_018307.2-457s1c1d2 -2.15 71% Jurkat 
55288 RHOT1 NM_018307.2-169s1c1d2 -3.02 23% Jurkat 
55312 RFK NM_018339.3-731s1c1 1.71 10% A549 
55312 RFK NM_018339.3-595s1c1 3.05 3% A549 
55312 RFK NM_018339.3-550s1c1 1.87 5% A549 
55351 STK32B NM_018401.x-185s1c1 -1.81 12% A549 
55351 STK32B NM_018401.x-570s1c1 -2.36 34% A549 
55500 ETNK1 NM_018638.x-714s1c1 -1.75 11% A549 
55500 ETNK1 NM_018638.x-581s1c1 2.65 15% A549 
55577 NAGK NM_017567.1-369s1c1 2.62 65% A549 
55577 NAGK NM_017567.1-621s1c1 3.09 10% A549 
55577 NAGK NM_017567.1-999s1c1 2.05 34% A549 
55750 AGK NM_018238.2-457s1c1 2.72 47% Jurkat 
55750 AGK NM_018238.2-1634s1c1 2.07 35% Jurkat 
55970 GNG12 NM_018841.2-238s1c1d1 2.21 4% A549 
55970 GNG12 NM_018841.2-272s1c1d1 1.79 32% A549 
56681 SAR1A NM_020150.3-398s1c1d3 -2.29 34% A549 
56681 SAR1A NM_020150.3-566s1c1d3 -2.07 9% A549 
56997 CABC1 NM_020247.3-1678s1c1 -1.56 47% MCF7 
56997 CABC1 NM_020247.3-1093s1c1 -1.93 0% MCF7 
56997 CABC1 NM_020247.3-683s1c1 -2.17 35% MCF7 
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57111 RAB25 NM_020387.1-571s1c1d1 -2.66 2% MCF7 
57111 RAB25 NM_020387.1-706s1c1d1 -3.05 2% MCF7 
57111 RAB25 NM_020387.1-387s1c1d1 -3.65 14% MCF7 
57381 RHOJ NM_020663.2-878s1c1d2 -4.05 #N/A #N/A 
57381 RHOJ NM_020663.2-1007s1c1d2 -2.22 #N/A #N/A 
57403 RAB22A NM_020673.2-500s1c1d2 5.07 127% Jurkat 
57403 RAB22A NM_020673.2-356s1c1d2 2.92 84% Jurkat 
57521 Raptor NM_020761.1-65s1c1 4.06 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.38 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.76 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 4.59 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.14 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 4.78 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.05 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.72 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.55 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.53 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.65 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.01 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.05 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.60 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.75 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.71 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.42 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.03 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.66 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.67 #N/A #N/A 
57521 KIAA1303 NM_020761.1-4689s1c1d1 2.53 28% A549 
57521 KIAA1303 NM_020761.1-2564s1c1d1 2.52 35% A549 
57521 Raptor NM_020761.1-65s1c1 2.49 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.79 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.49 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.73 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.17 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 2.63 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.60 #N/A #N/A 
57521 Raptor NM_020761.1-65s1c1 1.85 #N/A #N/A 
57538 ALPK3 NM_020778.1-1004s1c1 -2.51 #N/A #N/A 
57538 ALPK3 NM_020778.1-2799s1c1 -1.82 #N/A #N/A 
57538 ALPK3 NM_020778.1-3638s1c1 -1.83 #N/A #N/A 
57799 RAB40C NM_021168.2-388s1c1d2 -2.25 50% Jurkat 
57799 RAB40C NM_021168.2-253s1c1d2 -1.66 91% Jurkat 
58480 RHOU NM_021205.4-972s1c1d2 -3.88 #N/A #N/A 
58480 RHOU NM_021205.4-1218s1c1d2 -3.20 #N/A #N/A 
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60493 FASTKD5 NM_021826.4-1341s1c1 -2.47 7% A549 
60493 FASTKD5 NM_021826.4-1602s1c1 -2.00 5% A549 
64080 RBKS NM_022128.1-837s1c1 2.12 10% A549 
64080 RBKS NM_022128.x-101s1c1 2.29 5% A549 
64122 FN3K NM_022158.2-860s1c1 -1.93 #N/A #N/A 
64122 FN3K NM_022158.2-413s1c1 -3.33 #N/A #N/A 
64122 FN3K NM_022158.2-848s1c1 -1.60 #N/A #N/A 
64122 FN3K NM_022158.2-257s1c1 -2.32 #N/A #N/A 
64792 RABL5 NM_022777.1-178s1c1d1 -3.10 #N/A #N/A 
64792 RABL5 NM_022777.1-626s1c1d1 -2.38 #N/A #N/A 
64792 RABL5 NM_022777.1-451s1c1d1 -1.52 #N/A #N/A 
64792 RABL5 NM_022777.1-439s1c1d1 -2.66 #N/A #N/A 
65018 PINK1 NM_032409.1-785s1c1 -2.37 0% MCF7 
65018 PINK1 NM_032409.1-1601s1c1 -1.84 0% MCF7 
65018 PINK1 NM_032409.1-2473s1c1 -1.98 99% MCF7 
65018 PINK1 NM_032409.1-784s1c1 -2.10 10% MCF7 
65266 WNK4 NM_032387.2-723s1c1 3.60 #N/A #N/A 
65266 WNK4 NM_032387.2-534s1c1 4.00 #N/A #N/A 
65267 WNK3 NM_020922.x-5208s1c1 -2.15 122% MCF7 
65267 WNK3 NM_020922.x-2746s1c1 -1.98 74% MCF7 
65267 WNK3 NM_020922.x-4699s1c1 -1.70 60% MCF7 
65267 WNK3 NM_020922.x-2356s1c1 -2.35 95% MCF7 
65975 STK33 NM_030906.x-2319s1c1 -2.89 37% A549 
65975 STK33 NM_030906.x-3035s1c1 -2.19 95% A549 
65975 STK33 NM_030906.x-1436s1c1 -1.61 60% A549 
65975 STK33 NM_030906.x-2398s1c1 -1.89 49% A549 
79109 MAPKAP1 NM_024117.x-1308s1c1d1 -1.50 19% MCF7 
79109 MAPKAP1 NM_024117.x-526s1c1d1 -1.94 23% MCF7 
79675 FASTKD1 NM_024622.2-770s1c1 -1.65 28% Jurkat 
79675 FASTKD1 NM_024622.2-862s1c1 -1.61 42% Jurkat 
79877 DCAKD NM_024819.3-590s1c1 3.06 21% Jurkat 
79877 DCAKD NM_024819.3-419s1c1 3.28 35% Jurkat 
79877 DCAKD NM_024819.3-420s1c1 3.44 22% Jurkat 
79877 DCAKD NM_024819.3-997s1c1 1.55 10% Jurkat 
79899 FLJ14213 NM_024841.2-1143s1c1d1 1.96 #N/A #N/A 
79899 FLJ14213 NM_024841.2-963s1c1d1 2.87 #N/A #N/A 
79906 MORN1 NM_024848.1-117s1c1 1.69 #N/A #N/A 
79906 MORN1 NM_024848.1-118s1c1 2.73 #N/A #N/A 
80216 ALPK1 NM_025144.2-3416s1c1 -1.96 #N/A #N/A 
80216 ALPK1 NM_025144.2-1319s1c1 -2.36 #N/A #N/A 
80216 ALPK1 NM_025144.2-4083s1c1 -1.99 #N/A #N/A 
80347 COASY NM_025233.4-547s1c1 -2.01 37% A549 
80347 COASY NM_025233.4-2299s1c1 -2.74 7% A549 
81876 RAB1B NM_030981.1-260s1c1d2 -2.11 2% A549 
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81876 RAB1B NM_030981.1-374s1c1d1 -2.51 3% A549 
81876 RAB1B NM_030981.1-290s1c1d1 -1.93 47% A549 
83440 ADPGK NM_031284.3-507s1c1 -3.50 8% A549 
83440 ADPGK NM_031284.3-995s1c1 -3.55 3% A549 
83440 ADPGK NM_031284.3-1498s1c1 -2.18 6% A549 
83452 RAB33B NM_031296.1-801s1c1d1 -1.92 70% Jurkat 
83452 RAB33B NM_031296.1-2153s1c1d1 -2.66 42% Jurkat 
84100 ARL6 NM_032146.3-445s1c1d3 2.10 #N/A #N/A 
84100 ARL6 NM_032146.3-702s1c1d3 2.88 #N/A #N/A 
84100 ARL6 NM_032146.3-713s1c1d3 1.83 #N/A #N/A 
84206 MEX3B NM_032246.3-597s1c1 -1.66 165% Jurkat 
84206 MEX3B NM_032246.3-1299s1c1 -1.91 212% Jurkat 
84284 C1orf57 NM_032324.1-569s1c1 2.68 20% Jurkat 
84284 C1orf57 NM_032324.1-561s1c1 2.66 26% Jurkat 
84451   NM_032435.x-1423s1c1 -3.68 0% MCF7 
84451   NM_032435.x-4199s1c1 -2.02 14% MCF7 
84451   NM_032435.x-2263s1c1 -1.58 26% MCF7 
84705 GTPBP3 NM_032620.1-1158s1c1d2 -1.82 #N/A #N/A 
84705 GTPBP3 NM_032620.1-645s1c1d2 -2.74 #N/A #N/A 
84930 MASTL NM_032844.x-2725s1c1 -1.93 16% A549 
84930 MASTL NM_032844.x-1818s1c1 -1.95 17% A549 
84932 RAB2B NM_032846.2-502s1c1d2 -2.37 92% Jurkat 
84932 RAB2B NM_032846.2-405s1c1d2 -2.04 88% Jurkat 
89882 TPD52L3 NM_033516.4-396s1c1 -2.17 22% MCF7 
89882 TPD52L3 NM_033516.4-266s1c1 -1.74 40% MCF7 
89882 TPD52L3 NM_033516.4-563s1c1 -1.94 36% MCF7 
89941 RHOT2 NM_138769.1-227s1c1d1 -1.84 32% A549 
89941 RHOT2 NM_138769.1-1585s1c1d1 -2.50 13% A549 
89941 RHOT2 NM_138769.1-499s1c1d1 -3.56 ND A549 
94235 GNG8 NM_033258.1-51s1c1d1 2.13 #N/A #N/A 
94235 GNG8 NM_033258.1-48s1c1d1 1.74 #N/A #N/A 
115273 RAB42 NM_152304.1-586s1c1d2 -2.48 #N/A #N/A 
115273 RAB42 NM_152304.1-472s1c1d2 -1.95 #N/A #N/A 
115273 RAB42 NM_152304.1-336s1c1d2 -2.70 #N/A #N/A 
115827 RAB3C NM_138453.2-361s1c1d2 -1.83 #N/A #N/A 
115827 RAB3C NM_138453.2-683s1c1d1 -2.89 #N/A #N/A 
115827 RAB3C NM_138453.2-566s1c1d1 -1.72 #N/A #N/A 
116442 RAB39B NM_171998.1-594s1c1d2 -1.60 47% Jurkat 
116442 RAB39B NM_171998.1-393s1c1d2 -2.02 61% Jurkat 
116442 RAB39B NM_171998.1-468s1c1d2 -2.27 53% Jurkat 
127829 ARL8A NM_138795.2-535s1c1d1 3.04 93% Jurkat 
127829 ARL8A NM_138795.2-208s1c1d1 1.78 67% Jurkat 
130106 CIB4 XM_059399.4-218s1c1 2.51 #N/A #N/A 
130106 CIB4 XM_059399.4-491s1c1 1.58 #N/A #N/A 
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130106 CIB4 XM_059399.4-101s1c2 1.51 #N/A #N/A 
132158 GLYCTK NM_145262.2-178s1c1 -1.91 55% A549 
132158 GLYCTK NM_145262.2-1501s1c1 -2.15 36% A549 
132158 GLYCTK NM_145262.2-1510s1c1 -1.85 59% A549 
139728 PNCK NM_198452.1-229s1c1 2.22 21% MCF7 
139728 PNCK NM_198452.1-1391s1c1 1.64 27% MCF7 
143098 MPP7 NM_173496.2-493s1c1 -1.87 37% MCF7 
143098 MPP7 NM_173496.2-610s1c1 -2.44 44% MCF7 
158067 C9orf98 NM_152572.2-1877s1c1 -1.56 73% Jurkat 
158067 C9orf98 NM_152572.2-700s1c1 -2.17 14% Jurkat 
158067 C9orf98 NM_152572.2-1099s1c1 -2.30 10% Jurkat 
158158 RASEF NM_152573.2-907s1c1d2 -1.79 #N/A #N/A 
158158 RASEF NM_152573.2-1153s1c1d2 -2.06 #N/A #N/A 
158158 RASEF NM_152573.2-2189s1c1d2 -2.12 #N/A #N/A 
197258 FUK NM_145059.1-1966s1c1 -2.54 23% Jurkat 
197258 FUK NM_145059.1-3135s1c1 -2.34 9% Jurkat 
197258 FUK NM_145059.1-525s1c1 -3.21 16% Jurkat 
200894 ARL13B NM_182896.1-656s1c1d1 -2.40 37% Jurkat 
200894 ARL13B NM_182896.1-1057s1c1d1 -1.80 102% Jurkat 
203447 NRK NM_198465.1-2037s1c1 -1.51 #N/A #N/A 
203447 NRK NM_198465.1-6369s1c1 -1.81 #N/A #N/A 
203447 NRK NM_198465.1-3444s1c1 -1.79 #N/A #N/A 
203447 NRK NM_198465.1-1263s1c1 -1.94 #N/A #N/A 
204851 HIPK1 NM_152696.3-3218s1c1 -1.62 #N/A #N/A 
204851 HIPK1 NM_152696.3-2649s1c1 -1.78 29% MCF7 
204851 HIPK1 NM_152696.3-3011s1c1 -2.07 #N/A #N/A 
204851 HIPK1 NM_152696.3-2105s1c1 -2.60 #N/A #N/A 
220686   NM_199283.4-2143s1c1 -1.58 #N/A #N/A 
220686   NM_199283.4-1290s1c1 -1.82 #N/A #N/A 
220686   NM_199283.4-699s1c1 1.99 #N/A #N/A 
221079 ARL5B NM_178815.2-272s1c1d2 5.15 76% Jurkat 
221079 ARL5B NM_178815.2-589s1c1d2 3.83 249% Jurkat 
253260 RICTOR NM_152756.3-25s1c1 -1.60 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.01 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.20 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.50 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.30 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.51 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.73 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.19 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.09 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.06 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.67 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.24 #N/A #N/A 
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253260 RICTOR NM_152756.3-25s1c1 -1.75 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.59 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.19 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.90 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.64 #N/A #N/A 
253260 RICTOR NM_152756.2-5035s1c1d1 -1.59 26% A549 
253260 RICTOR NM_152756.3-25s1c1 -1.52 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.83 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.60 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.34 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.67 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.69 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.86 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.54 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.02 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.71 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -1.52 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.05 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.64 #N/A #N/A 
253260 RICTOR NM_152756.3-25s1c1 -2.05 #N/A #N/A 
253430 IPMK NM_152230.2-691s1c1 2.46 #N/A #N/A 
253430 IPMK NM_152230.2-1075s1c1 2.44 #N/A #N/A 
253430 IPMK NM_152230.2-1502s1c1 2.43 #N/A #N/A 
256356 GK5 NM_152776.1-1237s1c1 -4.51 69% Jurkat 
256356 GK5 NM_152776.1-356s1c1 -2.65 60% Jurkat 
260425 MAGI3 NM_020965.2-2984s1c1 -3.05 15% A549 
260425 MAGI3 NM_020965.2-1964s1c1 -2.08 8% A549 
282974 STK32C NM_173575.2-311s1c1 -2.72 16% A549 
282974 STK32C NM_173575.2-1898s1c1 -1.84 23% A549 
282974 STK32C NM_173575.2-839s1c1 -2.04 29% A549 
282974 STK32C NM_173575.2-1386s1c1 -1.93 21% A549 
283629 TSSK4 NM_174944.x-1134s1c1 -1.79 #N/A #N/A 
283629 TSSK4 NM_174944.2-217s1c1 -1.56 #N/A #N/A 
283629 TSSK4 NM_174944.2-408s1c1 -1.95 #N/A #N/A 
283629 TSSK4 NM_174944.x-495s1c1 -1.80 #N/A #N/A 
284086 NEK8 NM_178170.2-2231s1c1 -3.55 #N/A #N/A 
284086 NEK8 NM_178170.2-84s1c1 -3.78 #N/A #N/A 
284086 NEK8 NM_178170.2-2321s1c1 -2.08 #N/A #N/A 
284086 NEK8 NM_178170.2-1734s1c1 -1.77 #N/A #N/A 
284086 NEK8 NM_178170.2-210s1c1 -1.89 #N/A #N/A 
284086 NEK8 NM_178170.2-1494s1c1 -2.72 #N/A #N/A 
284656 EPHA10 NM_173641.1-546s1c1 -2.39 64% Jurkat 
284656 EPHA10 NM_173641.1-199s1c1 -2.30 107% Jurkat 
285282 RABL3 NM_173825.1-253s1c1d1 -1.66 #N/A #N/A 
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285282 RABL3 NM_173825.1-288s1c1d1 -2.69 #N/A #N/A 
285282 RABL3 NM_173825.1-511s1c1d1 -1.57 #N/A #N/A 
326624 RAB37 NM_175738.2-1059s1c1d2 -2.67 36% Jurkat 
326624 RAB37 NM_175738.2-711s1c1d2 -3.07 36% Jurkat 
339122 RAB43 NM_198490.1-326s1c1d1 3.32 106% Jurkat 
339122 RAB43 NM_198490.1-323s1c1d1 1.72 72% Jurkat 
344988 SAR1P3 XM_293671.3-48s1c1d2 1.73 #N/A #N/A 
344988 SAR1P3 XM_293671.3-90s1c1d2 4.57 #N/A #N/A 
347359 BMP2KL XM_293293.1-316s1c1 -1.56 #N/A #N/A 
347359 BMP2KL XM_293293.1-829s1c1 -2.68 #N/A #N/A 
347736 TXNDC6 NM_178130.2-862s1c1 -1.81 #N/A #N/A 
347736 TXNDC6 NM_178130.2-695s1c1 -2.86 #N/A #N/A 
347736 TXNDC6 NM_178130.2-1004s1c1 -2.14 #N/A #N/A 
374872 C19orf35 NM_198532.1-1942s1c1 -2.13 #N/A #N/A 
374872 C19orf35 NM_198532.1-163s1c2 -2.77 #N/A #N/A 
374872 C19orf35 NM_198532.1-2156s1c1 -1.74 #N/A #N/A 
375133 PI4KAP2 NM_199345.1-570s1c2 -1.67 #N/A #N/A 
375133 PI4KAP2 NM_199345.1-721s1c1 -2.02 #N/A #N/A 
375133 PI4KAP2 NM_199345.2-868s1c1 -1.52 #N/A #N/A 
387751 GVIN1 XM_495863.1-787s1c1d2 -2.09 #N/A #N/A 
387751 GVIN1 XM_495863.1-3014s1c1d2 -2.37 #N/A #N/A 
390877   XM_372705.1-33s1c1 1.80 #N/A #N/A 
390877   XM_372705.1-306s1c1 1.91 #N/A #N/A 
392226   XM_498286.1-954s1c1 -2.73 #N/A #N/A 
392226   XM_498286.1-166s1c1 -2.51 #N/A #N/A 
392226   XM_498286.1-790s1c1 1.69 #N/A #N/A 
392265   XM_498294.1-79s1c1 -2.42 #N/A #N/A 
392265   XM_498294.1-502s1c1 -2.77 #N/A #N/A 
392347   XM_373298.2-623s1c1 2.46 #N/A #N/A 
392347   XM_373298.2-598s1c1 -3.01 #N/A #N/A 
392347   XM_373298.2-411s1c1 -1.88 #N/A #N/A 
392347   XM_373298.2-94s1c1 3.29 #N/A #N/A 
402679   XM_380022.4-429s1c1 -2.18 #N/A #N/A 
402679   XM_380022.2-441s1c1 -3.15 #N/A #N/A 
402679   XM_380022.4-298s1c1 -3.98 #N/A #N/A 
402679   XM_380022.4-27s1c1 -2.35 #N/A #N/A 
440275 EIF2AK4 XM_496066.1-495s1c1 2.55 73% A549 
440275 EIF2AK4 XM_496066.1-405s1c1 2.05 56% A549 
440275 EIF2AK4 XM_496066.1-304s1c1 4.62 21% A549 
440345   XM_496125.1-7371s1c1 2.08 #N/A #N/A 
440345   XM_496125.1-7211s1c1 2.60 #N/A #N/A 
440345   XM_496125.1-352s1c1 1.96 #N/A #N/A 
441655   XM_497366.1-217s1c1 -2.37 #N/A #N/A 
441655   XM_497366.1-331s1c1 -1.55 #N/A #N/A 
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441971   XM_497790.1-98s1c1 -1.63 #N/A #N/A 
441971   XM_497790.1-373s1c1 -1.56 #N/A #N/A 
441971   XM_497790.1-446s1c1 -3.89 #N/A #N/A 
441971   XM_497790.1-119s1c1 -3.04 #N/A #N/A 
442313   XM_498204.1-610s1c1 -1.73 #N/A #N/A 
442313   XM_498204.1-650s1c1 -2.39 #N/A #N/A 
442558   XM_499301.1-934s1c1 -1.58 #N/A #N/A 
442558   XM_499301.1-514s1c1 -1.84 #N/A #N/A 
442558   XM_499301.1-568s1c1 2.11 #N/A #N/A 




APPENDIX C: shRNAs from Appendix B with greater than 50% target mRNA 
knockdown.  
NCBI ID Symbol TRC Clone Name 
mean pAKT Z-
score % mRNA 
cell 
line 
207 AKT1 NM_005163.x-642s1c1 -2.23 10% A-431 
207 AKT1 NM_005163.x-981s1c1 -2.02 17% A-431 
207 AKT1 NM_005163.x-1044s1c1d1 -1.70 14% A431 
207 AKT1 NM_005163.1-1410s1c1 -1.69 48% A-431 
207 AKT1 NM_005163.x-642s1c1d2 -1.55 16% A431 
207 AKT1 NM_005163.x-1044s1c1 -1.52 14% A-431 
387 RHOA NM_001664.1-616s1c1d2 -2.78 3% A549 
387 RHOA NM_001664.1-300s1c1d2 -2.67 15% A549 
387 RHOA NM_001664.1-382s1c1d2 -2.51 16% A549 
387 RHOA NM_001664.1-199s1c1d2 -2.51 5% A549 
388 RHOB NM_004040.2-452s1c1d2 -1.91 12% A549 
388 RHOB NM_004040.2-461s1c1d2 -1.80 22% A549 
389 RHOC NM_175744.3-328s1c1d2 -1.77 12% A549 
389 RHOC NM_175744.3-539s1c1d3 -1.50 13% A549 
403 ARL3 NM_004311.2-480s1c1d3 -2.65 13% A549 
403 ARL3 NM_004311.2-290s1c1d3 -1.57 3% A549 
640 BLK NM_001715.x-1031s1c1 -2.41 16% Jurkat 
640 BLK NM_001715.2-746s1c1 -2.12 30% Jurkat 
640 BLK NM_001715.x-1200s1c1 -2.03 29% Jurkat 
640 BLK NM_001715.2-1626s1c1 -1.66 43% Jurkat 
1152 CKB NM_001823.3-722s1c1 -2.70 34% MCF7 
1152 CKB NM_001823.3-1250s1c1 -2.50 8% MCF7 
1152 CKB NM_001823.3-1251s1c1 -1.80 20% MCF7 
1152 CKB NM_001823.3-877s1c1 -1.70 35% MCF7 
1606 DGKA NM_001345.4-592s1c1 2.41 22% Jurkat 
1606 DGKA NM_001345.4-382s1c1 2.52 42% Jurkat 
1915 EEF1A1 NM_001402.4-338s1c1d1 -2.53 4% A549 
1915 EEF1A1 NM_001402.4-807s1c1d1 -1.76 2% A549 
1968 EIF2S3 NM_001415.2-782s1c1d1 -2.28 45% A549 
1968 EIF2S3 NM_001415.2-646s1c1d1 -1.85 11% A549 
2049 EPHB3 NM_004443.3-1895s1c1 1.58 46% MCF7 
2049 EPHB3 NM_004443.3-3611s1c1 2.14 43% MCF7 
2050 EPHB4 NM_004444.x-459s1c1 -1.76 27% A549 
2050 EPHB4 NM_004444.x-2076s1c1 -1.55 8% A549 
2475 FRAP1 NM_004958.2-640s1c1 1.72 14% A549 
2475 FRAP1 NM_004958.2-4662s1c1 2.21 21% A549 
2475 FRAP1 NM_004958.2-3425s1c1d2 2.54 25% Jurkat 
2475 FRAP1 NM_004958.2-7897s1c1 2.56 21% A549 
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2475 FRAP1 NM_004958.2-3425s1c1 2.73 35% A549 
2791 GNG11 NM_004126.2-502s1c1d1 2.49 47% A549 
2791 GNG11 NM_004126.2-437s1c1d1 2.73 32% A549 
2931 GSK3A NM_019884.1-1173s1c1 -2.44 9% MCF7 
2931 GSK3A NM_019884.x-1428s1c1 -2.10 0% MCF7 
2965 GTF2H1 NM_005316.2-1316s1c1 -2.98 40% MCF7 
2965 GTF2H1 NM_005316.2-1755s1c1 -1.78 25% MCF7 
3717 JAK2 NM_004972.x-4564s1c1 3.73 23% A549 
3984 LIMK1 NM_002314.x-1512s1c1 -2.04 5% MCF7 
3984 LIMK1 NM_002314.x-1374s1c1 -1.78 3% MCF7 
4354 MPP1 NM_002436.2-1286s1c1 -3.06 26% A549 
4354 MPP1 NM_002436.2-1216s1c1 -1.73 24% A549 
4733 DRG1 NM_004147.2-665s1c1d1 1.51 18% A549 
4733 DRG1 NM_004147.2-514s1c1d1 1.89 10% A549 
4832 NME3 NM_002513.2-414s1c1 -2.96 15% 293T 
4832 NME3 NM_002513.2-310s1c1 -1.88 11% 293T 
5211 PFKL NM_002626.x-1630s1c1 -2.08 10% A549 
5211 PFKL NM_002626.4-2301s1c1 -1.69 11% A549 
5211 PFKL NM_002626.4-2309s1c1 -1.69 0% A549 
5213 PFKM NM_000289.3-429s1c1 -2.57 16% MCF7 
5213 PFKM NM_000289.3-1883s1c1 -1.52 35% MCF7 
5291 PIK3CB NM_006219.x-61s1c1d2 -1.74 40% MCF7 
5291 PIK3CB NM_006219.x-61s1c1 -1.63 40% MCF7 
5291 PIK3CB NM_006219.x-2289s1c1 -1.60 25% MCF7 
5291 PIK3CB NM_006219.x-1306s1c1 -1.57 29% MCF7 
5347 PLK1 NM_005030.3-1893s1c1 -2.01 25% MCF7 
5347 PLK1 NM_005030.3-1374s1c1 -1.93 35% MCF7 
5347 PLK1 NM_005030.3-1361s1c1 -1.89 0% MCF7 
5347 PLK1 NM_005030.3-1986s1c1 -1.50 48% MCF7 
5361 PLXNA1 NM_032242.2-4255s1c1 2.36 31% A549 
5361 PLXNA1 NM_032242.2-4656s1c1 2.82 38% A549 
5394 EXOSC10 NM_002685.1-1274s1c1 -3.51 7% A549 
5394 EXOSC10 NM_002685.1-1833s1c1 -1.87 24% A549 
5394 EXOSC10 NM_002685.1-2560s1c1 -1.64 25% A549 
5575 PRKAR1B NM_002735.1-593s1c1 2.77 8% MCF7 
5575 PRKAR1B NM_002735.1-620s1c1 3.24 7% MCF7 
5586 PKN2 NM_006256.1-309s1c1 -2.26 28% A549 
5586 PKN2 NM_006256.1-2250s1c1 -2.06 39% A549 
5631 PRPS1 NM_002764.x-592s1c1 1.70 42% MCF7 
5631 PRPS1 NM_002764.x-819s1c1 2.05 0% MCF7 
5634 PRPS2 NM_002765.x-871s1c1 1.81 16% MCF7 
5634 PRPS2 NM_002765.x-320s1c1 1.96 13% MCF7 
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5832 ALDH18A1 NM_002860.2-658s1c1 -2.59 8% A549 
5832 ALDH18A1 NM_002860.2-568s1c1 -2.13 44% A549 
5865 RAB3B NM_002867.x-446s1c1d1 -2.98 5% A549 
5865 RAB3B NM_002867.x-447s1c1d1 -2.71 8% A549 
5865 RAB3B NM_002867.x-907s1c1d1 -1.54 6% A549 
5868 RAB5A NM_004162.3-659s1c1d1 -3.94 46% #N/A 
5868 RAB5A NM_004162.3-2139s1c1d3 -1.86 16% #N/A 
5873 RAB27A NM_004580.3-477s1c1d2 -2.09 25% A549 
5873 RAB27A NM_004580.3-735s1c1d2 -1.72 5% A549 
5881 RAC3 NM_005052.2-664s1c1d2 -3.31 20% 293T 
5881 RAC3 NM_005052.2-331s1c1d2 -2.78 14% 293T 
5881 RAC3 NM_005052.2-544s1c1d2 -2.77 17% 293T 
6046 BRD2 NM_005104.2-2059s1c1 -2.57 21% 293T 
6046 BRD2 NM_005104.2-2401s1c1 -2.12 40% 293T 
6729 SRP54 NM_003136.2-1839s1c1d1 -2.80 25% A549 
6729 SRP54 NM_003136.2-849s1c1d1 -2.71 15% A549 
6729 SRP54 NM_003136.2-1903s1c1d1 -2.61 22% A549 
6733 SRPK2 NM_003138.1-749s1c1 -1.79 9% MCF7 
6733 SRPK2 NM_003138.1-2730s1c1 -1.61 3% MCF7 
6734 SRPR NM_003139.2-202s1c1d1 -4.08 4% A549 
6734 SRPR NM_003139.2-1086s1c1d1 -1.86 5% A549 
7083 TK1 NM_003258.x-610s1c1 -1.94 11% A549 
7083 TK1 NM_003258.x-530s1c1 -1.74 14% A549 
7083 TK1 NM_003258.x-327s1c1 -1.51 3% A549 
7284 TUFM NM_003321.3-668s1c1d1 -2.68 5% A549 
7284 TUFM NM_003321.3-1266s1c1d1 -1.71 2% A549 
7297 TYK2 NM_003331.x-3209s1c1 -2.87 13% A549 
7297 TYK2 NM_003331.x-4078s1c1 -2.54 15% A549 
8476 CDC42BPA NM_014826.x-4292s1c1 1.55 44% A549 
8476 CDC42BPA NM_003607.x-2992s1c1 2.33 5% A549 
8476 CDC42BPA NM_014826.x-2749s1c1 2.49 3% A549 
8476 CDC42BPA NM_003607.x-4535s1c1 2.58 6% A549 
8526 DGKE NM_003647.1-853s1c1 -1.70 20% MCF7 
8526 DGKE NM_003647.1-952s1c1 -1.54 5% MCF7 
8877 SPHK1 NM_182965.1-1063s1c1 -3.09 13% 293T 
8877 SPHK1 NM_182965.1-1640s1c1 -2.43 36% 293T 
8877 SPHK1 NM_182965.1-1116s1c1 -1.68 21% 293T 
9060 PAPSS2 NM_004670.2-177s1c1 -1.83 11% MCF7 
9060 PAPSS2 NM_004670.2-1768s1c1 -1.58 7% MCF7 
9064 MAP3K6 NM_004672.x-3795s1c1 -2.40 24% A549 
9567 GTPBP1 NM_004286.3-884s1c1d2 -4.45 23% 293T 
9567 GTPBP1 NM_004286.3-1015s1c1d2 -1.90 31% 293T 
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10000 AKT3 NM_005465.x-770s1c1 -3.04 33% A549 
10000 AKT3 NM_005465.x-1757s1c1 -1.83 47% A549 
10000 AKT3 NM_005465.x-569s1c1 -1.82 21% A549 
10154 PLXNC1 NM_005761.1-1236s1c1 -2.26 32% Jurkat 
10154 PLXNC1 NM_005761.1-3289s1c1 -2.25 31% Jurkat 
10519 CIB1 NM_006384.2-504s1c1 -2.80 7% A549 
10519 CIB1 NM_006384.2-376s1c1 -2.04 31% A549 
10783 NEK6 NM_014397.x-445s1c1 -2.40 3% MCF7 
10783 NEK6 NM_014397.x-484s1c1 -2.11 22% MCF7 
10966 RAB40B NM_006822.1-513s1c1d2 -3.48 40% A549 
10966 RAB40B NM_006822.1-354s1c1d1 -2.30 7% A549 
11021 RAB35 NM_006861.4-709s1c1d2 -3.93 37% A549 
11021 RAB35 NM_006861.4-486s1c1d2 -3.27 27% A549 
11021 RAB35 NM_006861.4-207s1c1d2 -2.58 19% A549 
11321 XAB1 NM_007266.1-835s1c1d2 2.33 4% A549 
11321 XAB1 NM_007266.1-220s1c1d2 2.73 18% A549 
11344 TWF2 NM_007284.3-522s1c1 -2.09 22% A549 
11344 TWF2 NM_007284.3-610s1c1 -1.50 9% A549 
25837 RAB26 NM_014353.4-721s1c1d2 -4.06 40% A549 
25837 RAB26 NM_014353.4-512s1c1d2 -2.21 48% A549 
26007 DAK NM_015533.2-1015s1c1 -1.70 10% A549 
26007 DAK NM_015533.2-1597s1c1 -1.51 0% A549 
29110 TBK1 NM_013254.x-1212s1c1 -2.46 35% A549 
29110 TBK1 NM_013254.x-1536s1c1 -1.75 33% A549 
51128 SAR1B NM_016103.2-267s1c1d2 -3.50 9% A549 
51128 SAR1B NM_016103.2-569s1c1d2 -1.95 8% A549 
51135 IRAK4 NM_016123.x-820s1c1 1.53 10% A549 
51135 IRAK4 NM_016123.x-374s1c1 1.88 29% A549 
51678 MPP6 NM_016447.x-528s1c1 -1.89 14% A549 
51678 MPP6 NM_016447.x-527s1c1 -1.57 27% A549 
55288 RHOT1 NM_018307.2-169s1c1d2 -3.02 23% Jurkat 
55288 RHOT1 NM_018307.2-900s1c1d2 -2.05 17% Jurkat 
55312 RFK NM_018339.3-731s1c1 1.71 10% A549 
55312 RFK NM_018339.3-550s1c1 1.87 5% A549 
55312 RFK NM_018339.3-595s1c1 3.05 3% A549 
55577 NAGK NM_017567.1-999s1c1 2.05 34% A549 
55577 NAGK NM_017567.1-621s1c1 3.09 10% A549 
55750 AGK NM_018238.2-1634s1c1 2.07 35% Jurkat 
55750 AGK NM_018238.2-457s1c1 2.72 47% Jurkat 
55970 GNG12 NM_018841.2-272s1c1d1 1.79 32% A549 
55970 GNG12 NM_018841.2-238s1c1d1 2.21 4% A549 
56681 SAR1A NM_020150.3-398s1c1d3 -2.29 34% A549 
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56681 SAR1A NM_020150.3-566s1c1d3 -2.07 9% A549 
56997 CABC1 NM_020247.3-683s1c1 -2.17 35% MCF7 
56997 CABC1 NM_020247.3-1093s1c1 -1.93 0% MCF7 
56997 CABC1 NM_020247.3-1678s1c1 -1.56 47% MCF7 
57111 RAB25 NM_020387.1-387s1c1d1 -3.65 14% MCF7 
57111 RAB25 NM_020387.1-706s1c1d1 -3.05 2% MCF7 
57111 RAB25 NM_020387.1-571s1c1d1 -2.66 2% MCF7 
57521 RAPTOR NM_020761.1-2564s1c1d1 2.52 35% A549 
57521 RAPTOR NM_020761.1-4689s1c1d1 2.53 28% A549 
60493 FASTKD5 NM_021826.4-1341s1c1 -2.47 7% A549 
60493 FASTKD5 NM_021826.4-1602s1c1 -2.00 5% A549 
79109 MAPKAP1 NM_024117.x-526s1c1d1 -1.94 23% MCF7 
79109 MAPKAP1 NM_024117.x-1308s1c1d1 -1.50 19% MCF7 
79675 FASTKD1 NM_024622.2-770s1c1 -1.65 28% Jurkat 
79675 FASTKD1 NM_024622.2-862s1c1 -1.61 42% Jurkat 
79877 DCAKD NM_024819.3-997s1c1 1.55 10% Jurkat 
79877 DCAKD NM_024819.3-590s1c1 3.06 21% Jurkat 
79877 DCAKD NM_024819.3-419s1c1 3.28 35% Jurkat 
79877 DCAKD NM_024819.3-420s1c1 3.44 22% Jurkat 
80347 COASY NM_025233.4-2299s1c1 -2.74 7% A549 
80347 COASY NM_025233.4-547s1c1 -2.01 37% A549 
81876 RAB1B NM_030981.1-374s1c1d1 -2.51 3% A549 
81876 RAB1B NM_030981.1-260s1c1d2 -2.11 2% A549 
81876 RAB1B NM_030981.1-290s1c1d1 -1.93 47% A549 
83440 ADPGK NM_031284.3-995s1c1 -3.55 3% A549 
83440 ADPGK NM_031284.3-507s1c1 -3.50 8% A549 
83440 ADPGK NM_031284.3-1498s1c1 -2.18 6% A549 
84284 C1orf57 NM_032324.1-561s1c1 2.66 26% Jurkat 
84284 C1orf57 NM_032324.1-569s1c1 2.68 20% Jurkat 
84451  NM_032435.x-1423s1c1 -3.68 0% MCF7 
84451  NM_032435.x-4199s1c1 -2.02 14% MCF7 
84451  NM_032435.x-2263s1c1 -1.58 26% MCF7 
84930 MASTL NM_032844.x-1818s1c1 -1.95 17% A549 
84930 MASTL NM_032844.x-2725s1c1 -1.93 16% A549 
89941 RHOT2 NM_138769.1-499s1c1d1 -3.56 ND A549 
89941 RHOT2 NM_138769.1-1585s1c1d1 -2.50 13% A549 
89941 RHOT2 NM_138769.1-227s1c1d1 -1.84 32% A549 
139728 PNCK NM_198452.1-1391s1c1 1.64 27% MCF7 
139728 PNCK NM_198452.1-229s1c1 2.22 21% MCF7 
143098 MPP7 NM_173496.2-610s1c1 -2.44 44% MCF7 
143098 MPP7 NM_173496.2-493s1c1 -1.87 37% MCF7 
197258 FUK NM_145059.1-525s1c1 -3.21 16% Jurkat 
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197258 FUK NM_145059.1-1966s1c1 -2.54 23% Jurkat 
197258 FUK NM_145059.1-3135s1c1 -2.34 9% Jurkat 
204851 HIPK1 NM_152696.3-2649s1c1 -1.78 29% MCF7 
260425 MAGI3 NM_020965.2-2984s1c1 -3.05 15% A549 
260425 MAGI3 NM_020965.2-1964s1c1 -2.08 8% A549 
282974 STK32C NM_173575.2-311s1c1 -2.72 16% A549 
282974 STK32C NM_173575.2-839s1c1 -2.04 29% A549 
282974 STK32C NM_173575.2-1386s1c1 -1.93 21% A549 
282974 STK32C NM_173575.2-1898s1c1 -1.84 23% A549 
326624 RAB37 NM_175738.2-711s1c1d2 -3.07 36% Jurkat 
326624 RAB37 NM_175738.2-1059s1c1d2 -2.67 36% Jurkat 
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APPENDIX D: 48 hit genes from Table S4 that are not known to be associated 
with PI3K/AKT signaling whose expression is not tissue-specific. nd, no data. 
NCBI ID SYMBOL Expressed widely? Result of KD? 
5575 PRKAR1B Yes ↑ phospho-AKT 
6011 GRK1 Yes ↑ phospho-AKT 
9943 OXSR1 Yes ↑ phospho-AKT 
55312 RFK Yes ↑ phospho-AKT 
79877 DCAKD Yes ↑ phospho-AKT 
1163 CKS1B nd ↓ phospho-AKT 
3706 ITPKA Yes ↓ phospho-AKT 
5394 EXOSC10 Yes ↓ phospho-AKT 
5586 PKN2 Yes ↓ phospho-AKT 
5881 RAC3 Yes ↓ phospho-AKT 
6729 SRP54 Yes ↓ phospho-AKT 
6872 TAF1 Yes ↓ phospho-AKT 
7083 TK1 Yes ↓ phospho-AKT 
9064 MAP3K6 nd ↓ phospho-AKT 
11021 RAB35 Yes ↓ phospho-AKT 
11158 RABL2B nd ↓ phospho-AKT 
11159 RABL2A nd ↓ phospho-AKT 
26164 GTPBP5 Yes ↓ phospho-AKT 
27289 RND1 nd ↓ phospho-AKT 
54676 GTPBP2 nd ↓ phospho-AKT 
54734 RAB39 nd ↓ phospho-AKT 
56997 CABC1 nd ↓ phospho-AKT 
57538 ALPK3 Yes ↓ phospho-AKT 
57551 TAOK1 Yes ↓ phospho-AKT 
64122 FN3K Yes ↓ phospho-AKT 
64792 RABL5 Yes ↓ phospho-AKT 
79646 PANK3 Yes ↓ phospho-AKT 
80216 ALPK1 Yes ↓ phospho-AKT 
81876 RAB1B Yes ↓ phospho-AKT 
83440 ADPGK Yes ↓ phospho-AKT 
83903 GSG2 Yes ↓ phospho-AKT 
84100 ARL6 Yes ↓ phospho-AKT 
84197 POMK Yes ↓ phospho-AKT 
89941 RHOT2 Yes ↓ phospho-AKT 
91461 PKDCC Yes ↓ phospho-AKT 
127933 UHMK1 Yes ↓ phospho-AKT 
130106 CIB4 Yes ↓ phospho-AKT 
158158 RASEF Yes ↓ phospho-AKT 
197258 FUK Yes ↓ phospho-AKT 
203447 NRK low ↓ phospho-AKT 
282974 STK32C Yes ↓ phospho-AKT 
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283629 TSSK4 Yes ↓ phospho-AKT 
284086 NEK8 Yes ↓ phospho-AKT 
285282 RABL3 Yes ↓ phospho-AKT 
347736 TXNDC6 Yes ↓ phospho-AKT 
374872 C19orf35 nd ↓ phospho-AKT 
402679 MARK2P10 nd ↓ phospho-AKT 
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